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Excessive states of sensations like fear, anxiety, risk assessment, and others, and the resulting psychiatric 
disorders, render humans incapable of directing their own life. Psychiatric disorders like generalized 
anxiety disorder (GAD) and major depressive disorder (MDD) are the sixth and the leading cause of 
disability worldwide, respectively, and represent a major burden for both patients and society. The risk 
for the development of these disorders is twice as high in women as in men and the available treatment 
options, while effective for many, are imperfect. In fact, 30 % of patients are classified as treatment-
resistant. Unfortunately, the underlying causes and mechanisms remain largely unknown, which has 
impeded the development of new drugs. In recent years, several studies showed a regulatory role of 
commensal gut microbiota on the development of CNS functioning and behaviour, which has led to the 
concept of a microbiota-gut-brain (MGB) axis. This describes a network of different systems as modulator 
for behaviour and its dysregulation as a cause for psychiatric disorders. In addition, a dysregulation of the 
peripheral immune system and the immune system of the brain, especially of microglia, was linked in 
numerous clinical and preclinical studies to the development of psychiatric disorders like GAD or MDD. 
The well-established link between gut microbiota and the immune system, as well as the role of the 
immune system in the MGB axis, introduced a complex interplay of systems whose deciphering and 
specific manipulation could give rise to novel treatment targets in psychiatric disorders. Hence, current 
research needs to concentrate on a different rationale to meet the medical necessities, ranging from 
augmentation strategies of available medication to innovative approaches directly targeting the immune 
system and / or the MGB axis. The recent discovery of pleiotropic effects of the second-generation 
tetracycline antibiotic minocycline not only on bacteria, but also on the immune system, CNS functioning, 
and behaviour, gave rise to a promising multimodal approach as a novel treatment. Therefore, using two 
different animal models for psychiatric disorders, selective breeding and chronic psychosocial stress, the 
present thesis aimed to identify the potential beneficial effects of minocycline. First, the influence of 
minocycline on a model of innate anxiety- and depressive-like behaviour, rats selectively bred for high 
anxiety-like behaviour (HAB), was analysed in comparison to rats non-selected for anxiety-like behaviour 
(NAB). In a battery of behaviour tests, the behavioural effects of minocycline, the selective serotonin 
reuptake inhibitor escitalopram, or a combination of both substances as augmentation regimen, on male 
and female HAB rats were characterized. To unravel potential underlying mechanisms associated with the 
immune system and / or the MGB axis, these tests were followed by the analysis of microglial density in 
the prelimbic and infralimbic prefrontal cortex (PFC), brain regions highly affected in MDD, and cecal 
microbiota composition. The obtained results demonstrate that under untreated conditions, HAB rats 
display a sustained highly anxious and depressive behavioural phenotype irrespective of sex. Male and 
female HAB rats also showed a reduced microglial density in the PFC and altered gut microbial 
composition compared to NAB rats independent of treatment. Three weeks of minocycline treatment 
alleviated the depressive-, but not anxiety-like, phenotype and further reduced microglial density in the 
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PFC exclusively in male HAB rats, while female HAB rats did not respond to the treatment. Escitalopram 
was able to decrease anxiety-like behaviour in the light-dark box in male NAB rats only, while the 
combinatory treatment did not result in any behavioural effect. Moreover, minocycline reduced plasma 
cytokine concentrations and induced a robust shift in gut microbiota composition in both HAB and NAB 
males. Detailed taxonomic analysis revealed a marked increase in the relative abundance of 
Lachnospiraceae and Clostridiales Family XIII, two bacterial families known to produce butyrate. 
Correspondingly, plasma concentrations of 3-OH-butyrate were elevated and positively correlated with 
the respective bacterial abundance in a trait-dependent manner. Thus, these results validate HAB rats for 
treatment-resistant to conventional antidepressants, as well as inflammation-associated, depressive-like 
behaviour and suggest that the antidepressant effect of minocycline is sex- and trait-dependent. The 
multimodal effects of minocycline also support the hypothesis of the MGB axis being a potential target in 
the treatment of MDD.  
In addition, the present thesis aimed to evaluate the influence of minocycline on stress-induced 
behavioural and physiological alterations in comparison to innate behaviour. This model provides a 
different approach to psychiatric disorders and allows to better identify the mode of action of 
minocycline. Humans face stressors daily that comprise both a chronic and psychosocial component, the 
type of stressor that represents the most acknowledged risk factor for psychiatric and somatic disorders. 
The chronic subordinate colony housing (CSC) paradigm is a mouse model of chronic psychosocial stress 
that closely mimics those challenges and induces harmful behavioural, physiological, and immunological 
changes. The fact that the CSC paradigm specifically induces anxiety-, but not depressive-like, behaviour, 
offers a unique opportunity to dissect distinct effects of minocycline, including innate versus stress-
induced anxiety. However, as the laboratory where the experiments were conducted relocated to a new 
facility, it was crucial to reproduce a valid and robust CSC-induced phenotype. This was confirmed by 
elevated anxiety-like behaviour, and increased adrenal, but decreased thymus, weight in male CSC mice. 
Based on these results, a potential beneficial effect of minocycline on stress-induced behavioural and 
physiological symptoms in the newly validated CSC paradigm was evaluated. Eight days after stressor 
termination, CSC mice showed robust stress-induced anxiety-like behaviour as well as increased spleen 
weight and an altered HPA axis activity compared to single-housed controls. Interestingly, minocycline 
was not able to ameliorate CSC-induced symptoms. Hence, under the applied treatment conditions, the 
CSC-induced behavioural and physiological phenotype appears to be independent of any target of 
minocycline. However, time- or dose-dependent effects need to be examined in future studies. 
Overall, my findings provide a closer insight into the interplay between the immune system, gut 
microbiota, and behaviour in two different models of psychiatric disorders. They further extend the 
knowledge about specific treatment conditions and a distinct pattern of action for minocycline. On a 
behavioural level, minocycline showed a specific antidepressant, but not anxiolytic, effect in male HAB 
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rats. In line with the available literature, these results indicate that the sex-dependent antidepressant 
effect of minocycline requires an a priori depressive-like phenotype. In addition, minocycline was 
suggested as anxiolytic after acute stress or trauma. Here, an anxiolytic effect could not be confirmed in 
the two animal models of anxiety-like behaviour. These findings propose that minocycline had no or only 
a delayed effect on innate or chronic stress-induced anxiety-like behaviour. Thus, my experimental data 
demonstrate that minocycline requires specific conditions for a behavioural effect and acts only 
antidepressant under the applied experimental conditions. Further, minocycline is proposed to exert its 
mechanism of action via its anti-inflammatory effects. Fittingly, male HAB rats showed an inflammatory 
phenotype that was altered by minocycline. Female HAB rats expressed a similar inflammatory 
phenotype, though, and the CSC procedure is known to induce a strong inflammatory response. The high 
inflammatory phenotype in CSC mice did not facilitate a behavioural effect of minocycline, indicating that 
the mechanism of action of minocycline is not based in a pro-inflammatory status per se. Thus, 
minocycline might require inflammation-induced depression for a behavioural effect.  
In summary, the results garnered from my thesis advance the knowledge about the behavioural influence 
of minocycline and show a specific effect on depressive-like behaviour dependent on sex, the 
inflammatory state, and the potential underlying cause of the disease. A future application of minocycline 
in psychiatric disorders needs close consideration of the patients’ circumstances and emphasizes that 
minocycline represents rather a promising medication of tailored and personalized treatment than as a 
broad-spectrum antidepressant.  
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Die Basis psychischer Erkrankungen sind grundlegende und evolutionär essentielle Emotionen, die in 
einem exzessiven und unangepassten Zustand ein pathologisches Ausmaß annehmen. Dadurch sind 
Patienten oftmals nicht mehr in der Lage, ihr Leben in geregelten Bahnen zu führen. Die generalisierte 
Angststörung (GAD) und Depressionen (MDD) zählen zu den wichtigsten Gründen für Erwerbsunfähigkeit, 
wobei GAD den sechsten und MDD den führenden Platz als Ursache weltweit einnimmt. Dadurch sind 
diese Krankheiten nicht nur verheerend für den Patienten, sondern haben auch großen Einfluss auf die 
Gesellschaft. Das Risiko, eine psychische Erkrankung zu entwickeln, ist in Frauen beinahe doppelt so hoch 
wie in Männern. Trotz der Verfügbarkeit verschiedener Medikamente mit erwiesenen Wirkung in vielen 
Patienten, reagieren 30 % der Patienten nicht auf die Medikation und werden letztendlich als 
behandlungsresistent eingestuft. Da die grundlegenden Mechanismen und die Ursachen psychischer 
Krankheiten weitestgehend unbekannt sind, ist die Entwicklung neuer Medikamente stark eingeschränkt. 
In den letzten Jahren wurden erstaunliche Fortschritte in der Erforschung zweier verschiedener Systeme 
erzielt. Die Bakterien der Darmflora, genannt Darm Mikrobiota, haben ungeahnten Einfluss auf das 
zentrale Nervensystem und das Verhalten. Dies führte zu der Begründung eines neuen Konzepts, der 
Mikrobiota-Darm-Hirn Achse, welche das Verhalten beeinflusst und, im Falle einer Dysregulation, zur 
Entwicklung psychischer Erkrankungen beitragen kann. Zudem wurde in einigen Patienten eine 
Fehlregulation des peripheren Immunsystems sowie des Immunsystems im Gehirn – insbesondere bei 
Mikroglia – festgestellt, die in unmittelbarem Zusammenhang zu psychischen Erkrankungen wie GAD oder 
MDD stehen. Das Zusammenspiel zwischen der Mikrobiota-Darm-Hirn-Achse und dem Immunsystem ist 
allgemein anerkannt und eröffnet ein komplexes System und Wechselspiel, dessen Entschlüsselung und 
spezifische Manipulation einen neuen Ansatz für Therapiemöglichkeiten bietet. Daher konzentriert sich 
die aktuelle Forschung auf die Entwicklung neuer Behandlungsstrategien. Diese decken ein weites 
Spektrum, beginnend bei dem Add-On von Substanzen zu gängigen Antidepressiva bis zur Entwicklung 
neuer Medikamente mit der Mikrobiota-Darm-Hirn Achse sowie dem Immunsystem als potentielles Ziel, 
ab. Kürzlich wurde bei einem herkömmlichen Antibiotikum eine Reihe von zusätzlichen, pleiotropen 
Funktionen entdeckt. Minozyklin ist ein Tetrazyklin der zweiten Generation, das neben seiner 
antibakteriellen Funktion auch das Immunsystem, das Gehirn und Verhalten beeinflusst und demzufolge 
mit seinem multimodalen Wirkungsspektrum einen neuen, vielversprechenden Ansatz für die Behandlung 
psychischer Erkrankungen bietet. Daher war es Ziel der vorliegenden Doktorarbeit, den Einfluss auf 
Minozyklin in zwei verschiedenen Tiermodellen für psychische Krankheiten, selektive Zucht und chronisch 
psychosozialer Stress, zu untersuchen. Zunächst wurde die Wirkung von Minozyklin auf verschiedene 
Verhaltensweisen in einem Tiermodell für angeborenes hohes Angstverhalten und depressions-ähnliches 
Verhalten, Ratten die selektiv auf hohes Angstverhalten gezüchtet wurden (HAB), untersucht. Um 
geschlechtsspezifische Effekte zu zeigen, wurde dies auf weibliche HAB Ratten und als Kontrolle auch auf 
männliche und weibliche Ratten, die nicht aufgrund ihres Verhaltens selektiert wurden (NAB), 
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ausgeweitet. Dazu wurde Escitalopram, ein selektiver Serotonin Wiederaufnahmehemmer, als 
Positivkontrolle eingesetzt, sowie eine Kombination beider Substanzen, da in Patienten Minozyklin nicht 
als Monotherapie, sondern als Add-On Medikation genutzt wird. Um mögliche grundlegende 
Wirkungsmechanismen von Minozyklin zu identifizieren, wurde sowohl die Anzahl der Mikroglia im 
infralimbischen und prelimbischen prefrontalen Cortex (PFC) ermittelt, einer Gehirnregion, die stark von 
MDD beeinflusst ist, als auch die Zusammensetzung der Darm Mikrobiota untersucht. Die vorliegenden 
Ergebnisse demonstrieren einen stabilen Phänotyp in unbehandelten männlichen und weiblichen HAB 
Ratten und eine reduzierte Dichte an Mikroglia im PFC in beiden Geschlechtern im Vergleich zu NAB 
Ratten. Zudem zeigen männliche HAB Ratten grundlegend eine andere Zusammensetzung der Darmflora 
als NAB Ratten. Die Behandlung der Tiere mit Minozyklin für 3 Wochen erzielte eine Verbesserung des 
depressions-ähnlichen Verhaltens, jedoch nicht des Angstverhaltens, und eine Reduzierung der Mikroglia 
Anzahl exklusiv in männlichen HAB Ratten, während weibliche HAB Ratten nicht auf die Behandlung 
reagierten. Escitalopram verringerte das Angstverhalten von männlichen NAB Ratten, während die 
Kombination beider Substanzen keinerlei Effekte zeigte. Zudem reduzierte Minozyklin die Konzentration 
zweier pro-inflammatorischen Zytokine im Plasma und veränderte merklich die Darm Mikrobiota 
Zusammensetzung in männlichen HAB und NAB Ratten. Eine detaillierte Analyse der Taxonomie zeigte, 
dass Minozyklin die relative Häufigkeit der beiden Butyrat-produzierenden Bakterienfamilien 
Lachnospiraceae und Clostridiales Familie XIII erhöhte. Diese Familien sind bekannt für ihre Produktion 
des Metabolits Butyrat. Dem entsprechend konnten auch erhöhte Plasma 3-OH-Butyrat Konzentrationen 
festgestellt werden, die mit der jeweiligen Bakterienhäufigkeit in Abhängigkeit des Phänotyps positiv 
korrelierten. Diese Ergebnisse validieren HAB Ratten nicht nur als Modell für behandlungsresistente 
Angsterkrankungen und MDD, sondern auch als Modell für entzündungs-assoziierte MDD, und implizieren 
einen geschlechts- und phänotyp-abhängigen Effekt von Minozyklin. Die multimodale Manipulation von 
Minozyklin und ihr Behandlungserfolg in HAB Ratten unterstreicht zudem die Mikrobiota-Darm-Hirn-
Achse als potentielles Ziel für neue Therapieansätze in psychischen Erkrankungen.  
Zudem war es Ziel der vorliegenden Doktorarbeit, den Einfluss von Minozyklin auf stress-induziertes 
Verhalten und auf die Physiologie als Vergleich zu angeborenem Verhalten zu untersuchen. Das genutzte 
Modell stellt eine alternative Herangehensweise für psychische Krankheiten dar und ermöglicht somit 
eine Erweiterung des Wissens über Minozyklin und seine Wirkungsweise. Es ist heutzutage allgemein 
anerkannt, dass Stress mit einer chronischen und psychosozialen Komponente ein starker Risikofaktor für 
die Entwicklung von stressbedingten somatischen und psychischen Erkrankungen wie MDD und GAD ist. 
Das Mausmodell der chronisch subordinierten Koloniehaltung (CSC) ist ein geeignetes Tiermodell, das 
verhaltensbedingte, physiologische und immunologische Veränderungen in Mäusen induziert, die 
vergleichbar mit den psychischen, somatischen und / oder gastrointestinalen Erkrankungen bei chronisch 
gestressten Menschen sind. Das CSC Modell erhöht zudem spezifisch das Angstverhalten, aber nicht das 
Zusammenfassung  viii 
 
 
depressions-ähnliche Verhalten in den Mäusen. Daher ermöglicht dieses Modell, die Wirkung von 
Minozyklin spezifisch auf Angstverhalten zu untersuchen, insbesondere im Vergleich von Stress-
induziertem und angeborenem Angstverhalten. Als Voraussetzung für diese Versuche war es essentiell, 
das CSC Modell nach dem Umzug der Verhaltenslaboratorien in ein neues Forschungsgebäude neu zu 
etablieren und einen validen und robusten Phänotyp zu reproduzieren. Dieser Phänotyp wurde durch 
erhöhtes Angstverhalten, vergrößerte Nebennieren und einen verkleinerten Thymus bestätigt. Basierend 
auf dieser Grundlage wurden danach Mäuse, die für 20 Tage dem CSC Modell ausgesetzt waren, mit 
Minozyklin behandelt. 8 Tage nach Beendigung des CSC Modells zeigten die Mäuse noch immer ein 
erhöhtes Angstverhalten sowie ein erhöhtes Gewicht der Milz und eine fehlregulierte Aktivität der HPA-
Achse. Minozyklin war nicht in der Lage, die stress-induzierten physiologischen und verhaltensbedingten 
Veränderungen zu verbessern. Dies deutet darauf hin, dass der CSC-induzierte Phänotyp unabhängig von 
einem Wirkungsbereich von Minozyklin entsteht, wobei aber nicht ausgeschlossen werden kann, dass 
eine längere Behandlungsdauer und eine höhere Minozyklin Dosis andere Effekte zeigen würde.  
Somit konnte die vorliegende Doktorarbeit einen detaillierten Einblick in die Wechselwirkungen zwischen 
dem Immunsystem, den Darm Mikrobiota, und Verhalten liefern und enthüllte spezifischere 
Wirkungsbedingungen für Minozyklin in zwei verschiedenen Tiermodellen für psychische Erkrankungen. 
Betrachtet man die Verhaltensergebnisse, zeigen die vorliegenden Versuche einen spezifischen Effekt von 
Minozyklin auf depressions-ähnliches Verhalten, aber nicht Angstverhalten, in männlichen HAB Ratten. 
Diese Ergebnisse implizieren, gemeinsam mit der aktuell bekannten Literatur, einen 
geschlechtsabhängigen Effekt von Minozyklin, sowie die Notwendigkeit einer vorliegenden 
Verhaltensstörung. Zusätzlich wurde eine angstlösende Wirkung von Minozyklin vorgeschlagen. Dies 
basierte auf Studien, die akuten Stress oder physiologisches Trauma nutzten. Da die Ergebnisse der 
vorliegenden Doktorarbeit keinen angstlösenden Effekt von Minozyklin nachweisen konnten, impliziert 
dies einen verzögerten oder sogar keinen Einfluss von Minozyklin auf Angstverhalten, das durch 
chronischen Stress verursacht wurde oder angeboren ist. Der Verhaltenseffekt von Minozyklin ist 
allgemein postuliert als eine Auswirkung der anti-inflammatorischen Wirkung des Antibiotikums. 
Männliche HAB Ratten zeigen ein verändertes Immunsystem im Gehirn und reagieren auf eine Minozyklin 
Behandlung. Allerdings zeigen auch weibliche HAB Ratten ein verändertes Immunsystem und das CSC 
Modell ist bekannt für seine immun-modulatorischen Effekte. Daher deuten diese Ergebnisse darauf hin, 
dass Minozyklin für seine Wirkung nicht per se ein verändertes Immunsystem als Voraussetzung benötigt, 
sondern auch hier spezielle Bedingungen notwendig sind. Minozyklin könnte daher einen entzündungs-
induzierten depressiven Phänotyp für einen Behandlungseffekt benötigen. 
Zusammenfassend erweitern die gesammelten Ergebnisse der vorliegenden Arbeit das Wissen über das 
Wirkungsspektrum von Minozyklin auf Verhalten und zeigen einen spezifischen antidepressiven Effekt, 
der geschlechtsabhängig ist und auf dem inflammatorischen Status sowie der potentiell 
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zugrundeliegenden Ursachen beruht. Eine zukünftige Anwendung von Minozyklin bei Patienten mit 
psychischen Erkrankungen muss sorgfältig durchdacht werden, da Minozyklin vielmehr als ein 
Medikament für individuelle, patientenbezogene Behandlung, denn als ein allgemeines Antidepressiva 
erscheint. 
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1.1  Psychiatric disorders 
 “If the human brain were so simple that we could understand it, we would be so simple that we couldn’t” 
– Emerson M. Pugh; Quoted by George E. Pugh 1977, The Biological Origin of Human Values 
The complexity of the brain is what makes us human – it shapes personality and emotions and determines 
whom we are. Unfortunately, that very complexity prevents us from understanding how exactly the brain 
forms a certain behaviour. Scientific research has tried to unravel the underlying networks for human 
emotions for centuries. However, the output seems sparse compared to the effort. This statement is 
particularly pertinent for diseases of the brain, and a greater understanding is crucial, not only regarding 
neurological aberrations, but in terms of psychiatric disorders. Most psychiatric disorders are 
characterized by emotional and cognitive dysfunctions. Therefore, a unified classification defined mental 
disorders as significant disturbances of cognition, emotional regulation, or behaviour that reflect a 
dysfunction in the developmental, biological or psychological process underlying mental functioning and 
impair daily life. This is often accompanied by distress or disability in social or occupational activities 
(American Psychiatric Association, 2013). Today, the global lifetime prevalence of mental disorders is 
estimated between 12.2 % and 48.6 % in adults. 17.4 % of global years lived with disability (YLDs) are 
attributed to psychiatric disorders. Mental disorders encompass a plethora of diseases that are divided in 
different categories like psychotic, neurodevelopmental, substance-related, mood or anxiety disorders, 
to only name a few, the two latter being discussed in more detail below. Additionally, mental disorders 
show a high degree of comorbidity. Approximately 30 % of patients suffer from a second comorbid mental 
disorder and about 18 % experience three or more disorders at the same time (American Psychiatric 
Association, 2013; GBD 2015 Disease and Injury Incidence and Prevalence Collaborators, 2016).  
 
1.1.1 Major depressive disorder  
Recently, major depressive disorder (MDD) has been described as the “cancer of the 21st century” 
(Holden, 2000). Fittingly, despite the fact that the WHO in 2012 estimated that MDD would become the 
second leading cause of disability by 2020; by 2017 it was already classified as leading cause of disability 
worldwide (World Health Organization, 2012, 2017). MDD is categorized as a depressive disorder by the 
Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5; for other depressive disorders see Fig. 
1). Depressive disorders are generally characterized by sadness, feeling of emptiness or irritable mood, 
and loss of interest and pleasure (anhedonia), accompanied by somatic and cognitive changes. The 
division into the different subtypes is dependent on duration, timing, presumed aetiology, as well as 
severity (American Psychiatric Association, 2013).  
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As the psychiatric disorder with the highest lifetime prevalence, MDD occurs in approximately 17 % of the 
population (Kessler et al, 2005) with a genetic heritability of about 40 % (American Psychiatric Association, 
2013). In university students, the prevalence of MDD is even higher at roughly 30.5 % (Ibrahim et al, 2013). 
Globally, about 322 million people suffer from MDD (12 % in the European region) and depression was 
ranked as single largest contributor to YLDs (7.5% in 2015) as well as a major contributor to suicide of 
approximately 800 000 per year (American Psychiatric Association, 2013; World Health Organization, 
2017). Importantly, a strong sex difference can be found with approximately 1.5- to 3-fold higher risk to 
develop MDD in women (American Psychiatric Association, 2013; Duman et al, 2016). MDD is 
characterized by pronounced changes in affective, cognitive, and neuro-vegetative functions for at least 
2 weeks nearly every day either as single episode (rare) or recurrent as in the majority of cases. The 
underlying aetiology of MDD is highly complex and includes environmental, psychosocial, genetic, 
epigenetic, neuroendocrine, neuro-immunological, and even dietary factors (American Psychiatric 
Association, 2013; Dash et al, 2015; Gururajan et al, 2016). The multifactorial nature of MDD is especially 
evident through the high comorbidity rates with various other somatic and affective diseases. Thus, the 
prevalence for depression is several times higher in patients suffering from chronic pain (Kim et al, 2012), 
bowel disorders (Fuller-Thomson and Sulman, 2006; Slyepchenko et al, 2016), or autoimmune (Martin-
Subero et al, 2016), and inflammatory diseases (Dantzer and Capuron, 2017) than in the general 
population. Further, about 90 % of MDD patients suffer from an additional anxiety disorder like 
generalized anxiety disorder (GAD) or social phobia (Alonso et al, 2004; Gorman, 1997). Unfortunately, 
this high rate of comorbidity can mask disease symptoms and complicates accurate diagnoses (Krishnan 
and Nestler, 2008). 
From a neurological point of view, numerous brain regions are involved in the pathophysiology of 
depression, like the hippocampus, amygdala, prefrontal and cingulate cortices, striatum, and the 
mesolimbic dopaminergic circuit (Berton and Nestler, 2006; Heshmati and Russo, 2014; Krishnan and 
Nestler, 2008; Ressler and Mayberg, 2007). Patients suffering from MDD show reduced grey-matter 
volume and glial density in the prefrontal cortex (PFC) and the hippocampus. Both regions are 
hypothesised to mediate the cognitive aspects of depressive symptoms (Krishnan and Nestler, 2008; 
Rajkowska, 2003; Rajkowska et al, 1999). Interestingly, the reduction in PFC grey-matter volume 
correlates with the severity of MDD symptoms only in men, but not in women (Carlson et al, 2015). 
Functional magnetic resonance imaging studies in women also revealed an association between the 
severity of MDD and a hypo-connectivity of the amygdala and frontal regions including the dorsolateral 
PFC (Satterthwaite et al, 2016). The reduction in hippocampal volume is mainly found in patients suffering 
from MDD for at least 2 years with several episodes (McKinnon et al, 2009) and is inversely related to the 
number of episodes (MacQueen et al, 2003). Likewise, volumetric changes in the PFC are dependent on 
number of episodes (Treadway et al, 2015; Yucel et al, 2008) and negatively correlated with disease 
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severity and duration (Bludau et al, 2016). Moreover, deep brain stimulation of Brodmann Area 25 
(infralimbic PFC) in MDD patients improves symptoms (Mayberg et al, 2005), proposing a dysregulation 
in specific areas as one mechanism in MDD.  
 
1.1.2 Anxiety disorders 
A second major group of psychiatric disorders are anxiety disorders that are characterized by the 
underlying emotional concept of excessive and irrational fear and anxiety. Both fear and anxiety describe 
highly adaptive responses to a threat for the individual’s health and homeostasis that overlap and interact. 
These terms are used interchangeably, though fear is rather described as the emotional response to a real 
or perceived imminent threat that determines the fight of flight response, whereas anxiety is the 
anticipation of it (McNaughton and Zangrossi, 2008). In the DSM-5, anxiety disorders include different 
mental states of excessive fear and anxiety (see Fig. 1) that are mutually highly comorbid but are triggered 
by distinct stimuli (American Psychiatric Association, 2013). Anxiety disorders have the highest lifetime 
prevalence for a group of psychiatric disorders of approximately 30 % and are considered the 6th highest 
contributor to YLDs (3.4%). Today, 264 million people live with anxiety disorders (Kessler and Wang, 2008; 
Neumann and Slattery, 2016) and, similar to MDD, women have an about 2-fold higher prevalence (4.6 % 
vs. 2.6 %; American Psychiatric Association, 2013; World Health Organization, 2017). The most common 
anxiety disorder is specific phobia pronounced as marked fear or anxiety related to a specific object or 
situation. Also, social anxiety disorder (SAD), which is characterized by persistent fear and avoidance of 
social situations, is the second most common anxiety disorder with a lifetime prevalence of 13 % 
(Bandelow et al, 2017). To give a conceptual framework for the present thesis, from here on the 
introduction will focus on GAD and its epidemiology to gain better insight into the underlying 
neurobiological mechanisms. 
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Figure 1. Schematic overview about commonly known kinds of depressive and anxiety disorders as 
classified by the Diagnostic and Statistical Manual of Mental Diseases DSM-5. The DSM-5 categorizes 
the abovementioned mental conditions as depressive disorders or anxiety disorders that are 
characterized by the same main features in mood. Depressive disorders and anxiety disorders share a high 
rate of comorbidity (American Psychiatric Association, 2013). Of note, the following subtypes of 
depressive disorders are not mentioned: depressive disorder due to another medical conditions and other 
specified depressive disorder. Regarding anxiety disorders, selective mutism in children, anxiety disorder 
due to another medical condition, other specified anxiety disorder, and unspecified anxiety disorder are 
not named. 
 
GAD is the third most prevalent anxiety disorder with a lifetime prevalence of approximately 6 %. It is 
characterized by persistent, excessive, and uncontrollable anxiety and worry / apprehensive expectation 
about various aspects of life for the majority of days over at least 6 months. These psychological symptoms 
are accompanied by physical symptoms like restlessness, difficulties to concentrate, irritability, or sleep 
disturbances (American Psychiatric Association, 2013; Kessler and Wang, 2008; Neumann and Slattery, 
2016; Somers et al, 2006). The majority of GAD cases are chronic, but with fluctuating severity, and a full 
remission is rarely achieved despite several treatment options (see section 1.1.3 for description; American 
Psychiatric Association, 2013). Moreover, GAD is a highly comorbid disorder with about 62 % of patients 
experiencing a MDD episode in the past year (Coplan et al, 2015). Similar to depressive disorders, a key 
brain region involved in anxiety-related disorders is the amygdala together with, but not exclusively, the 
PFC, hypothalamus, ventral hippocampus, the nucleus accumbens, and other brain regions (Lüthi and 
Lüscher, 2014; Ressler and Mayberg, 2007; Tovote et al, 2015). In line, GAD increases amygdala and 
dorsomedial PFC volume in women which correlates with symptom severity (Schienle et al, 2011). GAD 
patients also show a greater activation of the ventromedial PFC (Monk et al, 2006) as well as abnormal 
amygdala and PFC activation. This was accompanied by increased grey-matter volume and reduced 
connectivity between those structures (Hilbert et al, 2014), proposing region-specific functional changes 
in GAD. Further, the amygdala seems less while the anterior cingulate cortex is more responsive in women 
suffering from GAD, which could predict treatment outcome (Blair et al, 2008; Whalen et al, 2008).  
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1.1.3 Conventional treatment for psychiatric disorders 
A serendipitous finding in the late 1950s opened the door to a new world of treatment options and 
introduced the first medications for MDD. Iproniazid, commonly used as an antitubercular agent, 
concurrently improved depressed mood (Crane, 1956; López-Muñoz and Alamo, 2009). Around the same 
time, an antihistamine gave rise to a second antidepressant. Imipramine is a tricyclic antidepressant 
(Feighner, 1999) characterized by a 3-ring molecular structure (Kuhn, 1957, 1958). As both iproniazid and 
imipramine increase noradrenaline and serotonin (5-hydroxytryptamine, 5-HT) concentrations in the 
synaptic cleft, the first theory of catecholamine deficiency in depression was born (Schildkraut, 1965). In 
the 1970’s, the “second generation” of antidepressants was introduced like selective serotonin reuptake 
inhibitors (SSRIs; including citalopram or paroxetine), serotonin and noradrenaline reuptake inhibitors 
(SNRIs; e.g. reboxetine or venlafaxine), or selective dopamine uptake inhibitors (SDRI) like bupropion in 
the late 1980s (reviewed in López-Muñoz and Alamo, 2009; Ramachandraih et al, 2011; Slattery et al, 
2004). Over generations, not only clinical efficacy, onset of action, and tolerance were improved, but also 
undesirable side effects like body weight gain, insomnia, or the toxicity in overdose were reduced (Millan, 
2004; Ravindran and Stein, 2010). The broad spectrum of current antidepressants still mainly targets 
monoaminergic neurotransmission. Beside, positive results are obtained from antidepressants targeting 
different systems. These encompass strategies such as the melatonin receptor agonist agomelatine, 
glutamatergic modulators like ketamine or riluzole, anticholinergic modulators (e.g. scopolamine), or anti-
inflammatories like infliximab (for review see Berton and Nestler, 2006; Papakostas and Ionescu, 2015).  
Antidepressants are effective in the treatment of anxiety disorders, too, corresponding to the high 
comorbidity between those two diseases (Millan, 2004). Beside tricyclic antidepressants and monoamine 
oxidase inhibitors, benzodiazepines, anticonvulsants, or atypical antipsychotics are used (Hoffman and 
Mathew, 2009). Benzodiazepines like diazepam or lorazepam are powerful positive allosteric modulators 
of the γ-aminobutyric acid (GABA)A receptor. They potentiate the inhibitory function of GABA, leading to 
a rapid onset and strong anxiolytic effects. However, as this mechanism easily induces physical 
dependency, this option is chosen only in patients with an urgent need for treatment (Cloos and Ferreira, 
2008; Paulus et al, 2005; Ravindran and Stein, 2010). Interestingly, anticonvulsants and atypical 
antipsychotics are proposed rather as adjunctive treatment in case of treatment-resistance. In general, 
first choice treatment for anxiety disorders are SSRIs and SNRIs due to a high clinical efficacy (Hoffman 
and Mathew, 2009; Ravindran and Stein, 2010).  
In addition to pharmacotherapy, a number of other therapeutic options are approved. These include 
cognitive behavioural or interpersonal therapy (Matthews et al, 2005), bright light therapy (Oldham and 
Ciraulo, 2014), and physical exercise. Also, device-based therapy like transcranial magnetic stimulation or 
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deep brain stimulation (Mayberg et al, 2005; Papakostas and Ionescu, 2015) are applied to alleviate 
symptoms of both MDD and anxiety disorders.  
 
1.1.4 Selective serotonin reuptake inhibitors and alternative strategies 
SSRIs were the first antidepressants developed with the premise to counteract depression, initially 
starting with fluoxetine followed by citalopram and others (López-Muñoz and Alamo, 2009). Citalopram, 
the highly selective SSRI, is a racemic mixture containing two enantiomers that differ in configuration. The 
active component of citalopram is the S-enantiomer, whereas the R-enantiomer rather diminishes its 
function (Hyttel et al, 1992). S-citalopram or escitalopram, chemically known as (S)-(+)-1-[(3-dimethyl-
amino)propyl]-1-(p-fluorophenyl)-5-phthalancarbonitrile oxalate, shows a unique binding to the 5-HT 
transporter (SERT). It is capable of interacting with SERT at two different binding sites: a primary high-
affinity binding site, which is generally bound by SSRIs, and a secondary lower-affinity allosteric site that 
is proposed to stabilize and prolong binding to the primary site (Burke, 2002; Chen et al, 2005; Murdoch 
and Keam, 2005). Clinical studies provide evidence that escitalopram has a faster onset of action (1-week 
vs. 2-3 weeks) and a greater improvement of symptoms compared to other antidepressants. It also shows 
a high tolerability and few adverse side effects like insomnia, diarrhea, or dizziness (Burke, 2002). 
Escitalopram has comparable or even superior efficacy in patients suffering from MDD or GAD (Burke, 
2002; Davidson et al, 2004; Goodman et al, 2005; Montgomery et al, 2001; Murdoch and Keam, 2005; 
Ravindran and Stein, 2010; Sánchez et al, 2004). These clinical results are supported by preclinical 
evidence of reduced anxiety- and depressive-like behaviour. In rats, chronic escitalopram treatment 
ameliorates depressive-like behaviour in the forced-swim test (FST; Jayatissa et al, 2006; Sánchez et al, 
2003) and sucrose preference test (Montgomery et al, 2001). Moreover, microinfusion of citalopram 
(containing about 50 % escitalopram) into the infralimbic PFC of rats alleviated depressive-like symptoms 
in the FST (Gasull-Camós et al, 2017). In mice, repeated administration of escitalopram reversed anxiety- 
and depressive-like behaviour (Mombereau et al, 2010).  
Despite the availability of numerous antidepressants, only about 50 % MDD of patients respond 
sufficiently to the first antidepressant and even after repeated treatment, 30 - 40 % suffer persistently 
from symptoms (Ferrier, 1999; Hennings et al, 2009). Therefore, these patients are categorized as 
treatment-resistant. As not all substances that facilitate monoaminergic neurotransmission act anti-
depressive (like cocaine) and the current monoaminergic antidepressants show a delayed onset of action 
(2 – 3 weeks), secondary occurring mechanisms downstream of monoamines might yield promising 
potential. Thus, various novel theories and targets are relentlessly tested. One effective approach is 
medication augmentation. In agomelatine, different modes of action are fused and it shows, beside 
monoaminergic activity, improved sleep quality and sleep-wake rhythmicity (Millan et al, 2003). Further, 
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non-antidepressant medication can be administered as add-on to conventional antidepressants. Here, 
atypical antipsychotics that inhibit 5-HT receptors or act as partial dopamine (DA) agonists are generally 
used to augment treatment efficacy. A recent meta-analysis of 43 clinical trials proved an effective 
augmentation strategy of partial DA agonists in patients suffering from MDD but showed inadequate 
treatment response. Also, in a double-blinded clinical study in treatment-resistant depression, a 5-HT 
antagonist successfully improved conventional antidepressant treatment within 1 week (Citrome, 2015; 
Shelton et al, 2001). Notably, a recent meta-analysis of nine clinical trials demonstrated that ketamine, an 
ionotropic NMDA receptor antagonist, has substantial rapid antidepressant effects. However, these 
effects seem transient with a high heterogeneity in clinical response that urges for caution (Xu et al, 2016; 
Zhang and Ho, 2016). Preclinical studies also propose metabotropic glutamate receptor antagonists as 
potential novel treatment (Peterlik et al, 2016). Several additional targets are currently investigated like 
nitrous oxide, opioids, psychedelic drugs like psilocybin, or corticotropin-releasing factor (CRF) receptor 
antagonists (Berton and Nestler, 2006; Ceskova and Silhan, 2018; Millan, 2004; Peterlik et al, 2016), to 
just name a few. Importantly, a meta-analysis of 20 clinical trials revealed an improvement in depressive 
symptoms with anti-cytokine treatment (Kappelmann et al, 2018; see chapter 1.2.2). This provides strong 
evidence for a dysregulated immune system in MDD and support an inflammatory theory of psychiatric 
disorders.  
 
1.2 Inflammation and psychiatric disorders 
The immune system is a highly complex network involving multiple cell types and factors that provides a 
comprehensive protection to maintain body homeostasis. By means of inflammation, it responds to the 
invasion of exogenous material like external threats (invading pathogens) or internal causes like ischaemia 
or infected cells. The body has three essential levels of defence with the initial protection provided by 
epithelial barriers. Invading pathogens that pass the epithelium encounter two additional levels: the 
innate (natural) and the acquired immune systems. The central nervous system (CNS) bears its own line 
of defence mainly conducted by microglia. Though previously regarded as separate systems, nowadays a 
tight communication between the peripheral immune system and the immune system of the brain via 
short- and long-range interactions is commonly known. This bidirectional communication allows the 
immune system to recruit the whole body in immune regulation, thus engaging in a plethora of 
mechanisms. However, alterations in those communication pathways can account for various diseases 
that are, at the first glance, not expected to be inflammation-based. 
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1.2.1 The immune system  
Exogenous material is recognized by immune cells due to a protein structure on the cellular surfaces called 
antigens. The peripheral immune system generally responds in two different manners: The immediate, 
but unspecific, innate immune response that always reacts to the same extent. Second, the slower 
adaptive immune response that displays a highly specific recognition of antigens but requires a previous 
contact. The innate immune response is largely based on numerous cells performing tissue-specific 
phagocytosis that originate and differentiate from bone marrow progenitor cells. The major cells involved 
in peripheral phagocytosis are macrophages and dendritic cells that travel to lymph nodes for antigen 
presentation to T and B cells. The thereby initiated adaptive immune response provides a tailored and 
specific response to pathogens. It also forms an immunological memory comprising pathogen-specific 
antibodies to facilitate host defence during a future insult (Medzhitov and Janeway, 2002; Young et al, 
2014). Beside direct cell-to-cell contact, communication between immune cells is conducted via 
inflammatory mediators like acute-phase proteins, chemokines, or cytokines. The latter are soluble low 
molecular weight glycoprotein messengers, not only within the immune system but also within other 
systems of the body, forming an integrating network. They can be classified as pro- or anti-inflammatory 
as well as hematopoietic cytokines. Pro-inflammatory cytokines (e.g. interleukin (IL)-1, IL-6, tumour 
necrosis factor (TNF), or interferon (IFN)) are responsible to initiate the immune response while anti-
inflammatory cytokines like IL-3, IL-4, or IL-10, block or dampen it. Hematopoietic cytokines (IL-3 or IL-5), 
on the other hand, stimulate the differentiation of hematopoietic progenitor cells into red and white 
blood cells (Delves and Roitt, 2000; Yarlagadda et al, 2009).  
In the past, the CNS has been viewed as an immune-privileged organ protected from excessive peripheral 
signalling and pathogen or cell invasion by the blood brain barrier (BBB). Today, a close communication 
between the peripheral immune system and the immune system of the brain is known. Transduction of 
inflammatory signals is executed via three different routes: the humoral, neural, and the cellular route. 
The circumventricular organs like the choroid plexus, lacking the BBB and, thus, providing an unprotected 
entry site (Giunti et al, 2003), were long assumed as only access to the brain. However, this passage seems 
to be predominantly a relay station for signals. Circumventricular organs contain immune cells that detect 
circulating cytokines (Ericsson et al, 1995; Nadeau and Rivest, 1999; Vallières and Rivest, 1997). Upon 
recognition, cytokines are released into the perivascular compartment from which they are transported 
to the brain. There, cytokines can directly interact with glia cells and neurons to facilitate an inflammatory 
response (Ericsson et al, 1995; Quan et al, 1997; Stitt, 1990). In addition, BBB endothelial cells contain 
cytokine receptors (Ek et al, 2001) and specific saturable active transporters (Banks, 2005) to enable 
immune-to-brain signalling via the humoral route. Using the neural route, cytokines are proposed to 
stimulate vagal or trigeminal afferent fibres directly via short-range interactions to relay visceral 
information to the brain. In line, afferent dorsal root ganglia in rats also express IL-1β receptors (Obreja 
Introduction  24 
 
 
et al, 2002), ultimately affecting behaviour. Finally, activated peripheral immune cells can migrate into 
the brain utilizing the cellular route (Kerfoot et al, 2006). In the brain, immune cell-produced 
neuroendocrine mediators and peripheral cytokines can modulate different brain circuits including the 
hypothalamus-pituitary-adrenal (HPA) axis (Fig. 2; Banks, 2005; Chrousos, 1995; Cunningham and De 
Souza, 1993; Dantzer, 2018; Dantzer et al, 2000; Hopkins, 2007; Morimoto and Alexopoulos, 2011; 
Schedlowski et al, 2014; Silverman et al, 2005; Yarlagadda et al, 2009) 
 
 
Figure 2. Schematic overview of humoral and neural routes of communication between the peripheral 
immune system and the immune system of the brain. Activation of innate immune cells by microbiota 
antigens like lipopolysaccharide (LPS), recognized by the toll-like receptor 4 (TLR-4), leads to the release 
of cytokines. Peripheral cytokines are not able to cross the blood brain barrier via diffusion due to a high 
molecular weight. They enter the brain either through circumventricular organs or by active saturable 
cytokine transporters in the brain endothelium. In addition, perivascular macrophages can interact with 
brain endothelial cells to induce the release of prostaglandin E2 (PGE2), which activates neuronal 
regulation of the hypothalamo-pituitary-adrenal (HPA) axis and other systems. The HPA axis can in turn 
affect the inflammatory reaction of innate immune cells. Cytokines and PGE2 also stimulate microglia to 
induce a neuroinflammatory reaction and a subsequent release of inflammatory mediators. As neural 
pathway, primary afferent nerves like the vagus nerve respond to peripheral cytokines and project to 
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several brain regions like the nucleus of the solitary. Ultimately, the complex immune-to-brain signalling 
regulates body homeostasis in numerous systems in the periphery and the brain and, thus, behaviour 
(adapted from Dantzer et al, 2000; Hopkins, 2007; Schedlowski et al, 2014). 
 
The innate immune system of the brain 
The innate immune system of the brain is mediated mainly via resident microglia, but also perivascular 
macrophages and astrocytes are immunocompetent and contribute to immune functioning. Microglia 
constitute about 10 % of cells in the CNS and are of mesodermal origin arising from the yolk sac, colonizing 
the CNS during early development until the BBB is formed. In humans, from the middle of the first until 
early second trimester and, correspondingly, in rodents from embryonic day 10 to 19, microglia colonize 
the brain. During postembryonic homeostasis, microglia proliferate and represent an independent self-
renewing population (Kettenmann et al, 2011; Marin and Kipnis, 2017). A second phase of microglial 
originating from bone marrow colonizes the brain during the early postnatal development (Kettenmann 
et al, 2011). However, microglia do not colonize as mature cells, but as immature progenitors that develop 
together with the organism through three distinct stages. Global profiles of transcriptional stages in mice 
revealed that microglial development starts with early microglia until embryonic day 14, followed by pre-
microglia until postnatal day 9. During this time, microglia show a highly diverse transcriptomic profile. 
They are considered as being adult from the organism’s age of 4 weeks onwards with a less heterogeneous 
transcriptional pattern (Hammond et al, 2019; Matcovitch-Natan et al, 2016; Thion et al, 2018). 
Importantly, adult mouse microglia show a sex dimorphism. Microglia of females express higher levels of 
genes associated with the inflammatory response, apoptosis, and lipopolysaccharide (LPS) response 
compared to males, suggesting a more immune-activated state in line with a previously proposed stronger 
immune response in females (Klein and Flanagan, 2016; Thion et al, 2018). Male and female mice 
demonstrate a similar distribution of microglia throughout the brain (Thion et al, 2018), though region- 
and sex-specific density has been reported in rats (Schwarz et al, 2012). Infection during pregnancy can 
disrupt microglia maturation and proper immune functioning (Matcovitch-Natan et al, 2016). Also, a lack 
of microbiota – commensal bacteria colonizing the gastrointestinal tract (GIT) – during development can 
not only prevent microglial maturation (see chapter 1.3.2; Erny et al, 2015), but leads to sex-specific 
alterations in gene expression. Thus, at late embryonic stages, e.g. embryonic day 19, microglia of male 
germ-free (GF) embryos show alterations in the expression of genes linked to translation and metabolism. 
In contrast, female GF embryonal microglia remain largely unaffected at this age. Interestingly, microglia 
of adult female GF mice exhibit a dysregulation in genes linked to morphogenesis, adaptive immune 
response, and cell migration, while microglia of male GF adults remain unchanged. This differential 
temporal susceptibility to the absence of microbiota proposes males as susceptible during in utero 
development while females show a stronger reaction during adulthood (Thion et al, 2018). 
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Microglial dynamics 
Microglia, the macrophages of the brain, regulate various processes like early brain wiring, synaptic 
pruning, transmission, and plasticity, as well as neurogenesis (Hu et al, 2015; Paolicelli et al, 2011; Salter 
and Beggs, 2014; Thion and Garel, 2017; Tremblay et al, 2011; Walker and Yirmiya, 2016; Yirmiya and 
Goshen, 2011). Additionally, they protect the brain from invading pathogens and integrate peripheral 
immune signalling, leading to a neuroinflammatory response (Dheen et al, 2007; Garden and Möller, 
2006). To execute these functions, adult microglia show pronounced morphological and functional 
plasticity. Under “resting” conditions, ramified microglia have a small round cell body and numerous 
motile processes and branches. They occupy and surveil individual territories of surrounding tissue to 
detect potential activating stimuli like pathogens or components of the immune system (Askew et al, 
2017; Sousa et al, 2017). Upon detection, within 1 h microglia can adopt different stages of activation, 
depending on the nature of the stimuli, and migrate to the site of injury for phagocytosis (Davalos et al, 
2005). Those stages of activation can be characterized morphologically as well as by functional and 
molecular properties. Morphologically, microglia can be categorized into three different stages after 
activation, ranging from primed (ellipsoid-like soma and highly ramified), to reactive (amoeboid cell body 
with lesser processes), and amoeboid or phagocytic with not more than a few unbranched processes 
(Torres-Platas et al, 2014). Activation of microglia is accompanied by enhanced proliferation and, thereby, 
an increase in microglial number (Kettenmann et al, 2011), followed by apoptosis (Liu et al, 2001). This 
temporally controlled rate of proliferation and apoptosis ensures a stable level of microglia under healthy 
conditions (Askew et al, 2017; Garden and Möller, 2006). On a molecular level, microglial activation leads 
to either an M1 (pro-inflammatory) or an M2 (anti-inflammatory) state (Hu et al, 2015) that entails the 
production and secretion of cytokines to stimulate other microglia and immunocompetent cells in the 
brain (Hammond et al, 2019). The M1 state is characterized by the synthesis and secretion of pro-
inflammatory cytokines, e.g. IL-1β, IL-6 or TNF-α, and the inducible nitric oxide synthase, acting 
antimicrobial through a classical inflammatory reaction. On the other hand, the M2 phenotype expresses 
arginase-1, as well as anti-inflammatory mediators like IL-10, and is more associated with tissue repair 
and homeostasis (Fig. 3; Cherry et al, 2014; Hu et al, 2015; Rock et al, 2004; Sousa et al, 2017).  
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Figure 3. Polarization stages of microglia. Under physiological conditions, resting phagocytes like 
microglia remain ramified and survey the surrounding tissue to regulate neuronal homeostasis. Upon 
stimulation, microglia adopt different stages of activation dependent on the stimuli. Microglia then 
assume a more amoeboid morphology and acquire either the M1 or the M2 stage. M1 microglia express 
pro-inflammatory cytokines (like tumour necrosis factors (TNF), the inducible nitric oxide synthase (iNOS), 
the major histocompatibility complex II (MHC II), interleukin (IL)-1, IL-6, IL-12, or IL-23) and stimulate the 
immune system. M2 microglia are characterized by anti-inflammatory cytokine expression (e.g. arginase-
1 (Arg-1), IL-1 receptor antagonist (IL-1Ra), IL-10, or the transforming growth factor TGF-β) and a 
subsequent resolution of inflammation. Microglia are able to switch between the M1 and M2 stage 
(adapted from Hu et al, 2015). 
 
Thus, at the initial stage of tissue injury, the M1 microglial type dominates to eliminate dead tissue or 
pathogens and is later replaced by the M2 phenotype for tissue repair (Kigerl et al, 2009). To identify the 
morphological and functional stage of microglia, several membrane and intracellular protein markers 
beside the aforementioned are utilized. The M1 stage can also be identified using the cluster of 
differentiation molecules (CD) 11b (CD11b) or CD68, while M2 microglia express CD86 (for an overview 
see Kettenmann et al, 2011). Although these proteins enable the identification of activation stages, 
general marker for microglia are a useful tool to get a broader overview about cell populations. In this 
sense, in 1996 the ionized calcium-binding adaptor molecule 1 (Iba-1) was isolated from monocytes of the 
brain and is nowadays commonly recognized as a rather specific marker for microglia. Iba-1 is constantly 
expressed in microglia and upregulated in response to activation to regulate calcium homeostasis, 
mobility, and phagocytosis (Imai et al, 1996; Ito et al, 1998; Ohsawa et al, 2000). This bears some 
limitations, though, as peripheral macrophages that translocate to the brain are also monocytes and 
express Iba-1. Further, a response-dependent upregulation in protein levels might exacerbate the valid 
interpretation of intensity measurements that are used to identify cellular density in 
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immunohistochemically stained brain slices (Imai et al, 1996; Imai and Kohsaka, 2002). Recently, a novel 
marker for microglia was isolated from human, rat, and mouse immortalized microglia. In a series of 
control experiments, these publications showed that the transmembrane protein 119 indeed specifically 
marks microglia but not macrophages independent of cellular activity (Bennett et al, 2016; Bohlen et al, 
2017; Satoh et al, 2016), and might represent a reasonable alternative to Iba-1. 
Characterization of microglial states with those markers showed that a balanced microglial functioning in 
the brain is crucial for a healthy organism. A dysregulation, like a failed M1-M2 transition after microglial 
activation, resulting in a prolonged M1 pro-inflammatory state, is associated with detrimental effects on 
health (Cherry et al, 2014; Liao et al, 2012). Several lines of evidence link abnormal microglial dynamics 
to diseases. A loss-of-function mutation in microglia leading to neurodegenerative diseases like 
leukodystrophy (Rademakers et al, 2012). On the other hand, an over-activation is associated to various 
disorders like pathological pain (Walker and Yirmiya, 2016), Alzheimer’s and Parkinson’s disease, 
amyotrophic lateral sclerosis, or multiple sclerosis (Butovsky and Weiner, 2018; Cherry et al, 2014; ElAli 
and Rivest, 2015; Salter and Beggs, 2014; Tang and Le, 2016).  
 
1.2.2 Inflammatory theory of psychiatric disorders 
Understanding the causes of mental disorders is a main goal in psychiatric research. In 1991, a new theory 
based on clinical observations was published as potential mechanism in the development of MDD: the 
“macrophage hypothesis of depression” (Smith, 1991) that connects both the peripheral and the brain 
immune system to depression. This hypothesis was soon promoted by Maes and colleagues providing 
evidence for an altered immune system activation in depression (Maes, 1995; Maes et al, 1992, 1995a, 
1995b) and numerous studies support an inflammatory theory of psychiatric disorders.  
In agreement, elevated levels of pro-inflammatory cytokines, like the acute-phase C-reactive protein 
(CRP), IL-6, or TNF-α, are found in the blood or cerebrospinal fluid (CSF) of patients suffering from autism 
spectrum disorder (ASD), SAD, or GAD (Hoge et al, 2009; Kim et al, 2018; Vargas et al, 2005; Vogelzangs 
et al, 2013). Activated T cells of GAD patients secrete correspondingly higher levels of pro-inflammatory 
cytokines (Vieira et al, 2010). In MDD patients, elevated levels of IL-6, TNF-α, or CRP (Dowlati et al, 2010; 
Köhler et al, 2016; Raison, 2014; Young et al, 2014), and their soluble receptors in the plasma (Maes et al, 
1995a) as well as CSF (Levine et al, 1999) can be found, concluding the existence of an exaggerated 
systemic immune (re)activity in psychiatric disorders. Interestingly, a comprehensive study on cytokine 
plasma concentrations revealed both increased and decreased levels in MDD patients. After 12 weeks of 
treatment, in responding patients pro-inflammatory cytokine levels stabilized, but remained unchanged 
in non-responders (Syed et al, 2018). In the brain, MDD patients show enhanced concentration of TNF in 
the PFC (Dean et al, 2010) and activated microglia in one in six patients (Bayer et al, 1999). Importantly, 
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the dysregulated immune response in mood disorders shows a sex dependency. Thus, women suffering 
from GAD, SAD, or panic disorder do not express elevated levels of plasma CRP (Vogelzangs et al, 2013). 
In the orbitofrontal cortex of MDD suicide victims, IL-4 mRNA seems upregulated in women, whereas in 
men IL-13 mRNA is elevated (Tonelli et al, 2008). Conversely, the stimulation of inflammation has potential 
negative effects on mood and facilitates the development of psychiatric disorders. An immune challenge 
in healthy volunteers can coincide with the manifestation of depression and anxiety symptoms (Grigoleit 
et al, 2011; Schedlowski et al, 2014). Chronic administration of IFN-α, commonly used in hepatitis C or 
multiple sclerosis, dose-dependently induces depressive and anxiety symptoms in up to 45 % of treated 
patients (Friebe et al, 2010; Malek-Ahmadi, 2001; Zheng et al, 2015). In addition, though a low-dose 
injection of Salmonella abortus does not affect physical sickness symptoms, the elevated plasma cytokine 
concentrations correlate with endotoxin-induced levels of anxiety and depressed mood (Reichenberg et 
al, 2001). The high rate of comorbidity of MDD with inflammation-associated disorders like asthma (de 
Miguel Díez et al, 2011), rheumatoid arthritis (Covic et al, 2012), or autoimmune (Benros et al, 2013; 
Martin-Subero et al, 2016) and inflammatory diseases (Dantzer and Capuron, 2017; see chapter 1.1.1), 
strengthens a causal role of the immune system in mood disorders.  
This inflammatory theory of mood disorders led to the assumption that treatment outcome is affected by 
the inflammatory state and anti-inflammatory agents might augment antidepressant therapy. In support, 
in MDD patients plasma CRP concentrations negatively correlate with the treatment success of 
escitalopram (Uher et al, 2014). Contrary, antidepressant augmentation with the TNF-α antibody 
infliximab was more successful in patients with higher plasma CRP concentrations (Raison et al, 2013). 
Non-steroidal anti-inflammatory drugs like aspirin or celecoxib, or anti-cytokine medication also 
successfully augment the effects of antidepressant medications (Kappelmann et al, 2018; Köhler et al, 
2014; Mendlewicz et al, 2006; Müller et al, 2006).  
Preclinical studies using inflammatory animal models of psychiatric disorders, such as maternal immune 
activation or sickness behaviour induced by an immune challenge with LPS or IFN-α, provide additional 
evidence for a crucial role of over-activated peripheral and brain inflammation in mood disorders. In this 
sense, enhanced cytokine concentrations due to maternal immune activation infiltrate the brain (Golan 
et al, 2004; Lin et al, 2003) and induce autism-like (Patterson, 2009), depressive-, and anxiety-like 
behaviour in adult mice (Babri et al, 2014; Khan et al, 2014). An immune challenge in adult mice causes 
depressive-like behaviour, an effect that is accompanied by increased microglial M1 morphology (Henry 
et al, 2008; Zheng et al, 2015). Further, genetic activation of microglia exacerbates LPS-induced 
depressive-like behaviour in mice (Corona et al, 2013). Chronic stress is a commonly acknowledged risk 
factor for psychiatric disorders that is accompanied by an over-activated immune system and chronic low-
grade inflammation (for review see Langgartner et al, 2019). Fittingly, mice exposed to the chronic, 
unpredictable mild stress (CUMS) model develop a depressive- and anxiety-like phenotype concomitant 
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with an upregulation of pro-inflammatory cytokines (Goshen et al, 2008). In turn, caspase-1 knockout (KO) 
or IL-1 receptor KO acts protective in stress-induced anxiety- and depressive-like behaviour (Goshen et al, 
2008; Wong et al, 2016). Stress-induced behavioural alterations are also accompanied by increased 
microglial M1 morphology (Burke et al, 2014; Kreisel et al, 2014; Xu et al, 2017; Yirmiya et al, 2015), 
occurring in various brain regions like the PFC (Hinwood et al, 2012, 2013; Tynan et al, 2010). Interestingly, 
glial loss in the PFC of rats, as well as a stress-induced reduction in hippocampal microglia density of mice, 
induces depressive-like behaviour (Banasr and Duman, 2008; Gong et al, 2018; Kreisel et al, 2014; Tong 
et al, 2017). In line with clinical studies, infliximab can prevent stress-induced depressive-like behaviour 
(Liu et al, 2016), and an IL-1 receptor antagonist reverses ischemic stroke-induced depressive symptoms 
(Craft and Devries, 2006) in mice. Moreover, in previously treatment-resistant rats, augmentation of 
fluoxetine with aspirin reverses CUMS-induced depressive-like behaviour (Wang et al, 2011).  
Overall, the comprehensive body of evidence demonstrates a role of the inflammatory system in 
psychiatric disorders (Anderson et al, 2012; Berthold-Losleben et al, 2009; Dantzer, 2018; Griez et al, 2015; 
Hayley, 2011; Köhler et al, 2016; Miller et al, 2009; Robson et al, 2017; Salim et al, 2012; Yirmiya et al, 
2015; Young et al, 2014). It is important to note that not all clinical studies show increased levels of pro-
inflammatory cytokines (Kubera et al, 2000; Young et al, 2014) but report even reduced levels in 
depression (Lehto et al, 2010b, 2010a). Thus, rather an inflammatory dysregulation, not necessarily an 
over-activation, and in particular a deviation from microglial homeostasis, contributes to psychiatric 
disorders. Considering this, effects of immune-modulatory medication might be restricted to a subset of 
patients and require the definition and analysis of biomarkers to achieve a personalized and tailored 
treatment. Of note, in MDD an auto-immune reaction against the serotonergic system was indicated that 
might be supported by pro-inflammatory cytokines (Maes et al, 1995b; Robson et al, 2017; Sluzewska et 
al, 1997). Therefore, augmentation with anti-inflammatory agents might increase the efficacy of 
antidepressants. A possible agent is the anti-inflammatory tetracycline antibiotic minocycline that is 
currently under evaluation as treatment for psychiatric disorders.  
 
1.2.3 The antibiotic minocycline 
Since the discovery of penicillin (Chain et al, 1940), antibiotics have been developed and various different 
classes emerged. Tetracyclines are bacteriostatic antibiotics composed of a four-ring core essential for 
the antibiotic function and different attached side groups (Fig. 4). They inhibit protein synthesis by binding 
to the 30S bacterial ribosome (Goldman et al, 1983; Tritton, 1977). Dependent on the year of discovery, 
tetracyclines are subdivided into three generations (Chopra and Roberts, 2001).  
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Figure 4. Chemical structure of tetracycline, doxycycline, and minocycline. (adapted from Valentín et 
al, 2009).  
 
The first tetracycline discovered was the broad-spectrum antibiotic chlortetracycline, isolated from 
Streptomyces aureofaciens in 1948 (Duggar, 1948), that targets both gram-negative and gram-positive 
bacteria as well as atypical organisms. Soon after, the naturally occurring tetracycline (first-generation), 
and the semisynthetic second-generation doxycycline and minocycline were identified. The latter (7-
dimethylamino-6-demethyl-6-deoxytetracyline) was synthesised in 1972 and is distinguishable by a 
modification on three sides, leading to a prolonged half-life of 12 – 18 h compared to 6 – 10 h of 
tetracycline (Agwuh and MacGowan, 2006; Noble et al, 2009). Besides their anti-microbial functions, 
tetracyclines caught attention due to pleiotropic effects in inhibiting matrix metalloproteinases, the ability 
to scavenge reactive oxygen species, anti-apoptotic and anti-inflammatory effects, as well as protective 
effects in the neurodegenerative disorders Huntington’s and Alzheimer’s disease (Chopra and Roberts, 
2001; Griffin et al, 2010; Sloan and Scheinfeld, 2008). In addition, they act beneficial on nociceptive, 
inflammatory, and neuropathic pain (reviewed in Bastos et al, 2012; Burke et al, 2014). 
Minocycline appears to be almost completely absorbed from the stomach and small bowel (Agwuh and 
MacGowan, 2006; Saivin and Houin, 1988) into the blood stream and can easily cross the BBB due to 
structural high lipophilicity (Agwuh and MacGowan, 2006; Barza et al, 1975). So far, it shows a low 
propensity for antibiotic resistance and a low incidence of side effects. Therefore, it is commonly used for 
the treatment of acne vulgaris and infections of the respiratory tract, Lyme disease, cholera, or syphilis 
(Chopra and Roberts, 2001; Gump et al, 1977; reviewed in Noble et al, 2009). Minocycline a potent 
regulator of neuroplasticity in the brain (Choi et al, 2007; reviewed in Plane et al, 2010; Quintero et al, 
2006) with neuroprotective effects demonstrated by reducing tissue damage after spinal cord injury in 
rats (Festoff et al, 2006) and in multiple sclerosis in humans (Zhang et al, 2008). It facilitates neurogenesis 
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and neuronal survival in animal models of ischemia, restores hippocampal neurogenesis, and induces the 
recovery of neural stem cell populations after infection (Das et al, 2011; Ekdahl et al, 2003; Liu et al, 2007; 
Yrjänheikki et al, 1998). The pleiotropic effects of minocycline also encompass a beneficial influence on 
oxidative stress, glutamate excitotoxicity, and the attenuation of decreased DA, and norepinephrine levels 
(reviewed in Noble et al, 2009; Plane et al, 2010; Soczynska et al, 2012). Importantly, minocycline has 
strong anti-inflammatory properties. In rodents, minocycline attenuates inflammatory responses by 
inhibiting peripheral and pro-inflammatory cytokine production in the brain in vivo and in vitro (Kobayashi 
et al, 2013; Levkovitz et al, 2015; Naura et al, 2013; O’Connor et al, 2009b; Singh et al, 2014a; Wang et al, 
2017, 2018). Furthermore, minocycline inhibits microglial proliferation (Seabrook et al, 2006; Tikka et al, 
2001) and reduces inflammation-promoting T cells-microglia interactions in vitro (Giuliani et al, 2005). 
These studies are supported by several groups showing an anti-inflammatory effect of minocycline on 
microglia in vivo (Bye et al, 2007; Ekdahl et al, 2003; Neigh et al, 2009; Pabreja et al, 2011; Tikka and 
Koistinaho, 2001; Wang et al, 2017; Wu et al, 2002; Yrjänheikki et al, 1998; Zheng et al, 2015). Further, 
minocycline specifically abolishes microglia M1 polarization (Kobayashi et al, 2013) as well as induction of 
M1 microglia and cytokine production in the PFC in chronic pain (Burke et al, 2014; Xu et al, 2017), 
providing evidence for a direct effect of minocycline on microglia in the brain. Although the exact 
mechanisms underlying the beneficial effects of minocycline remain not fully understood, these studies 
strongly suggest the inhibition of the activation and proliferation of a variety of immune cells as well as 
positive effects on neuronal signalling as causal.  
Interestingly, and potentially due to its anti-inflammatory effects and the inflammatory theory of 
psychiatric disorders, minocycline gained traction in the psychiatric area. In rodents, minocycline can 
alleviate cardiac arrest/CPR- (Neigh et al, 2009) and stress-induced anxiety (Levkovitz et al, 2015; Wang 
et al, 2018; Wong et al, 2016), and restores LPS- (Henry et al, 2008) and stress-induced social avoidance 
(Kreisel et al, 2014). However, most studies focus on minocycline as a potent novel treatment for 
depression. In naïve rats, minocycline decreases depressive-like behaviour (Molina-Hernández et al, 
2008b, 2008a) and prevents LPS- as well as streptozotocin-induced cytokine secretion and depressive-like 
behaviour in mice (Henry et al, 2008; O’Connor et al, 2009a). In the learned helplessness paradigm, a 
single intracerebroventricular (icv) infusion of minocycline enhances escape attempts, indicative of 
decreased depressive-like behaviour (Arakawa et al, 2012). Likewise, subchronic treatment in rats 
prevents a stress-induced depressive-like phenotype (Wang et al, 2017; Xu et al, 2017). In both rats and 
mice, chronic minocycline treatment is effective in various tests. It reverses stress- or inflammation-
induced decreased sucrose consumption in the sucrose preference test, elevates the time spent struggling 
in the FST, and decrease the time spent immobile in the tail-suspension test (TST). All of these behavioural 
effects are accompanied by a diminished inflammatory response (Burke et al, 2014; Tong et al, 2017; 
Wang et al, 2018; Wong et al, 2016; Zheng et al, 2015).  
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In keeping with these promising preclinical studies, minocycline is tested in clinical trials as adjunctive 
medication in the treatment of psychiatric disorders. In patients with Schizophrenia, minocycline could 
improve both positive and negative symptoms (Ghanizadeh et al, 2014; Kelly et al, 2015a; Levkovitz et al, 
2010; Miyaoka et al, 2008), an effect that appears to be dependent on an inflammatory status in the 
patients (Deakin et al, 2018). Currently, it is under evaluation as a preventive treatment for at-risk mental 
states in schizophrenia and psychosis (Qurashi et al, 2017). Further, it modulates decision making (Kato 
et al, 2012; Watabe et al, 2012, 2013) and alleviates symptoms of ASD (Ghaleiha et al, 2016). In 1996, the 
first effective treatment of MDD was reported in a case study (Levine et al, 1996). Thereafter, several 
studies show that minocycline is beneficial on depressive symptoms and general well-being (Dean et al, 
2017; Miyaoka et al, 2012; Soczynska et al, 2017). Additionally, it is effective in improving symptoms of 
HIV-induced mild-to-moderate depression (Emadi-Kouchak et al, 2016) and is evaluated in bipolar 
depression (Husain et al, 2016). A meta-analysis of ten studies reveals a moderate antidepressant effect 
of minocycline in MDD (Rosenblat and McIntyre, 2017) and in treatment-resistant depression, an 
improvement is likewise indicated (Husain et al, 2017; Raison et al, 2013). The surprisingly small clinical 
effect seen in single studies supports the aforementioned suggestion that anti-inflammatory agents in 
general and minocycline in particular might be only effective in a subset of patients with a distinct 
inflammatory profile. Of note, there are opposite treatment indications for minocycline. It can worsen 
symptoms of Parkinson’s disease in both a monkey and a mouse model (Diguet et al, 2004) and induces a 
depersonalization disorder in a patient treated for acne (Cohen, 2004). 
 
1.3 Microbiota theory of psychiatric disorders 
Bacteria are found on all external and internal surfaces of the body, including the skin, saliva, oral mucosa, 
conjunctiva, and the GIT with a high intra- and interindividual diversity. This diversity is defined as number 
and abundance of distinct types of organisms within one organism (alpha diversity) or between organisms 
(beta diversity; Human Microbiome Project Consortium, 2012). The vast majority of commensal bacteria 
is found in the gut (Gill, 2006) followed by the skin and the remaining body with approximately the same 
amount (Berg, 1996). It has been postulated several times within the last 50 years that bacteria 
outnumber the cells of the human body by 10:1. However, revisiting these estimations and considering 
all cells in the human body including blood cells, the ratio actually appears closer to 1:1 (Sender et al, 
2016).  
Although microorganisms are universally present, research targeting the interaction of gut microbiota and 
their microbiome (collective genome) on the brain and, subsequently, on behaviour has only recently 
been recognized. To gain better insight, several different approaches are utilized in this context, like the 
Introduction  34 
 
 
simple but efficient model of GF animals (Luczynski et al, 2016). Furthermore, depletion via antibiotics or 
manipulation of the composition by administering specific bacteria are applied (Sekirov et al, 2010). Those 
approaches enable research to reveal a strong impact of microbiota on behaviour and 
neuroendocrinology in rodents (Bercik et al, 2011a; Bravo et al, 2011; Messaoudi et al, 2011; Sudo et al, 
2004; Turnbaugh et al, 2006). The initiation of large-scale metagenomics projects like the ‘Human 
Microbiome Project’ (NIH HMP Working Group, 2009) further contributes to unravel the complex host-
microbiota interplay. Thus, microbiota not only affect metabolism (Le Chatelier et al, 2013) and growth 
(Blanton et al, 2016), but also behaviour and neuroendocrinology, as shown in rodents (Bercik et al, 
2011a; Bravo et al, 2011; Messaoudi et al, 2011; Sudo et al, 2004; Turnbaugh et al, 2006). 
 
1.3.1 The gut microbiota 
“Bad digestion is the root of all evil” – has been postulated already as early as 400 B. C. by Hippocrates 
(Hawrelak et al, 2004), and underlines the importance of a balanced microbiota composition for an 
healthy organism. Three main factors shape the individual microbiota composition: initial colonization, 
age, and diet (Gill, 2006; Wu et al, 2011). In mammals, the sterile maternal uterus restricts gut colonization 
to the exposure to a complex microflora during delivery. The hygienic conditions at birth and the following 
days (Hanson et al, 1990), the mode of delivery, as well as breastfeeding critically determines the initial 
composition of the microbiota and ensures the formation of a healthy and stable community (Bäckhed et 
al, 2015; Brunel and Gouet, 1993; Guarner and Malagelada, 2003; Human Microbiome Project 
Consortium, 2012; Redondo-Lopez et al, 1990). During the first 4 month of life, the dynamic microbiota 
adapts to dietary changes and then gradually evolves and matures within the first 3 years. The majority 
of bacterial strains colonize during that time and, once acquired, are retained for decades with only 
varying in the relative abundance of each community. Thus, the adult mammalian gut hosts an immensely 
complex and diverse ecosystem within the nine-meter GIT with a surface area of approximately 250 – 400 
m2 (Hawrelak et al, 2004; Sonnenburg et al, 2004). The small intestine, caecum, and large intestine (colon) 
present three distinct microbial habitats that drive a spatial longitudinal heterogeneity by chemical and 
nutrient gradients as well as compartmentalized host immune activity. They are inhabited by 1013 to 1014 
microorganisms (Gill, 2006) with 500 to 1000 species whose microbiome encompass approximately 2 to 
4 million genes (Hooper and Gordon, 2001). These numbers were derived from faecal samples, though, 
and it has recently been suggested that the actual number of species reaches at least 35,000 (Frank et al, 
2007). In rats and mice, similar as in non-human primates and humans, the gut microbiota is dominated 
by the two bacterial phyla of Bacteroidetes and Firmicutes, whereas other phyla present only a minor 
Introduction  35 
 
 
proportion (Fig. 5; Benson et al, 2010; Eckburg et al, 2005; Gu et al, 2013; Ley et al, 2005; Nagpal et al, 
2018). 
 
 
Figure 5. Relative abundance of major gut bacterial phyla in 
mice, rats, non-human primates (NHP), and human subjects. In 
all species, Bacteroidetes and Firmicutes are the dominant 
bacterial phyla. In rodents, Bacteroidetes prevailed Firmicutes 
abundance, while in NHP and humans it remained comparable. 
Other phyla present a minor proportion in gut microbiota 
composition with the highest abundance of Proteobacteria und 
rats and of Actinobacteria in human samples (adapted from 
Nagpal et al, 2018). 
 
 
 
The small intestine contains a low bacterial diversity (Frank et al, 2007), while in the caecum and colon a 
high diversity and density in bacterial communities with distinct nutrient niches can be found (for review 
see Donaldson et al, 2015; Lee et al, 2013; Sekirov et al, 2010). Diet strongly determines microbiota 
composition in the gut. Comparison of American vs. Venezuelan and Malawian (Yatsunenko et al, 2012), 
or European and Burkina Faso populations (De Filippo et al, 2010), reflected culturally-defined differences 
in diet by their microbiota composition. Despite these differences, a core microbiota has been identified 
in nearly half of human subject samples as well as rodents (Benson et al, 2010; Ley et al, 2006; Qin et al, 
2010; Tap et al, 2009) and adult diet-induced changes seem to be fast but dynamic. In mice, a first 
alteration can be observed after 1 to 4 days of dietary change that are mostly reversible (Carmody et al, 
2015). In humans, changes were observable already after 1 day with a fast recovery to the original 
microbiota phenotype 2 days after diet termination (David et al, 2014; Wu et al, 2011). Of note, an impact 
of genetics on gut microbiota composition is discussed controversially (Benson et al, 2010; Carmody et al, 
2015; Goodrich et al, 2016; Khachatryan et al, 2008; Parks et al, 2013; Turnbaugh et al, 2009; Wen et al, 
2008).  
 
Microbiota and the immune system 
Reciprocally, the gut microbiota plays a crucial role for the development and proper functioning of the 
GIT (Stappenbeck et al, 2002) by regulating energy intake, absorption and storage, and utilizing calories 
from otherwise indigestible polysaccharides (Bäckhed et al, 2004, 2007; Carmody et al, 2015; Turnbaugh 
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et al, 2008). Most importantly, it mediates development and fine-tuning of the immune system. The large 
interface between gut epithelium and microbiota allows for countless confrontations with antigens of 
bacteria recognized by several pattern recognition receptors like toll-like receptors (TLRs) or NOD-like 
receptors (NLRs) (reviewed in Creagh and O’Neill, 2006; Wells et al, 2011). TLRs are the primary receptors 
recognizing microbial structures as well as viruses, fungi and protozoans. Upon recognition of a microbe-
associated molecular pattern, TLRs induce the pro-forms of IL-1β and IL-18 and initiate intracellular 
signalling to “prime” the system for an inflammatory response (Creagh and O’Neill, 2006; Guo et al, 2015; 
Kahlenberg et al, 2005; Su et al, 2016). Simultaneously, NLRs detect bacteria and, as part of the 
inflammasome complex like the NLRP3 inflammasome, cleave cytokine pro-forms into their bioactive 
forms (Creagh and O’Neill, 2006; Wells et al, 2011). TLRs are also located on macrophages and microglia 
and detect circulating microbe-associated molecular pattern in the whole body (Dantzer et al, 2008; Su et 
al, 2016). Therefore, the unique GIT immune system integrates information and regulates an appropriate 
homeostasis between immune tolerance and inflammatory reaction (reviewed in Macpherson and Harris, 
2004; Schenk and Mueller, 2008). GF mice provided the first evidence for the impact of microbiota on 
host immunity, presenting – beside impairments in gut functionality - abnormal numbers of immune cells 
and cytokines, as well as deficits in lymphoid structures. Both re-colonization with microbiota from 
healthy mice (Bouskra et al, 2008; Ishikawa et al, 2008; MacPherson and Uhr, 2004; Rook and Stanford, 
1998; Shanahan, 2002) or distinct microbial populations successfully induced immune cell maturation and 
differentiation in GF mice (Christensen et al, 2002; Ivanov et al, 2008; Mazmanian et al, 2005). The crucial 
role of bacteria in immunoregulation is also a cornerstone of the ‘hygiene’, or ‘old friends’ hypothesis, 
stating that a boost in inflammatory diseases nowadays is associated to a failure in immunoregulation. 
This failure is potentially attributed to a lacking exposure to a widespread microbial environment and 
diversity and, thereby, insufficient maturation and differentiation of immune cells. Consequently, this 
leads to a dysregulated pattern of cytokines that potentially promotes susceptibility to inflammatory and, 
thus, mental diseases (Blaser, 2017; Langgartner et al, 2019; Lowry et al, 2016; Rook et al, 2013; Rook and 
Lowry, 2008). 
 
Microbiota perturbation 
The gut microbiota composition is highly susceptible to perturbations during pregnancy as well as early 
postnatal periods. Changes during this particular time can alter HPA-axis responsiveness, impair memory, 
as well as a increase the for disorders like ASD or inflammatory bowel disease (IBD; David et al, 2014; Faith 
et al, 2015; Fischbach and Segre, 2016; Golubeva et al, 2015; Gur et al, 2019; Jasarevic, et al, 2015; 
O’Mahony et al, 2009; Zerbo et al, 2015; Zijlmans et al, 2015). A recent study in the Bangladeshi 
population demonstrated a disturbed and immature microbial composition in young children with 
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moderate or severe acute malnutrition. Food intervention could briefly restore the composition, however, 
long-term effects remain elusive (Subramanian et al, 2014). Moreover, antibiotic treatment during 
bacterial infection strongly affects microbiota. Though beneficial for health, several studies show the 
negative effects of antibiotics on commensal bacteria in both humans (Dethlefsen et al, 2008; De La 
Cochetière et al, 2008) and animals (Croswell et al, 2009; Sekirov et al, 2008). In humans, only 5 days of 
antibiotic treatment decrease microbiota diversity, richness and evenness (Dethlefsen et al, 2008). 
Despite a recovery of the original structure after approximately 4 weeks, some taxa hardly recover even 
within 2 years (Jernberg et al, 2007). In addition, long-lasting side effects like antibiotic-associated 
diarrhoea or prolonged pathogen colonization are demonstrated in both humans (McFarland, 2006) and 
mice (Brandl et al, 2009) with profound effects on the immune system found in the latter (Hill et al, 2010). 
Antibiotic-induced microbiota depletion in mice induces and retains signatures of inflammation even after 
microbiota recovery (Lichtman et al, 2016). Eventually, these long-term effects entail the chance of 
developing numerous somatic and psychiatric disorders irrespective of species (Lurie et al, 2015; for 
review see Sekirov et al, 2008; Ubeda and Pamer, 2012).  
Further, physiological as well as social stress alters microbiota composition and enhances immune activity 
in mice (Bailey et al, 2010, 2012; Langgartner et al, 2017b; Tannock and Savage, 1974). Chronic 
psychosocial and physiological stress increase secretion of pro-inflammatory cytokines in mouse 
mesenteric lymph nodes but decrease immune reactivity in the colon. This is accompanied by a significant 
histological damage of the colon and a spontaneous colitis with aggravated symptoms after a chemical 
challenge, underlining the impact of stress on colon homeostasis and inflammation (Jarillo-Luna et al, 
2007; Reber et al, 2006, 2007, 2008). Importantly, these stress effects seem mediated via a compromised 
intestinal barrier function (termed leaky gut) as a broad-spectrum antibiotic treatment blocks colonic 
inflammation in mice (Reber et al, 2011). Also, rural upbringing acts stress-protective in humans, 
presumably via an environmental microbiota-mediated downregulation of the immune system (Böbel et 
al, 2018). These microbiota-immune system interactions are bidirectional, as an infection modulates 
microbial composition in humans (Khachatryan et al, 2008).  
 
1.3.2 Microbiota -gut-brain axis and its implication in psychiatric disorders 
The gut-brain axis was initially introduced as a concept to describe a complex reflex network that includes 
the CNS, the neuroendocrine and immune system, the sympathetic and parasympathetic arm of the 
autonomic nervous system, and the enteric nervous system. In this multidirectional communication 
network, efferent fibres from the brain, like the vagus and pelvic nerve, induce a top-down physiological 
response through motor, sensory, and secretory aspects of the GIT, smooth muscles, and glands. Also, 
emotions are transmitted from the limbic system, modulating the endocrine system and ANS. Bottom-up 
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signalling from the GIT reaches mainly cortical areas like the cingulate and insular cortex and the amygdala 
to modulate brain functioning (reviewed in Grenham et al, 2011; O’Mahony et al, 2011). The role of 
enteric microbiota, which have been regarded as isolated system without direct influence on body 
function, has only recently been recognized and integrated into this network and its impact on the now 
called microbiota-gut-brain (MGB) axis remains to be studied.  
Communication between the host and gut microbiota can occur via various key routes (Fig. 6). On the one 
hand, microbial changes can be translated into behaviour through the vagus nerve. In line, chronic colitis-
induced anxiety (Bercik et al, 2011b) and anxiolytic and antidepressant effects of the probiotic 
Lactobacillus rhamnosus (Bravo et al, 2011) are absent after vagotomy. Similarly, a subclinical dose of 
pathogenic bacteria induces anxiety-like behaviour in the absence of gut inflammation (Goehler et al, 
2005; Lyte et al, 2006). Gut microbiota can also produce soluble substances like the neurotransmitter 5-
HT or DA and metabolites like short-chain fatty acids (SCFAs; see chapter 1.3.3). These substances 
circulate in the body and alter several systems (O’Mahony et al, 2011, 2015; Sherwin et al, 2016; Stilling 
et al, 2016). Interestingly. microbiota are proposed to modulate tryptophan levels, thereby potentially 
influencing 5-HT signalling (Dinan et al, 2015). Immune-to-brain signalling is another important part of the 
MGB axis. Using the neural, humoral, and the cellular route, inflammatory signals from the periphery are 
able to modulate brain function (see chapter 1.2.1). In the brain, pro-inflammatory cytokines like IL-1 or 
IL-6 can induce the release of corticotropin-releasing hormone (CRH), which in turn activates the HPA-axis 
(Silverman et al, 2005; Webster et al, 1998). Together with an immunological modulation, gut microbiota 
determine HPA axis development while the HPA axis influences gut microbiota composition and intestinal 
barrier function (Kelly et al, 2015b; Sudo et al, 2004).  
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Figure 6. Schematic illustration of the complex and bidirectional communication network comprising 
the microbiota-gut-brain axis. Several lines of communication are active in the microbiota-gut brain axis. 
Neuronal transmission via the vagus nerve and spinal pathways links gut microbiota and the brain. Soluble 
factors like short-chain fatty acids (SCFAs), neurotransmitters, and cytokines produced by immune cells 
and gut microbiota circulate in the blood, eventually reaching and affecting the brain. Peripheral cytokines 
also modulate function of the hypothalamic-pituitary-adrenal axis that in turn affects immune cells 
(adapted from Dinan et al, 2015).  
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Providing a direct causal evidence for the influence of gut microbiota on brain and behaviour has been 
proven difficult. The first landmark study in 2004 demonstrated that in GF mice, the HPA axis reactivity is 
enhanced in response to stress (Clarke et al, 2013; Neufeld et al, 2011; Sudo et al, 2004). The same 
phenomenon is seen in GF rats (Crumeyrolle-Arias et al, 2014), demonstrating the importance of gut 
microbiota in the development of an appropriate stress response. Further, GF mice present a variety of 
behavioural alterations, like decreased anxiety- and depressive-like behaviour (Clarke et al, 2013; Heijtz 
et al, 2011; Luczynski et al, 2016; Zeng et al, 2016; Zheng et al, 2016) and altered social preference 
(Arentsen et al, 2015; Desbonnet et al, 2014). Comparable results are obtained after antibiotic application 
(Bercik et al, 2011a; Desbonnet et al, 2015). Curiously, in GF rats an increase in anxiety-like behaviour was 
observed (Crumeyrolle-Arias et al, 2014). GF mice also show an increased permeability of the BBB 
(Braniste et al, 2014) and changed neurotransmitter signalling as well as brain-derived neurotrophic factor 
expression in the limbic system (Arentsen et al, 2015; Clarke et al, 2013; Matsumoto et al, 2013; Neufeld 
et al, 2011; Sudo et al, 2004). After an immunological challenge, GF mice exert a blunted peripheral 
immune response (Clarke et al, 2013; Erny et al, 2015) and also brain immune function seems impaired. 
They present an immature microglia phenotype but increased microglial numbers and activity in various 
brain regions like the cortex and hippocampus, which can be replicated by antibiotic administration in 
normal mice (Erny et al, 2015). Interestingly, female GF mice show the same behavioural and 
immunological alterations as males but unchanged brain biochemistry (Clarke et al, 2013; Erny et al, 2015; 
Neufeld et al, 2011). Fascinatingly, Bercik and colleagues could show that anxiety-like behaviour can be 
transmitted via microbiota (Bercik et al, 2011a). In this study, microbiota samples are transferred from 
highly anxious NIH Swiss mice to GF BALB/c mice that initially showed normal anxiety-like behaviour, but 
adopt the behavioural phenotype after the transfer. Behavioural abnormalities, as well as a hyperactive 
HPA axis, could be partially reversed by early colonization with microbiota of healthy mice. However, this 
strongly dependent on the time point of application (Clarke et al, 2013; Sudo et al, 2004). In addition, 
impaired microglial functioning and maturity is restored after the application of a mixture of SCFAs (Erny 
et al, 2015), underlining the crucial regulatory role of gut microbiota on MGB axis functioning.  
As GF mice show prominent alterations in both behaviour and physiology, the question arose if similar 
connections are found in the presence of psychiatric disorders. In a rat model of depressive-like 
behaviour, olfactory bulbectomy, rats show increased depressive-like behaviour accompanied by a shift 
in microbial composition (Park et al, 2013). In humans, a strong comorbidity between psychiatric disorders 
and gut-associated diseases is known. In detail, comorbidities of anxiety and depression in patients 
suffering from chronic gut disorders are frequent. 50 to 90 % of patients show symptoms of both and IBD 
patients experience a 3 times higher rate of depression (Fuller-Thomson and Sulman, 2006; Walker et al, 
2008; Whitehead et al, 2002). MDD patients show a distinct alteration in microbial composition together 
with alterations in cytokine levels (Jiang et al, 2015; Kelly et al, 2016). Importantly, upon transplantation 
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of microbiota from depressed patients into microbiota-depleted rats, depressive-like symptoms occurred 
(Kelly et al, 2016), providing evidence for the importance of microbiota in the regulation of behaviour. 
Considering the association between MGB axis functioning and psychiatric disorders, probiotic bacteria 
are proposed as a potential treatment option. In this context, the term ‘psychobiotics’ was coined, 
describing bacteria with beneficial effects on health (Dinan et al, 2013). Preclinical studies show promising 
results of the probiotics Bifidobacterium longum or Lactobacillus rhamnosus on anxiety- and depressive-
like behaviour (Bravo et al, 2011; reviewed in Foster and McVey Neufeld, 2013; Mayer et al, 2015) as well 
as immune function (Desbonnet et al, 2010) and HPA axis activity (Ait-Belgnaoui et al, 2012, 2014) in rats 
and mice. However, in clinical studies the success is rather small. Aside a mixture of both bacteria 
alleviating psychological distress in healthy volunteers (Messaoudi et al, 2011), a meta-analysis of ten 
trials using psychobiotics in psychiatric disorders reveals only a general improvement in well-being (Dinan 
et al, 2013; Romijn and Rucklidge, 2015). Indeed, it was indicated that a stronger manipulation of 
microbiota might be necessary to achieve behavioural alterations in humans. Antimicrobials like 
minocycline (see chapter 1.2.3) might represent a valid alternative. 
 
1.3.3 The short-chain fatty acid butyrate 
SCFAs are monocarboxylic acids that are produced by microbiota. They are the main group of gut 
microbiota metabolites and important messengers in the MGB axis (Roy et al, 2006). Acetate, a C2 body, 
propionate, a C3 body, and butyric acid, a C4 body, occur in an approximate ratio of 60:20:20 in colon and 
faeces (Hallert et al, 2003; Hamer et al, 2008; Mortensen and Clausen, 1996; Topping and Clifton, 2001). 
The chemical structure of butyric acid is dependent on the surrounding pH. In the colon with a pH higher 
than 4.8, butyric acid dissociates almost completely into butyrate and H+ (Fallingborg, 1999; Stilling et al, 
2016). Therefore, in the present thesis it will be referred to as butyrate. Bacteria producing butyrate 
represent a functional rather than a phylogenetic group of gram-positive bacteria that are located almost 
exclusively in the colon. The two most important groups are the Clostridial Cluster IV and XIVa comprising 
Clostridium, Eubacterium, Lachnospiraceae, and multiple others. However, as these bacteria are 
anaerobic in nature, cultivation and identification of them has been proven rather difficult. Therefore, the 
mentioned bacterial cluster might be only a fraction of identifiable genera of butyrate-producing bacteria 
(for review see Louis and Flint, 2009; Pryde et al, 2002). Under physiological conditions, butyrate is 
synthesized almost exclusively by bacterial fermentation and utilized by surrounding bacteria. About 95 
% is rapidly absorbed into adjacent tissue for energy metabolism and the blood stream at micromolar 
concentrations, though, limiting the site of action not only to the GIT (Canani et al, 2011; Duncan et al, 
2009; Pryde et al, 2002). SCFAs utilize different transporters that are expressed on multiple organs 
including the GIT. Moreover, they are expressed on cells of the BBB and on neurons, astrocytes, 
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oligodendrocytes, and microglia in the brain (Bergersen et al, 2002; Cuff et al, 2002; for review see 
Ganapathy et al, 2008; Kim et al, 2014; Lee et al, 2012; Moreira et al, 2009; Vijay and Morris, 2014). High 
levels of butyrate appear to facilitate the production of the structurally related β-hydroxybutyrate (3-OH-
butyrate; Hird and Symons, 1962; Iriki et al, 2009). 3-OH-butyrate is generally synthesized by host cells 
under conditions of ketogenic diet or fasting (Seyfried and Mukherjee, 2005), but also by astrocytes 
(Seyfried et al, 2005), and exploits the same transporters as SCFAs (Vijay and Morris, 2014). At target sites, 
SCFAs and 3-OH-butyrate bind to four different receptors (Kimura et al, 2011; Offermanns and 
Schwaninger, 2015; Singh et al, 2014b; Yonezawa et al, 2013).  
Butyrate plays an essential role as a key regulator of colonic homeostasis and the main source for energy 
metabolism in intestinal epithelial cells, mediating a symbiotic relationship between host and microbiota 
(for review see den Besten et al, 2013; Clausen and Mortensen, 1995). In support, butyrate enhances 
epithelial barrier integrity and its producers are underrepresented in patients with IBD (Frank et al, 2007; 
for review see Galvez et al, 2005; Scheppach and Weiler, 2004). SCFA receptors are also found on 
numerous immune cells and well known for their immunomodulatory function (Kim et al, 2014), like 
suppressing colonic inflammation (Singh et al, 2014b) as well as IL-12 production in monocytes (Säemann 
et al, 2000). Importantly, butyrate was identified as a potent histone deacetylase inhibitor as it was shown 
that sodium butyrate (SB) enhances expression of genes involved in metabolism, cell proliferation, 
migration and differentiation, and considerably more (for review see Bourassa et al, 2016; Canani et al, 
2012; Cavaleri and Bashar, 2018; Li et al, 2012; Stilling et al, 2016). Interestingly, histone deacetylase 
inhibitors have been hypothesized as therapeutic agent in mood disorders based on potent anti-
depressive effects in preclinical studies (reviewed in Machado-Vieira et al, 2011). In recent years, butyrate 
came into focus in neuroscience research due to its versatile character and expression pattern of both 
transporters and receptors, demonstrating a passage into the brain. In the brain, butyrate and 3-OH-
butyrate act neuroprotective and beneficial in learning and memory, and stimulate neurogenesis (Kim et 
al, 2009; for a detailed overview see Stilling et al, 2016; Zou et al, 2009). They exert their anti-
inflammatory properties in the brain also by maintaining a mature microglial phenotype (Erny et al, 2015), 
inhibiting microglial activation or attenuating an overactivation (Fu et al, 2015; Huuskonen et al, 2004; 
Kim et al, 2004; Park et al, 2005), and eventually inducing microglial apoptosis (Chen et al, 2007). Short-
term treatment with SB reduces the time spent immobile in the FST and TST and is able to reverse chronic 
mild stress- and early-life stress-induced depressive-like behaviour in male rats and mice without affecting 
locomotor activity (Han et al, 2014; Resende et al, 2013; Valvassori et al, 2015; Yamawaki et al, 2012). 
Chronic SB treatment also ameliorates innate depressive-like behaviour in Flinders Sensitive Line rats (FSL; 
Wei et al, 2015). In mice, chronic SB administration can reverse physiological as well as social defeat stress-
induced depressive-like behaviour (Han et al, 2014; Tsankova et al, 2006) either alone or in combination 
with fluoxetine (Schroeder et al, 2007).  
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These studies provide evidence for a strong influence of butyrate and 3-OH-butyrate on behaviour in 
rodents. Considering the anti-inflammatory effects of butyrate, an immunomodulatory mechanism for 
behavioural manipulation seems likely. Thus, a well-considered application of butyrate might be a 
potential novel treatment option for psychiatric disorders. 
 
1.4 Stress theory of psychiatric disorders 
1.4.1 Stress and its responsive systems 
The definition of a stressor states it as anything that disrupts the physiological balance of the body, 
independent of whether it is an actual or perceptual disruption, or threat to the intrinsic complex and 
dynamic equilibrium termed homeostasis (Goldstein and McEwen, 2002). Those stressors can be of 
physical or psychological nature, describing external challenges or anticipated disruptions of homeostasis, 
respectively. Therefore, stress describes a state in which homeostasis is threatened and the body adapts 
in behaviour and physiology to re-establish balance (Bartolomucci, 2007; Chrousos, 2009; McEwen, 2004). 
This reaction involves mainly two efficient and highly conserved physiological systems – the sympathetic 
nervous system and the HPA axis. The sympathetic nervous system provides an exclusively neuronal and 
immediate response to stressor exposure within seconds. It comprises neurons originating from the 
thoracolumbar regions of the spinal cord that project to effector organs and chromaffin cells in the 
medulla to trigger the release of adrenaline or noradrenaline (reviewed in Ulrich-Lai and Herman, 2009). 
In contrast, the hormonal driven HPA axis takes minutes to elicit its role. In response to a stressor, CRH 
and arginine vasopressin (AVP) are secreted from parvocellular neurons of the paraventricular nucleus of 
the hypothalamus (PVN) into the portal blood stream to reach the anterior pituitary gland and trigger the 
synthesis of adrenocorticotropic hormone (ACTH). ACTH is released into the peripheral blood stream and 
by stimulating the cortex of the adrenal glands, synthesis and secretion of glucocorticoids (GC) into the 
blood stream is induced. Termination of this response is mediated via a negative feedback loop. GCs can 
cross the BBB and bind to glucocorticoid and mineralocorticoid receptors at different levels like the 
hypothalamus and the hippocampus (Harris et al, 2013; Lupien et al, 2009). Beside those two main 
systems, the immune system is an important mediator during stress as both pro- and anti-inflammatory 
cytokines regulate and are regulated by the stress response (Fig. 7; McEwen, 2008; Sternberg, 2006; 
Turnbell and Rivier, 1999). In more detail, cytokines like IL-1 can enter the brain and initiate CRH release 
in the hypothalamus to activate the HPA axis (Berkenbosch et al, 1987; Sapolsky et al, 1987; Turnbell and 
Rivier, 1999). On the other hand, GC can regulate multiple aspects of the immune response. Thus, GC can 
shift T cells from a pro- to an anti-inflammatory profile (Agarwal and Marshall Jr., 2001) and inhibit LPS-
induced cytokine production in the periphery (Ma et al, 2004) and in the brain (Tanaka et al, 1997). By 
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inhibition of the expression of cell-adhesion molecules, GC also prevent immune cell migration (Pype et 
al, 1999).  
 
 
Figure 7. Schematic illustration of the hypothalamo-pituitary-adrenal (HPA) axis and its effects on the 
immune system. Stressor exposure activates parvocellular neurons in the paraventricular nucleus of the 
hypothalamus that secrete corticotropin-releasing hormone (CRH) into the portal system of the median 
eminence. CRH reaches the anterior pituitary and induces synthesis and secretion of adrenocorticotropic 
hormone (ACTH) into blood vessels for systemic circulation. Upon reaching the inner adrenal cortex, ACTH 
initiates the synthesis and release of glucocorticoids into the blood stream. Cortisol modulates immune 
organs and cells and thus secretion of pro-inflammatory cytokines and their effects on brain functioning. 
Additionally, glucocorticoids act as a negative feedback loop at several levels to terminate the stress 
response and return to homeostasis. In addition, the sympathetic nervous system can activate or inhibit 
peripheral immune function (adapted from Sternberg, 2006). 
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Stress is a condition that accompanies daily life independent of species. Every threat to body homeostasis 
is answered by a stress response, pronounced as increased attention and arousal, energy mobilization, 
and increased cardiovascular and respiratory rates, whereas digestive and reproductive functions are 
inhibited. As the immune system is also inhibited by GCs, it enables the organism to react quickly to any 
change, a condition called “allostasis” (McEwen, 1998, 2008). Keeping this balance increases the chance 
of an individual’s survival. However, if the essentially beneficial acute stress response exceeds a certain 
severity or temporal threshold, meaning it is inadequate, prolonged, or excessive (also called “allostatic 
load or overload”), it has detrimental consequences on behaviour and physiology. These are caused by 
changes in the brain and a resulting impaired ability to appropriately regulate and terminate the stress 
response (for review see de Kloet et al, 2005; McEwen, 2008). Evidently, the stress response is meant to 
be of a limited duration and intensity, the parameters that generally determine the definition of stress. 
Acute stress is described to last minutes to hours whereas chronic stress persists for days or even months 
(Dhabhar, 2000). Further, stress intensity is recognizable in physiological parameters like heart rate, blood 
levels of GC (cortisol in humans and corticosterone in rodents; hereafter CORT) and catecholamines, or 
levels of cytokines. In acute stress, an increase in plasma GC levels after 15-30 min will return to baseline 
after 60 to 120 min (de Kloet et al, 2005). Contrary, in chronic stress a persistent elevation 
(hypercorticism) or reduction (hypocorticism) of CORT is noticed (Albeck et al, 1997; Heim et al, 2000; 
Schmidt et al, 2010b). Interestingly, also unchanged basal plasma CORT levels are found after chronic 
stress (Reber et al, 2007) accompanied by a sensitized reaction to a heterotypic stressor (Uschold-Schmidt 
et al, 2012). In general, the HPA axis adapts to chronic or repeated exposure to a homotypic stressor as a 
protective mechanism of the body from harmful long-term CORT stimulation. These adaptions are found 
on the level of the adrenal gland (Uschold-Schmidt et al, 2012) as well as a compromised negative 
feedback loop of the HPA axis (Aguilera, 1994).  
 
1.4.2 Stress in psychiatric disorders 
Acute and chronic stress have both been accepted as potent risk factors for somatic and mental disorders 
(Langgartner et al, 2019; Lupien et al, 2009; Masis-Calvo et al, 2018; McEwen, 2007). The exposure to a 
stressor, even if only for a short period, can lead to the development of allergic manifestations, migraines, 
hyper- or hypotensive attacks, panic attacks, and psychotic episodes. On the other hand, chronic stress 
has been shown to cause severe somatic and mental diseases like cardiovascular diseases, IBD, anxiety, 
depression, and neuroendocrine and immune dysregulation (Chrousos, 2009; Langgartner et al, 2015). 
Today, most of the challenges humans face on a daily basis are work-related and in a social context. In 
this type of chronic stress, internal believes of worthlessness, performing insufficiently, and competition 
for resources and social rank are combined with stressful social situations (Cohen et al, 2007; Tamashiro 
et al, 2005). Thus, chronic psychosocial stress, the combination of psychological and social stress, 
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represents a potent natural stressor that has been accepted as one of the major risk factors for the 
development of a variety of disorders (Lupien et al, 2009; Masis-Calvo et al, 2018).  
A mechanism common throughout stress-induced diseases is reduced GC signalling. Mice exposed to 
chronic psychosocial stress reliably show a reduced HPA axis activity and a GC insensitivity of adrenals, 
but a hyperactive HPA axis in response to a heterotypic stressor (Langgartner et al, 2015). Further, in a 
model of innate depression and anxiety, rats selectively bred for low- or high anxiety, a pathological 
dexamethasone suppression test is shown (Keck et al, 2002). This phenomenon also visible in MDD 
patients and a sign of a dysregulated negative feedback loop (Holsboer, 2000). Patients suffering from 
stress-related diseases like geriatric depression or fibromyalgia also show hypocorticism (Heim et al, 2000) 
which correlated with the onset of IBD (Reber, 2012). In MDD patients, the most consistently reported 
abnormality is an elevation in plasma cortisol and CSF CRH levels. In addition, they present a blunted stress 
reactivity and an impaired recovery, as well as increased levels of CRH mRNA and protein in limbic brain 
regions (Burke et al, 2005; Dinan and Cryan, 2016; Merali et al, 2004). Interestingly, in vitro and in vivo 
stimulation revealed a reduced GC response in those patients, pointing rather towards a GC resistance 
that is probably caused by reduced receptor expression and / or functionality (Holsboer, 2000; 
Langgartner et al, 2015; Pariante and Miller, 2001). These changes in GC signalling show the significance 
of a balanced stress response to react appropriately to a disruption of homeostasis. Moreover, GC 
resistance and thus reduced CORT signalling potentially leads to a disinhibition of immune function and a 
pro-inflammatory state in patients. GCs are well accepted as modulators of the immune response 
(Dhabhar, 2009; Kadmiel and Cidlowski, 2013; Pruett, 2003) and a GC resistance of certain immune cells 
has been proposed to contribute to chronic stress-induced inflammation in both rodents and humans 
(Foertsch et al, 2017; Miller and Raison, 2016). This inflammatory overactivation or chronic low-grade 
inflammation has been shown several times in both clinical and pre-clinical studies as connected to mental 
disorders (Engler et al, 2017; Eraly et al, 2014; Hodes et al, 2014; Kivimäki et al, 2014; Langgartner et al, 
2015; Rohleder, 2014; Stefanski and Engler, 1998). Importantly, in a landmark study, Hodes and colleagues 
could provide evidence that in mice, psychosocial stress-induced inflammation is causative for the 
development of anxiety- and negative affective-related responses (Hodes et al, 2014). Contrary, IL-6 KO 
mice appear to be resilient to stress (Hodes et al, 2014) and immunomodulation prior to chronic stress 
can act stress-protective (Reber et al, 2016b, 2016a). Given the aforementioned association between 
inflammation and psychiatric disorders (see chapter 1.2.2), an interplay between chronic stress and the 
immune system as underlying pathophysiology of psychiatric disorders seems highly likely.  
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1.5 Rodent models of psychiatric disorders 
Animal models are essential experimental tools to study and potentially unravel the mechanisms 
underlying a particular pathophysiology. In general, three strategies are utilized to develop animal models 
for research in psychiatric disorders: genetic manipulation, selective breeding to obtain a particular 
phenotype, and environmental manipulations that can be combined (reviewed in Neumann et al, 2011; 
Slattery and Cryan, 2014). However, to obtain an appropriate animal model, three basic criteria have to 
be fulfilled - construct, face, and predictive validity. These three aspects state that a valid animal model 
should have the same causative mechanisms and underlying theories (construct validity), a similar 
phenotype (face validity), and a comparable reaction to manipulation (predictive validity) as the human 
disease it should mimic (Cryan et al, 2002; Geyer and Markou, 1995; Slattery and Cryan, 2014). Most 
animal models fulfil at least face and predictive validity. Genetic manipulation is performed mainly in mice 
and an endless number of knockout (KO) lines has been developed and characterized. Those line target 
selected genes potentially involved in anxiety- and depression-related behaviour, and stress-sensitivity 
(for review see Neumann et al, 2011). Selective breeding represents a more natural approach as the 
animal itself is not externally manipulated. Hence, it enables the research of underlying mechanisms of 
idiopathic diseases without the influence of a previous manipulation. Among many others, the FSL rats 
are commonly used as a model for depressive-like behaviour (Overstreet, 1993; Overstreet and Wegener, 
2013). Similarly, rats or mice selectively bred for high (HAB) and low (LAB) anxiety-like behaviour are a 
valid model for anxiety-like behaviour with a concomitant depressive-like phenotype (Landgraf et al, 
2007), to only name two. Utilizing an environmental approach, the chronic subordinate colony housing is 
a mouse model of chronic psychosocial stress that, unlike other stress models, leads specifically to the 
development of anxiety- but not depressive-like behaviour. Therefore, it offers the unique opportunity to 
dissect those two psychiatric disorders and their underlying pathophysiological mechanisms.  
 
1.5.1 Rats selectively bred for high and low anxiety-like behaviour 
An excellent example for successful selective breeding to gain a better insight and reveal neuroendocrine, 
neuronal, and neurogenetic parameters involved in anxiety-related behaviour, are HAB and LAB rats. In 
1993, commercially available Wistar rats were tested for their anxiety-like behaviour on the elevated plus-
maze (EPM) at the age of 9 to 10 weeks and classified according to the percentage of time spent on the 
open arm as HAB (< 10 %) or LAB (> 50 %) rats (Landgraf and Wigger, 2002; Liebsch et al, 1998a). 
Continuous and bidirectional breeding eventually resulted in the HAB and LAB breeding lines. The highly 
anxious phenotype was shown in several behavioural tests like a reduced centre time in the open field 
(Liebsch et al, 1998b), increased time in the dark compartment in the light-dark box (Slattery and 
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Neumann, 2010), less time on the board in the modified hole board test (Ohl et al, 2001) and impaired 
fear extinction in cued fear conditioning (Muigg et al, 2008). The specific phenotype of those lines was 
shown to be stable over years and independent of season (Beiderbeck et al, 2012; Liebsch et al, 1998b; 
Neumann et al, 2010). Furthermore, the phenotype remained unchanged independent of sex (Bosch and 
Neumann, 2008; Landgraf et al, 2007) and age (Landgraf and Wigger, 2002) across several European 
laboratories (Salome et al, 2002; Veenema et al, 2007). Concomitant with high anxiety-related behaviour, 
this breeding line yields other behavioural abnormalities. Compared to LAB rats, HAB rats showed reduced 
locomotor activity in the open field (Liebsch et al, 1998b) an on the EPM but unchanged baseline 
locomotion in the home cage (Liebsch et al, 1998a; Slattery and Neumann, 2010), increased time spent 
floating during the FST, indicative for a depressive-like phenotype, and increased risk assessment (Ohl et 
al, 2001). Further, these two breeding lines differ in social and aggressive behaviour. LAB rats spend less 
time in social contact with cage mates (Ohl et al, 2001), showed impaired abilities in a social discrimination 
task (Landgraf and Wigger, 2002), and even a lack of social preference in the social preference test 
(Beiderbeck et al, 2014). The low anxiety-like phenotype in male LAB rats is also accompanied by abnormal 
levels of aggression (reviewed in Neumann et al, 2010). HAB rats show normal aggressive and social 
behaviour in general. However, during lactation HAB dams display higher levels of maternal aggression 
and maternal care (reviewed in Bosch, 2011). On a physiological level, HAB rats show an altered stress 
reactivity (Liebsch et al, 1998b, 1998a). Thus, a hyper-responsive HPA axis activity potentially caused by a 
hyperdrive of the AVP system (Keck et al, 2002; Landgraf et al, 1999) and a pathological 
dexamethasone/CRH challenge test are observed (Keck et al, 2002). In addition, they show vegetative and 
sleep dysregulations under basal conditions and in response to an acute stressor (Carnevali et al, 2016; 
Landgraf and Wigger, 2002). The exact underlying mechanism remains unclear, however a single a 
nucleotide polymorphism (SNP) located in the AVP promoter region (Murgatroyd et al, 2004) as well as 
increased neuropeptide S functional activity, due to a synonymous SNP in the gene coding for its receptor 
(Slattery et al, 2015), in HAB rats strongly propose a genetic background. As a consequence, HAB rats 
show increased synthesis and release of AVP in several brain regions compared to LAB rats (Bosch et al, 
2006; Bosch and Neumann, 2008, 2010; Keck et al, 2002; Wigger et al, 2004), probably causing the highly 
anxious behaviour. Moreover, in the PVN of HAB rats increased levels of CRH mRNA were found compared 
to LAB rats. An increased HPA axis reactivity is closely connected to psychiatric disorders like anxiety, 
which likely contributes to the behavioural phenotype (Bosch et al, 2006).  
A single injection with the benzodiazepine diazepam is able to reduce the thermal pain threshold and 
alleviate anxiety-like and depressive-like behaviour in HAB rats and enhance time on the open arm in LAB 
rats (Jochum et al, 2007; Liebsch et al, 1998a). When the SSRI paroxetine was administered in a chronic 
regimen, 8 weeks of treatment improved depressive-like behaviour as well as pain sensitivity and 
normalized HPA axis reactivity and AVP mRNA levels in HAB rats (Keck et al, 2003). Another SSRI, 
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citalopram, alleviates the high-anxiety phenotype in HAB rats after the same treatment regimen (Jochum 
et al, 2007).  
The visible differences in behaviour and physiological parameters in HAB rats that are also present in 
patients suffering from anxiety disorders or depression, propose HAB rats as a valid model to study the 
underlying mechanisms for innate anxiety and comorbid depression. Further, since 8 weeks of paroxetine 
treatment were necessary to alleviate symptoms, HAB rats might be a feasible model to study treatment-
resistant diseases. 
 
1.5.2 Chronic subordinate colony housing 
Traditionally, animal models of chronic non-social stress are composed of repeated and/or permanent 
applications of uncontrollable and unpredictable stressors like noise, restraint or forced-swim stress, 
predator cues, shaking, or a combination of these that induce measurable changes on a molecular, 
behavioural and physiological level (Bartolomucci et al, 2005; Willner, 1997). However, these models do 
not mimic a natural stressful situation for an individual, as the majority of disease-promoting stressful 
stimuli in humans are of psychological or social nature. Therefore, animal models for chronic psychosocial 
stress such as submission, social defeat, or social exclusion are of higher clinical relevance. Nowadays, 
several models are commonly used in research like the chronic social defeat stress model during 
adolescence (Schmidt et al, 2007) or during adulthood (Berton et al, 2006), the chronic intermittent social 
defeat/overcrowding model (Reber et al, 2006), or the chronic subordinate colony housing (CSC; Reber et 
al, 2007). Interestingly, even though these models differ in their detailed procedure, like duration and 
frequency of stress, the outcome is largely comparable with high face and predictive validity. All of these 
models primarily result in thymus atrophy, adrenal hypertrophy, HPA axis dysregulation, as well as 
elevated levels of anxiety-related or depressive-like behaviour (Berton et al, 1998; Gruver and Sempowski, 
2008; Heinrichs et al, 1992; Keeney and Hogg, 1999; Reber et al, 2007; Stefanski and Engler, 1999).  
The recently developed CSC paradigm combines psychological and social aspects of stress continuously 
for 24h on 20 consecutive days. This very robust and reliable animal model comprehensively mimics the 
type of health-compromising stressors human face on a daily basis, thereby providing strong construct 
validity. Importantly, the CSC paradigm is based on natural behaviour in mice utilizing the natural drive of 
male mice to establish a hierarchical order within a given colony. The largest male will (usually) emerge 
as dominant and eventually force the other mice into a subordinate position. In the CSC paradigm, four 
experimental mice (CSC mice) are housed together on day 1 with a larger, dominant resident, resulting in 
immediate subordination of the intruder CSC mice. To counteract any possible habituation, CSC mice are 
transferred into the homecage of another dominant resident on day 8 and 15, adding an unpredictable 
Introduction  50 
 
 
and uncontrollable component to the model. The formation of the hierarchical structure normally occurs 
during the first 30 min of the encounter, however a dominant position of the resident is not guaranteed. 
Thus, this critical timeframe is analysed to confirm the subordinate position of each CSC mouse. Resident 
males are trained before CSC housing to avoid extensive aggressive behaviour and harmful attacks 
towards the CSC mice and reliably (>99 % of CSC colonies) obtain the dominant position. This is displayed 
by aggressive attacks, threatening and offensive behaviour towards CSC mice like chasing or mounting. 
CSC mice in turn show an subordinate position by defensive behaviour like submissive upright and flight 
(Reber et al, 2007; Reber and Neumann, 2008a). As appropriate controls, single-housed mice are used 
(SHC; Reber and Neumann, 2008a; Singewald et al, 2009). The CSC procedure promotes the long-lasting 
(at least 8 days after stressor termination; Slattery et al, 2012) development of both somatic and affective 
disorders as well as reduced GC signalling (high face validity), thereby representing a potent model to 
study the underlying mechanisms of relevant stress-induced pathologies.  
In detail, 19 consecutive days of CSC induce several symptoms indicative for chronic stress like altered 
body weight gain, enlarged adrenal glands, pituitary and spleen, as well as decreased thymus weight 
(Reber et al, 2007; Uschold-Schmidt et al, 2012). As reported previously (Choi et al, 2006; Razzoli et al, 
2006, 2011; Zelena et al, 1999), during the CSC procedure, both decreased (Peters et al, 2012; Reber et 
al, 2007, 2008; Reber and Neumann, 2008a; Schmidt et al, 2010a; Singewald et al, 2009) as well as 
unchanged body weight (Füchsl et al, 2014; Slattery et al, 2012; Veenema et al, 2008) are observed. 
Notably, after the CSC procedure, CSC mice gain significantly more weight compared to SHC controls 
(Slattery et al, 2012), proposing a potential compensatory mechanism to ensure sufficient energy supply 
in preparation for subsequent stressful events. Beside changes in body weight, the HPA axis is 
dysregulated in the CSC model, a symptom often seen in patients suffering from MDD or anxiety disorders 
(Faravelli et al, 2012; Lamers et al, 2013). Enlarged adrenal glands are mediated by cell hyperplasia jointly 
with a reduced in vitro responsiveness of adrenal explants to an ACTH challenge. This adrenal insensitivity 
seems not to be restricted to in vitro stimulation of adrenal explants. Though morning basal plasma CORT 
levels remain comparable to those of SHC mice, plasma ACTH levels can be elevated (Reber et al, 2007; 
Uschold-Schmidt et al, 2012; Veenema et al, 2008). Contrary, CSC mice show hypocorticism in the evening 
as they appear to be unable to mount the circadian rise in plasma CORT (Reber et al, 2007). Interestingly, 
CSC mice react to a mild heterotypic stressor (like exposure to an elevated platform) with exaggerated 
plasma CORT levels, while for an increase in ACTH levels the encounter with a strong heterotypic stressor 
like 6 min of forced-swim stress was necessary (Füchsl et al, 2013; Uschold-Schmidt et al, 2012). Likewise, 
an enlarged pituitary is caused by cell hyperplasia and accompanied by the increased capability to produce 
and secrete ACTH (Füchsl et al, 2013). Thus, the HPA axis and GC signalling is dysregulated on several 
levels, though the feedback loop appears to be uncompromised (Füchsl et al, 2013). An exaggerated CORT 
response is nevertheless present after a heterotypic stressor, proposing the activation of an alternative 
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mechanism. Exposure to CSC also results in spontaneous colitis (Langgartner et al, 2017b; Reber et al, 
2007, 2011) and aggravated DSS-induced colitis, indicated by an increase in the histological damage score 
(Reber et al, 2008; Veenema et al, 2008), and colorectal cancer (Peters et al, 2012). Of note, DSS-induced 
colitis is a frequently used model for IBD which is closely associated with chronic stress and mood 
disorders and presents a high comorbidity in humans (Fuller-Thomson and Sulman, 2006; reviewed in Hibi 
et al, 2002; Maunder, 2005). Concomitantly, relative mRNA expression of IL-1β, TNF-α, and IFN-γ is 
increased in the colon (Langgartner et al, 2017b). Also, lamina propria mononuclear and mesenteric lymph 
node cells secrete more cytokines, the colon contains more macrophages, dendritic cells and T helper 
cells, and a splenomegaly is observed (Foertsch et al, 2017; Reber et al, 2007, 2008, 2011). This chronic 
low-grade inflammation after 20 days of CSC is probably mediated by the reduced adrenal sensitivity and 
a GC resistance in certain immune cell subpopulations like splenocytes. As mentioned in chapter 1.4.2, GC 
resistance-induced low-grade inflammation is associated with mental disorders, thus supporting the CSC 
as a valid model for chronic psychosocial stress. In line, the CSC model was shown to induce several 
behavioural phenotypes. Hence, increased ethanol intake already after 14 days of CSC (Peters et al, 2013) 
as well as hyperactivity during the dark phase is observed one week after stressor termination (Slattery 
et al, 2012). Further, the CSC model profoundly and reliably increases general anxiety-related behaviour 
as seen in at least five different behavioural tests. CSC mice show a decreased time in the light box of an 
light-dark box (Peters et al, 2013; Reber and Neumann, 2008a) and reduced percentage of time spent on 
the open arm of an elevated plus-maze (Reber et al, 2007, 2008, 2016b; Reber and Neumann, 2008a), as 
well as reduced time in its distal part during open arm exposure (Singewald et al, 2009). During the open 
field test, CSC mice entered the centre zone and explored a novel object less (Langgartner et al, 2017b; 
Slattery et al, 2012; Veenema et al, 2008) and spent more time in the centre zone of an elevated platform 
(Uschold-Schmidt et al, 2012). CSC exposure does not induce social anxiety but rather a lack of social 
preference that is reversed after 7 days. Importantly, the anxiety-like phenotype is not, in contrast to 
other chronic stress models, accompanied by increased depressive-like behaviour (Slattery et al, 2012). 
Taken together, the CSC model represents a powerful tool to unravel the underlying mechanisms of 
chronic psychosocial stress-induced somatic and affective pathologies, in particular the highly anxious 
phenotype as well as systemic low-grade inflammation (Fig. 8), underlining the translational value.  
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Figure 8. Summary of the main effects of the chronic subordinate colony housing (CSC) paradigm on 
physiological, behavioural, and immunological parameters in male mice. After 20 days of CSC exposure, 
CSC mice show, compared to single-housed controls (SHC), alterations in glucocorticoid (GC) signalling as 
well as affective and somatic alterations. CSC mice develop reduced GC signalling on several levels as well 
as affective and somatic changes. Given that in humans chronic psychosocial stress can lead to somatic 
and affective disorders in combination with reduced GC signalling, the CSC model represents a promising 
tool to mimic stress-related pathologies and unravel the underlying mechanisms (adapted from 
Langgartner et al, 2015). 
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1.6  Aims of the present thesis 
Given the imperfect treatment options in psychiatric disorders with a rate of 30 % non-responders, the 
twice as high prevalence in women compared to men, and a clear involvement of both the inflammatory 
system and the MGB axis as novel treatment approaches, the experiments performed during the present 
thesis aimed to:  
1) Evaluate the effects of chronic treatment with minocycline on depressive- and anxiety-like 
behaviour in HAB and non-selected (NAB) rats in a sex-dependent manner followed by a detailed 
analysis of the underlying systemic mechanisms. 
2) Verify the CSC paradigm in mice and investigate potential beneficial effects of minocycline on 
chronic stress-induced anxiety-like behaviour and other physiological symptoms induced by 
chronic psychosocial stress. 
1.6.1 Evaluation of minocycline in a rat model of innate anxiety and depression 
Advancing research within the last decades paved the way for innovative approaches in the treatment of 
psychiatric disorders. A number of studies provide striking evidence for a regulatory role of gut microbiota 
in the development of the brain and peripheral immune system as well as appropriate behaviour, while a 
dysbiosis in gut microbiota composition has been associated with psychiatric disorders like MDD. At the 
same time, an imbalanced inflammatory system was strongly connected to the development of affective 
diseases. Minocycline showed promising results in the treatment of psychiatric disorders, presumably via 
its anti-inflammatory and bactericidal effects, and produced the first clinical results as augmentation 
treatment. Therefore, 4 main questions emerged:  
i) Can the previously indicated antidepressant and anxiolytic effect of minocycline alone or as 
augmentation to escitalopram ameliorate the behavioural phenotype of HAB rats in 
comparison to NAB rats?  
ii) Are the effects of minocycline comparable in male and female HAB or NAB rats? 
iii) Are HAB rats characterized by alterations in the number of microglia within the PFC, and are 
the behavioural effects of minocycline connected to changes in brain microglia? 
iv) Does the gut microbiota composition differ between HAB and NAB rats and does minocycline 
exert differential effects on their gut microbiome? 
These questions were addressed by treating male and female HAB and NAB rats with minocycline, 
escitalopram, or a combination of both, for 3 weeks. Concomitant with a beneficial behavioural effect, an 
alteration in PFC microglial density and – due to its antibacterial effect – gut microbiota composition was 
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predicted. Aiming to connect peripheral and central systems and support a complex interplay as depicted 
in the MGB axis, peripheral immune responses as well as the gut microbiome and one of its metabolites 
were analysed.  
 
1.6.2 Verification of the CSC paradigm and potential beneficial effects of minocycline 
An essential approach to mimic psychiatric disorders besides selective breeding is environmental 
manipulation. The CSC paradigm, as an animal model of chronic psychosocial stress, induces concomitant 
affective and somatic alterations. The specific induction of anxiety-, but not depressive-like, behaviour 
after CSC exposure offers a unique opportunity to dissect the impact of minocycline on anxiety-like 
behaviour and on innate versus stress-induced parameters. The following research questions emerged in 
this context: 
i) Is the CSC paradigm robust enough and can – as a prerequisite for subsequent experiments – 
be re-established after relocation of the laboratory into a new facility? 
ii) Is treatment with minocycline able to reverse CSC-induced behavioural and physiological 
symptoms? 
To answer these questions, the CSC paradigm was re-established and, subsequently, minocycline was 
administered for 8 days after termination of the CSC paradigm. Following, selected stress-related 
parameters as well as HPA axis functionality were assessed. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Material and Methods 
The Material and Methods include sections taken, and adapted, from one first author publication: Anna 
K. Schmidtner, David A. Slattery, Joachim Gläsner, Andreas Hiergeist, Katharina Gryksa, Victoria Malik, 
Julian Hellmann-Regen, Isabella Heuser, Thomas C. Baghai, André Gessner, Rainer Rupprecht, Barbara Di 
Benedetto, Inga D. Neumann. Minocycline alters behavior, microglia and the gut microbiome in a trait-
anxiety-dependent manner. (In preparation) 
Individual contributions of external authors are indicated in the respective method. 
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2.1 Effects of minocycline, escitalopram, or a combination of both on rats 
The following methods were utilized to assess the influence of minocycline, escitalopram, or a 
combination of both substances on social, anxiety-, and depressive-like behaviour. In addition, the 
influence on the peripheral immune system, the immune system of the brain, and the microbiome were 
analysed. 
 
2.1.1 Animals and husbandry 
Male and female NAB rats were either purchased from Charles River (200 – 250 g; Sulzfeld, Germany) or, 
like all male and female HAB rats, bred at the University of Regensburg. All rats were housed in groups of 
3 – 4 in standard polycarbonate rat cages according to their experimental group (i.e. sex, trait and 
treatment). Criteria for selection as a HAB rat was met if the rat spent < 10 % of time on the open arm of 
an EPM at the age of 9 weeks (Landgraf and Wigger, 2002). Age- and sex-matched rats were used as social 
stimuli in the social preference / avoidance test (SPAT). All rats were housed under standard laboratory 
conditions (12 h light : dark cycle, lights on at 06:00 h, 22 ± 1 °C, 55 ± 5 % humidity) with free access to 
food and tap water (vehicle) or drug solution (minocycline and / or escitalopram) and allowed to habituate 
to room conditions at least 7 days prior to experiments. The experiments were approved by the 
Committee on Animal Health and Care of the local government, and performed according to the Guide 
for the Care and Use of Laboratory Animals of the Government of Oberpfalz, the ARRIVE guidelines 
(Kilkenny et al, 2010), and recommendations from the NIH. All efforts were made to minimize the number 
of animals used and their suffering. 
 
2.1.2 Experimental protocol 
At the age of 11 – 12 weeks, rats were assigned to the respective treatment and the effects of minocycline 
hydrochloride (kindly provided by Charité Berlin), escitalopram oxalate (kindly provided by Lundbeck A/S), 
or a combination of both substances on social, anxiety-, and depressive-like behaviour were evaluated. In 
the first set of experiments, male and female HAB and NAB rats received 40 mg / kg / day minocycline, 10 
mg / kg / day escitalopram, or a combination of both substances with the same concentrations dissolved 
in tap water for 22 days (n = 8 – 16 per group). The doses were chosen based on previous studies (Hinwood 
et al, 2012, 2013; Jayatissa et al, 2006; Liu et al, 2007; Raghavendra et al, 2003). In a second cohort of 
animals, 80 mg / kg /day minocycline, based on a recent study (Amorim et al, 2017), was administered in 
the same fashion exclusively to male and female HAB rats (n = 9 – 10 per group). Body weight and fluid 
consumption were monitored daily to calculate the respective concentrations needed for oral drug 
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administration via drinking water and to prepare fresh solutions daily. On day 15 of treatment, social 
behaviour was tested in SPAT, followed by the evaluation of anxiety-like behaviour in the light-dark box 
(LDB; day 17) and on the EPM on day 19 of treatment. To analyse depressive-like behaviour, the pre-swim 
(day 21) and the FST on day 22 were performed (Fig. 9). The order of tests was chosen to minimize test 
interactions by introducing the least stressful experiment first (SPAT) and the most stressful one last (FST). 
Vaginal smears were taken after the EPM and FST to control for oestrus cycle-dependent effects. 
Immediately after the FST, rats were deeply anesthetized and transcardially perfused. Blood was collected 
from the right atrium, stored in EDTA-coated tubes (Sarstedt, Nürnbrecht, Germany) on ice and 
centrifuged at 5000 rpm for 10 min at 4 °C. Plasma was stored at - 20 °C for determination of cytokine and 
microbiome metabolite concentrations. Liver and fecal boli were collected, snap-frozen using dry ice and 
stored at - 80 °C until measurement of minocycline concentrations with high-pressure liquid 
chromatography (HPLC). Cecal samples were collected from the cecal pouch and frozen on - 80 °C for 
microbiome analysis. All microbial samples were collected carefully under sterile conditions to avoid 
contamination. 
 
 
 
Figure 9. Experimental time course of male and female NAB and HAB rats treated with either vehicle, 
minocycline, escitalopram, or a combination of both, for 22 days in the drinking water. 15 days after 
beginning of the treatment, social preference was tested in the social preference / avoidance test (SPAT), 
followed by the evaluation of anxiety-like behaviour in the light-dark box (LDB) on day 17 and on the 
elevated plus-maze (EPM) on day 19. Depressive-like behaviour was tested on day 21 in the pre-swim and 
analysed on day 22 during the forced-swim test (FST). Afterwards, all rats were deeply anesthetized and 
transcardially perfused. 
 
2.1.3 Behavioural testing 
All behavioural experiments were performed during the day to avoid bias of dark-cycle locomotor activity 
changes (09:00 to 12:00) except the SPAT, which was performed during the socially active phase of rats 
(19:00 to 21:00; Lukas et al, 2011). Behaviour was recorded by an overhead camera and analysed by an 
observer blind to the treatment or via automated scoring using NOLDUS software (Ethovision XT version 
12, NOLDUS information technology, Wageningen, Netherlands). 
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2.1.3.1 Social preference / avoidance test 
The SPAT was conducted using a previously described adapted protocol (Lukas et al, 2011) to test for 
social motivation and interaction. Briefly, during the active phase (1 h after lights off) rats were placed 
into a novel arena (40 x 80 x 40 cm; red light) and granted 30 s of habituation. Afterwards, an empty wire-
mesh cage (non-social stimulus; 20 x 9 x 9 cm) was placed at one short sidewall of the arena for 4 min of 
free exploration. The empty cage was then replaced by an identical one containing an unknown sex- and 
weight-matched conspecific (social stimulus) for an additional 4 min period. Before each trial, the arena 
was cleaned thoroughly with water containing a low concentration of detergent. Each rat was recorded 
and behaviour was analysed using JWatcher behavioural observation software (V 1.0, Macquarie 
University and UCLA). The time spent with active olfactory investigation of the non-social and social 
stimulus (investigation time) was used as an indicator for social preference.  
 
2.1.3.2 Anxiety-like behaviour 
To assess levels of innate non-social anxiety-like behaviour, two different tests were performed: the LDB 
and the EPM. These tests are based on a natural conflict between the animal’s exploratory drive and the 
innate fear of open and lit areas. The more anxious an animal, the less time it spends in exposed, 
potentially threatening areas and vice versa.  
 
2.1.3.2.1 Light-dark box 
The rat LDB was performed as previously described (Slattery and Neumann, 2010; Waldherr and 
Neumann, 2007) to evaluate both anxiety-like behaviour and locomotion. It consists of two 
compartments: a light (40 x 50 cm, 100 Lux) and a dark box (40 x 30 cm, 0 Lux) connected by a small 
opening (7.5 x 7.5 cm) to enable transitions between the compartments. Rats were placed into the light 
box facing away from the opening and recorded for 5 min. The time spent in each box was scored live as 
indicator for anxiety-like behaviour using the plus-maze DOS program (©Ernst Fricke, 1993). As a measure 
of locomotor activity, total distance travelled was assessed using automated scoring.  
 
2.1.3.2.2 Elevated plus-maze 
As the second test for anxiety-related behaviour, rats were tested on the EPM (Pellow and File, 1986; 
Waldherr and Neumann, 2007). Briefly, the 70 cm elevated plus-shaped maze consists of two closed arms 
protected by two walls (50 x 10 x 40 cm; 10 lux) and two open arms (50 x 10 cm; 100 lux), connected by a 
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central neutral zone (10 x 10 cm). Rats were placed into the neutral zone facing one closed arm and 
recorded for 5 min. The percentage time spent on the open arms as an indicator for anxiety and closed 
arm entries as indicator for locomotor activity were analysed live using the plus-maze DOS program. 
 
2.1.3.3 Forced-swim test 
The FST was conducted according to a previously described adapted protocol to assess active vs. passive 
stress-coping with the latter being an indicator of depressive-like behaviour (Cryan et al, 2005; Detke et 
al, 1995; Slattery and Cryan, 2012). Briefly, for the pre-swim, rats were placed into a round plexiglass 
cylinder (21 x 46 cm) filled with water (23-25 °C) to a depth of 30 cm for 15 min, dried, and returned to 
their home cage. After 24 h, rats were replaced into the swim cylinder under the same conditions for 5 
min (FST). Water was changed between each rat and both sessions were recorded for subsequent analysis. 
Using a time sampling technique, the predominant behaviour (struggling, swimming, or immobility) in 
each 5-s period of the FST was rated, providing 60 scores in total per rat. Struggling behaviour was 
characterized as upward-directed movement of the forepaws usually along the side of the cylinder, while 
swimming behaviour was defined as horizontal movement through the swim cylinder including crossing 
into another quadrant. Immobility was expressed as floating with minimal movements to maintain the 
head above the water (Cryan et al, 2005; Detke et al, 1995; Slattery and Cryan, 2012).  
 
2.1.4 Perfusion and brain slicing 
Immediately after the FST, rats were euthanized with CO2 and transcardially perfused at a speed of 20 ml 
/ min using 100 ml 0.01 M phosphate buffered saline (1 x PBS; pH 7.4) and 250 ml 1 x PBS supplemented 
with 4 % paraformaldehyde (Sigma-Aldrich, Schnelldorf, Germany; pH 7.4). Afterwards, brains were 
removed, post-fixed for 24 h in 4 % paraformaldehyde solution, and cryo-protected in 30 % sucrose in 1 x 
PBS at 4 °C. After 3 days, brains were rapidly frozen using 2-methylbutane (Sigma-Aldrich) cooled by dry 
ice. Whole rat brains were cut in 40 µm coronal cryo-sections in series of 6 and stored free-floating in 30 
% ethylene glycol / 30 % glycerol (Sigma-Aldrich) in 1 x PBS at -20 °C until immunofluorescent-
immunohistochemistry was performed.  
 
2.1.5 β-hydroxybutyrate assay 
3-OH-butyrate concentrations (stimulated by microbial butyrate production) in plasma were determined 
with a commercial assay kit (Sigma-Aldrich) in 1 / 10 diluted samples. The enzyme reaction results in a 
Material and Methods  60 
 
 
colorimetric product proportional to the presence of the metabolite 3-OH-butyrate. Lower limit of 
quantification was 4.16 ng / ml. 
 
2.1.6 Luminex ® multiplex cytokine detection 
Performed and validated by Martina Toelge (Microbiomix, Regensburg, Germany) in collaboration with 
Dr. Joachim Gläsner at the Institute of Microbiology (University Hospital Regensburg). 
To quantify IFN-and IL-12 subunit 40 (IL-12p40) concentrations in rat plasma, a rat cytokine multiplex 
bead immunoassay (Invitrogen, Darmstadt, Germany) was used. All required reagents were provided 
with the kit and prepared according to the manufacturer’s protocol. The assay was performed in a 96-
well filter bottom microplate. Beads were protected from light throughout the whole procedure. The 
lyophilized standard was reconstituted in an appropriate volume of assay diluent and 3-fold serially 
diluted to generate a set of 7 standards, while standard diluent alone was used as a blank. The wells of 
the assay microplate were pre-wetted with 200 µl of wash solution for 30 s and then aspirated using a 
vacuum. The concentrated bead mix was diluted 20-fold with wash solution, vortexed, and sonicated for 
1 min (Bandelin Sonorex TK22) just before adding 50 µl of the solution to each well. The microplate was 
washed twice by adding 200 µl of wash solution per well, soaking for 30 s, and aspirating. All wells were 
filled with 50 µl of incubation buffer, and 100 µl of the prepared standard dilutions were added to the 
appropriate wells. 50 µl of assay diluent were added to each sample well followed by the addition of 
50 µl of the sample (pre-diluted in assay diluent if applicable). The microplate was covered and incubated 
overnight at 4°C on an orbital shaker (600 rpm). Following incubation, the liquid was aspirated and the 
microplate was washed twice. Then, 100 µl of biotinylated detection antibody (10-fold diluted in biotin 
dilution buffer) were added, the microplate was covered, and incubated for 1 h at room temperature 
(RT) with shaking. After washing twice again, 100 µl of R-phycoerythrin-conjugated streptavidin (10-fold 
diluted in streptavidin dilution buffer) were added, the microplate was covered, and incubated (30 min, 
RT) with shaking. After washing again 3 x 2 – 3 min, each well was filled with 110 µl of wash solution to 
suspend the beads. The microplate was covered and placed on an orbital shaker at RT until analysis. 
Acquisition of raw data was performed by the Luminex xMAP 100 system (Luminex, Austin, TX, USA). The 
software was set to acquire data using 75 µl of sample per well and count 100 events per single bead set. 
Raw data was captured as mean fluorescence intensity (MFI), and the concentration of each analyte in 
the samples was calculated based on 4- or 5-parameter logistic fit standard curves using the LiquiChip 
Analyzer software (Qiagen, Hilden, Germany). The lower limit of quantification was 2 pg / ml (IFN-γ) and 
10 pg / ml (IL-12p40), respectively. 
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2.1.7 Minocycline tissue extraction and high-pressure liquid chromatography analysis 
Performed by Julian Hellmann-Regen at the Department of Psychiatry, Section Clinical Neurobiology 
(Campus Benjamin Franklin, Charité Berlin). 
A sensitive and specific HPLC method was developed and optimized for detection and rapid resolution of 
minocycline isolated from rat liver tissue and fecal boli. The method was specifically optimized for the 
detection of rather low tissue levels of minocycline in order to be able to quantify minocycline 
concentrations following oral ingestion. Samples were homogenized in calcium-free PBS at a ratio of 1:5 
(w / v) by 30 strokes in glass-PTFE potter homogenizers. To facilitate extraction of minocycline from the 
tissue and promote adherence to solid phase columns, all homogenates were subsequently acidified by 
adding 0.02 vol of orthophosphoric acid (85%, w / v). After centrifugation (1000 x g, 5 min, 4 °C), 1 ml of 
the resulting supernatant was loaded onto a 30 mg HLB Oasis column (Waters, Milford MA, USA), that 
was preconditioned by serially rinsing with 3 ml methanol and 3 ml ultrapure water. After loading, 
columns were washed three times with 1 ml 5% Methanol in ultrapure water, and finally eluted slowly at 
atmospheric pressure in 1 ml methanol. After elution, samples were placed under a gentle stream of argon 
and evaporated to dryness in a heat block at 50 °C. After evaporation, the residues were reconstituted in 
200 µl of HPLC mobile phase. Following a brief centrifugation (5 min, 15.000 x g), samples were injected 
directly onto a C8 Inertsil column, 5 µm, 4.6 x 250 mm, protected by a C8 guard column (GL Sciences, 
Tokyo, Japan). HPLC analysis was performed using a Shimadzu 10-series system with a binary pump, 
isocratic elution at 1.4 ml / min and UV detection at 350 nm. The mobile phase contained acetonitrile-
methanol-ultrapure water-acetic acid (2.5:10:85:2.5, v / v). The HPLC assay showed linearity in the range 
of 0.05-50 µg / ml. Within a total run time of only 12 min, minocycline was resolved after 3.8 min, not 
affected by endogenous substances, and the last endogenous peak occurred at 7.5 minutes. The limit of 
quantitation was 50 ng / ml. Recovery from liver homogenates and fecal boli averaged 95% as compared 
with compound diluted directly in mobile phase. Intra- and inter-assay coefficient of variation averaged 
about 5 % and 10 % at 5 µg / ml. All chemicals were purchased from Sigma-Aldrich.  
 
2.1.8 Analysis of microglia 
Carried out in collaboration with PD Dr. Barbara Di Benedetto and Dr. Victoria A. Malik at the Institute 
of Psychiatry and Psychotherapy (University Hospital Regensburg). 
2.1.8.1 Immunofluorescent-immunohistochemistry 
Three coronal sections from the infralimbic and prelimbic PFC of male and female HAB and NAB rats (AP 
+ 2.76 - 4.3 mm from bregma) were selected and washed 3 x 20 min in 1 x PBS to remove the storage 
solution. Then, all slices were blocked for 1 h at RT in 1 x PBS supplemented with 2 % normal goat serum 
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(Vector Labs, USA) and 0.1 % Triton-X 100 (Sigma-Aldrich), followed by incubation with the primary 
antibody rabbit anti-Iba-1 (1:1000, WAKO, Japan) in the same solution at 4 °C over night. After washing 3 
x 10 min with 1 x PBS, slices were incubated for 2 h at RT with the corresponding secondary antibody anti-
rabbit Alexa Fluor 488 (1:1000, Invitrogen) and DAPI (1:1000, Sigma-Aldrich) in 1 x PBS containing 2 % 
normal goat serum. Slices were again rinsed 3 x 10 min with 1 x PBS and mounted with Aqua-Poly/Mount 
(Polysciences, USA) for confocal analysis. 
 
2.1.8.2 Confocal microscopy and quantification of microglia cells  
Confocal microscopy was performed with an Olympus confocal microscope (inverted type IX81, Olympus 
Europe Holding GmbH, Hamburg, Germany). For each treatment condition, 6 brains were analysed with 
an average of 5 images (20 optical sections, 1 µm Z-step size) per rat. Pictures were taken randomly from 
the prelimbic / infralimbic regions of the PFC of at least two coronal sections per brain (see Fig. 16 for 
location of the infralimbic and prelimbic PFC). Using the “cell counter” plugin from ImageJ (NIMH, 
Bethesda, MD, USA), total numbers of total cells (DAPI+) and Iba-1-positive (Iba+) cells in each field were 
separately quantified. Percentage of microglia cells were calculated by normalizing total counts of Iba+ 
cells on DAPI+ cells per picture, to account for potential differences in cell densities due to perfusion-
dependent tissue shrinkages, and averaged per each brain. 
 
2.1.9 Analysis of intestinal microbiome by 16S-rDNA pyrosequencing 
Performed by Dr. Joachim Gläsner and Dr. Andreas Hiergeist at the Institute of Microbiology (University 
Hospital Regensburg). 
2.1.9.1 Isolation of DNA from stool specimen 
Cecum content was collected from male HAB and NAB rats, immediately cooled on dry ice and stored 
without any preservative at - 80 °C until processing. After thawing, samples (100 mg wet weight each) 
were mixed with a pool of three spike bacteria (Salinibacter ruber, Rhizobium radiobacter, Alicyclobacillus 
acidiphilus) containing a defined number of 16S-rDNA copies. Cells were lysed by exposure to S.T.A.R. 
Buffer (Roche, Mannheim, Germany) / proteinase K, five cycles of freezing in liquid nitrogen and boiling, 
and repeated bead beating in the TissueLyser II (Qiagen). DNA purification was performed with the 
MagNA Pure 96 instrument (Roche) using the MagNA Pure 96 DNA and Viral NA Large Volume Kit (Roche). 
Total nucleic acids and dsDNA was quantified using the NanoDrop 1000 spectrophotometer 
(ThermoFisher Scientific) and the dsDNA-specific Quant-iT PicoGreen reagent (Invitrogen) in a VICTOR3 
fluorescence reader (PerkinElmer, Waltham, MA, USA), respectively. 
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2.1.9.2 Quantification of 16S-rDNA copies  
In the isolated DNA, 16S-rRNA gene copy numbers of total bacteria were determined by quantitative 
polymerase chain reaction (PCR) on a LightCycler 480 II Instrument (Roche, Basel, Switzerland). PCR 
reactions included 1 μM each of universal eubacterial 16S-rRNA gene primers 764F and 907R and the 
LightCycler 480 SYBR Green I Master kit (Roche). Quantification standards were generated by cloning a 
complex PCR amplicon mixture derived from a cecal microbiome DNA preparation into the pGEM-T.Easy 
vector (Promega, Madison, WI, USA). qPCRs were performed over 40 cycles (95 °C for 10s, 60 °C for 15 s 
and 72 °C for 15 s) with an initial 10-min hot start at 95 °C. To identify errors in DNA isolation before 
amplification and pyrosequencing, additional spike bacteria-specific qPCRs were performed (data not 
shown, primers and probes are specified in Table 1). 
 
Table 1. Primers used for quantification of 16S-rDNA copy numbers by qPCR and for pyrosequencing. 
Name DNA sequence (5’ - 3’) Escherichia 
coli 16S-rDNA 
nucleotide 
position 
Purpose of use Reference 
764F CAAACAGGATTAGATACCC 764 Quantification of 
total 16S-rDNA 
copies 
(Imase et al, 
2008) 
907R CCGTCAATTCCTTTRAGTTT 907 Quantification of 
total 16S-rDNA 
copies 
(Lane, 1991) 
341F CCATCTCATCCCTGCGTGTCTCCGACTCAG
<MID>CCTACGGGAGGCAGCAG 
341 Pyrosequencing 
and total 16S 
quantification 
standards 
(Klindworth et 
al, 2013) 
1061R CCTATCCCCTGTGTGCCTTGGCAGTCTCAG
CRRCACGAGCTGACGAC 
1061 Pyrosequencing 
and total 16S 
quantification 
standards 
(Klindworth et 
al, 2013) 
Aacidi-
238TM 
6FAM-
AGCTAGTTGGTGAGGTAACGGCCCACC-
BBQ 
238 Quantification of 
16S-rDNA copies 
of Alicyclobacillus 
acidiphilus 
(Stämmler et al, 
2016) 
Aacidi-
193F 
GAGGAAAGTTGCAAATGCAACA 193 Quantification of 
16S-rDNA copies 
of Alicyclobacillus 
acidiphilus 
(Stämmler et al, 
2016) 
Aacidi-
453R 
aggagctttccactctccttat 453 Quantification of 
16S-rDNA copies 
of A. acidiphilus 
(Stämmler et al, 
2016) 
Rradio-
166TM 
LC670-AATTAATACCGCATACGCCCTACG-
BBQ 
166 Quantification of 
16S-rDNA copies 
(Stämmler et al, 
2016) 
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of Rhizobium 
radiobacter 
Rradio-
126-F2 
GGAACATACCCTTTCCTGCGG 126 Quantification of 
16S-rDNA copies 
of Rhizobium 
radiobacter 
(Stämmler et al, 
2016) 
Rradio-
197-R2 
GCCAATCCTTCCCCGATAAATC 197 Quantification of 
16S-rDNA copies 
of Rhizobium 
radiobacter 
(Stämmler et al, 
2016) 
Salini-
180TM 
LC640-CACGTCGTCTGGATCCCGCATG-
BBQ 
180 Quantification of 
16S-rDNA copies 
of Salinibacter 
ruber 
(Stämmler et al, 
2016) 
Salini-
7F 
AGAGTTTGATCATGGCTCAG 7 Quantification of 
16S-rDNA copies 
of Salinibacter 
ruber 
(Stämmler et al, 
2016) 
Salini-
413R 
TACGCCCCATAGGGGTGT 413 Quantification of 
16S-rDNA copies 
of Salinibacter 
ruber 
(Antón et al, 
2002) 
 
 
2.1.9.3 Amplification of V3-V6 16S-rDNA variable region and 454 pyrosequencing 
Extracted DNA underwent partial 16S-rRNA gene amplification by PCR using the forward primer 341F 
containing a 10-bp multiplex identifier (MID) sequence, and the reverse primer 1061R. A total of 10 ng 
dsDNA was used as a template to amplify the hypervariable regions V3 through V6 of the 16S-rRNA gene. 
PCR was performed in a final volume of 30 μl containing 0.12 μM of each primer, 2 mM MgCl2, and 1 U 
Platinum Taq DNA Polymerase (Invitrogen). The PCR amplification was carried out over 30 cycles (30 s at 
95 °C, 45 s at 64 °C, 45 s at 72 °C) with an initial 5-min hot start at 95 °C and a final extension step (7 min 
at 72 °C). The resulting 790-bp amplicons were recovered from gels using the QIAquick Gel Extraction kit 
(Qiagen) and further purified with Agencourt AMPure XP beads (Beckman Coulter, Krefeld, Germany). 
Copy numbers of amplicons suited for pyrosequencing, i. e., containing Lib-L-adaptors, were determined 
using the KAPA Library Quant 454 Titanium / Lib-L Universal Kit (KAPA Biosystems, Wilmington, DE, USA). 
For DNA library preparation, equimolar concentrations of 1 x 106 adaptor-labeled amplicon molecules / 
µl for each sample were pooled. This library was re-amplified by emulsion PCR using the GS FLX Titanium 
LV emPCR kit (Lib-L) applying 0.4 copies per bead and sequenced on a GS FLX+ instrument (454 / Roche) 
with the GS FLX Titanium Sequencing Kit XL+ using an acyclic flow pattern (Flow Pattern B). 
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2.1.9.4 16S-rRNA gene sequence processing and operational taxonomic unit clustering 
Raw sequencing data was pre-processed with the GS Run Processor v2.9 application (Roche) to remove 
adapter sequences and low quality reads. Quality filtering was performed by the default “Long Amplicons 
3 pipeline” resulting in 917 Mb from 1,398,617 passed filter wells with a median read length of 677 bases. 
A combination of QIIME (v1.9.1; Caporaso et al, 2010) and R (version 3.4.0; R Core Team, 2017) with 
installed Bioconductor package (Huber et al, 2015) was used to further process and analyse the sequence 
data. Reads were de-multiplexed and filtered for quality using QIIME’s split_libraries.py script with default 
parameters except minimum and maximum read length, which were set to 400 bp and 800 bp, 
respectively. This read length threshold covered 99.99% of all sequencing reads. The filtered reads were 
mapped to operational taxonomic unit (OUT)s built on the SILVA database (release 128; Quast et al, 2013) 
using QIIME’s pick_closed_reference_otus.py script with default parameters. The reference database 
OTUs used here constituted computationally built clusters of the SILVA SSU ribosomal RNA database. The 
clustering into OTUs at a 97% identity threshold and the classification were achieved by UCLUST 1.2.21 
(Edgar, 2010). Raw sequencing data has been deposited in the European Nucleotide Archive 
(http://www.ebi.ac.uk/ena/data/view/PRJEB30124). 
 
2.1.9.5 Microbial composition and community structure analysis 
Classified reads were grouped by taxonomy to generate box plots, showing relative abundances on each 
taxonomic level. Microbial diversity within a single sample (i. e., number and evenness of taxa; syn.: alpha-
diversity) and the diversity between samples (syn.: beta-diversity, characterized by a Bray-Curtis 
dissimilarity matrix) were calculated and plotted with the vegan 2.4-1 package of R. Taxa box plots were 
generated using the ggplot2 package within R.  
2.1.10 Statistical analysis 
Carried out in cooperation with Dr. Andreas Hiergeist at the Institute of Microbiology (University 
Hospital of Regensburg). 
For statistical comparisons of behaviour, immunological parameters, and plasma 3-OH-butyrate levels the 
software package SPSS (version 12) was used. Behavioural data and 3-OH-butyrate levels were compared 
using either a two-tailed Student’s T-test, one-way analysis of variance (ANOVA; factor treatment), two-
way ANOVA (factors trait x treatment) or two-way ANOVA for repeated measures (factors trait x 
treatment x stimulus) followed by a post hoc test using Bonferroni correction for multiple comparisons 
when appropriate. For analysis of cytokine concentrations, a non-parametric Mann-Whitney U test was 
applied (for detailed statistical analysis see respective statistics tables and graph descriptions). Data are 
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presented as mean + SEM. For microbiome data, the Shannon indices of diversity, observed OTU numbers, 
16S-rDNA copy numbers, and relative abundances of bacterial taxa were analysed in R by ANOVA with a 
subsequent Tukey’s test. Bray-Curtis distances as depicted in the principal coordinates analysis (PCoA) 
plot were analysed in R by pairwise multilevel comparison using the vegan package in R followed by a 
Bonferroni correction. Correlations between bacterial families and plasma butyrate were calculated using 
Spearman’s correlation coefficients in GraphPad Prism (GraphPad software version 6.0, San Diego, 
California, USA). Significance was accepted at p ≤ 0.05. 
 
2.2 CSC studies 
To assess effects of minocycline on stress-induced behavioural and physiological alterations as well as 
specify its effects on anxiety-like behaviour, the CSC paradigm was first validated in the new behavioural 
laboratories. In a second cohort of mice, minocycline was administered subchronically for 8 days after 
stressor termination.  
 
2.2.1 Animals and husbandry 
Male C57BL/6N (hereafter BL6 mice; 20 – 22 g; purchased from Charles River) and CD1 mice (30 – 32 g; 
Breeding colony University Hospital Regensburg; used as dominant residents) were single-housed in 
standard polycarbonate mouse cages (BL6 mice) or polycarbonate observation cages (38 x 22 x 35 cm; 
CD1 residents) upon arrival. All animals were housed under standard laboratory conditions (12 h light – 
12 h dark, lights on at 07:00 h, 22 ± 1 °C, 55 ± 5 % humidity, free access to food and tap water (vehicle) or 
drug solution (minocycline)) and allowed to habituate at least 7 days to room conditions prior to 
experiments. The experiments were approved by the Committee on Animal Health and Care of the local 
government, and performed according to the Guide for the Care and Use of Laboratory Animals of the 
Government of Oberpfalz, the ARRIVE guidelines (Kilkenny et al, 2010), and recommendations from the 
NIH. All efforts were made to minimize the number of animals used as well as their suffering. 
 
2.2.2 Experimental protocols 
As the department moved to a new facility, characteristic parameters of the CSC paradigm had to be 
confirmed a priori. Thus, BL6 mice (n = 14 – 17 per group) were exposed to the CSC paradigm, tested for 
anxiety-like behaviour in the LDB (day 19) and on the EPM (day 20; Fig. 10A), and subsequently rapidly 
decapitated for sample collection (see below).  
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To evaluate a possible role of minocycline in stress-induced physiological and behavioural alterations, a 
second cohort of BL6 mice was exposed to the CSC paradigm. On day 20, SHC and CSC mice were injected 
intraperitoneal (i.p.; 5 ml / kg) with either 0.9 % saline (Braun, Melsungen, Germany) or 80 mg / kg 
minocycline dissolved in saline, single-housed, and tested in the LDB after 60 min (n = 12 – 14). For the 
following 7 days (day 21 to 28), mice were treated continuously either with the same dose of minocycline 
dissolved in tap water or tap water as vehicle. Body weight and fluid consumption were measured on a 
daily basis to calculate accurate concentrations for fresh drug solutions and oral administration via 
drinking water. On day 7 of treatment, mice were tested again for anxiety-like behaviour in the open field 
/ novel object recognition test (OF / NOR), followed by the mouse FST on day 8 (see Fig. 10B). The order 
of tests was chosen to minimize test interactions by introducing the least stressful experiment first (OF / 
NOR) and the most stressful one last (FST). Afterwards, mice were rapidly decapitated and trunk blood 
was collected identical as in rats for analysis of plasma ACTH and CORT levels. Left and right adrenal 
glands, thymus, and spleen were removed, pruned from fat and weighed separately. Adrenal glands were 
stored in ice-cold 1 x PBS for subsequent in vitro stimulation with either saline or ACTH (see chapter 2.2.5). 
Of note, thymus as well as adrenals were not collected and stimulated in all animals due to operational 
errors.  
 
 
Figure 10. Experimental time course of the chronic subordinate colony housing (CSC) paradigm for 20 
days with or without acute and subchronic minocycline treatment. Upon arrival, mice were single-
housed for one week and then assigned as either single-housed controls (SHC) or CSC mice. In order to 
induce chronic psychosocial stress, CSC mice were housed together with a larger, dominant resident for 
20 consecutive days. In detail, four CSC mice were placed into the homecage of a dominant resident on 
day 1 of the CSC procedure for the following 7 days. On day 8 and again on day 15 of CSC, the four CSC 
mice were transferred into the homecage of another unfamiliar resident to avoid habituation. For 
confirmation of a valid CSC model, CSC and SHC mice were tested in the light-dark box (LDB) and elevated 
plus-maze (EPM) on day 19 and 20, respectively. After the EPM, mice were rapidly decapitated to assess 
stress-induced physiological parameters (A). In order to evaluate the effects of minocycline on CSC-
induced parameters, a second cohort of mice was injected acutely with minocycline after 20 days of CSC 
and tested in LDB 1 h later. A subchronic treatment was continued for 7 days with evaluation of anxiety-
like behaviour on day 27 in the open field / novel object recognition test (OF / NOR) and depressive-like 
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behaviour in the forced-swim test (FST) on day 28, followed by rapid decapitation and analysis of 
physiological and neuroendocrine parameters (B). Illustration of social defeat adapted from Melanie 
Royer©, 2019. 
 
2.2.3 Chronic subordinate colony housing paradigm 
As described before (Langgartner et al, 2015; Reber et al, 2007), one week after arrival, BL6 mice were 
randomly assigned as SHC or CSC mice in a weight-matched manner. Four CSC mice were housed together 
with a dominant male CD1 resident in its home cage for 20 consecutive days to induce chronic 
psychosocial stress. To avoid habituation to the stressful situation, the dominant resident was replaced 
on day 8 and day 15 by an unfamiliar resident. Referring to previous studies demonstrating group-housing 
to be stressful in male mice per se (Singewald et al, 2009), SHC mice were used as appropriate control 
group. SHC mice remained undisturbed in their home cage except for change of bedding and weighing on 
day 8 and 15. On day 19 and / or 20, anxiety-like behaviour was analysed followed by analysis of 
physiological and neuroendocrine parameters. 
 
2.2.4 Behavioural testing 
All behavioural experiments were conducted during the day to avoid bias of dark-cycle locomotor activity 
changes (09:00 to 12:00). Behaviour was recorded by an overhead camera and analysed by an observer 
blind to the treatment or via automated scoring using NOLDUS software. 
 
2.2.4.1 Anxiety-like behaviour 
To assess levels of innate non-social anxiety-like behaviour, three different tests were performed: the 
LDB, the EPM, and the OF / NOR. These tests are based on a natural conflict between the animal’s 
exploratory drive and the innate fear of open, lit areas and novel objects. The more anxious an animal, 
the less time it spends in exposed, potentially threatening areas and in contact with an unknown object, 
and vice versa.  
 
2.2.4.1.1 Light-dark box 
As previously described (Costall et al, 1989; Reber and Neumann, 2008b), the mouse LDB consists of two 
compartments: a light (27 x 27 x 27 cm, 300 lux) and a dark box (18 x 27 x 27 cm, 50 lux), separated by a 
partition wall with a small opening (6 x 7 cm) to allow transitions. Initially, the opening was closed and 
mice were placed into the dark box for a 30 s habituation period. Afterwards, mice were allowed to 
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explore the whole LDB freely for 5 min. Using NOLDUS software, time spent in each compartment 
indicating anxiety-like behaviour and distance travelled as a measure of locomotor activity were 
automatically analysed.  
 
2.2.4.1.2 Elevated plus-maze 
The mouse EPM, as previously described (Reber et al, 2007), consists of two open (6 x 30 cm; 100 Lux) 
and two closed (6 x 30 x 16 cm; 25 Lux) arms connected by a neutral platform (6 x 6 cm) that are elevated 
35 cm above the ground. The mouse was placed into the neutral zone facing a closed arm and recorded 
for 5 min. The percentage time spent on the open arms was analysed live using the plus-maze DOS 
program as an indicator for anxiety-like behaviour. Closed arm entries were used as an indicator for 
locomotor activity.  
 
2.2.4.1.3 Open field / novel object recognition test 
In the OF / NOR, conducted as previously described (Langgartner et al, 2017b), each mouse was placed in 
the centre of an open field box (40 x 40 x 38.5 cm; 300 lux) and allowed to explore freely for 5 min. 
Afterwards, an unknown object (metal cylinder; 3.5 cm in diameter, 1.5 cm in height) was placed in the 
centre of the box for 5 additional min of exploration. Using NOLDUS software, time spent in the centre 
(20 x 20 cm) and time spent exploring the novel object were measured as an indicator for anxiety-like 
behaviour. Distance moved during the 10 min of testing was used as a parameter for locomotor activity.  
 
2.2.4.2 Forced-swim test 
The mouse FST was performed according to a previous protocol (Porsolt et al, 1977; Slattery et al, 2012). 
Briefly, mice were placed into a small plexiglass cylinder (12 cm in diameter, 40 cm in height) filled with 
23 ± 2 °C water up to 13 cm for 6 min. The duration of immobility during the last 4 min was analysed using 
JWatcher behavioural observation software. A mouse was considered immobile when floating motionless 
except for movements necessary to keep its head above the water. 
 
2.2.5 ACTH stimulation of adrenal explants in vitro 
Following CSC and 8 days of minocycline administration, stimulation of in vitro adrenal explants with ACTH 
was performed as previously described (Füchsl et al, 2014; Peters et al, 2014; Uschold-Schmidt et al, 
2012). After pruning left and right adrenals from fat, adrenals were cut in two halves each containing 
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cortical and medullary tissue. Both halves were weighed and pre-incubated in 200 ml Dulbecco’s Modified 
Eagle’s Medium F-12 (Sigma-Aldrich) supplemented with 0.1 % bovine serum albumin (Sigma-Aldrich) at 
37 °C and 5 % CO2. After 4 h, the medium was replaced and each half of one adrenal was supplemented 
with either 0.9 % saline (basal; Braun) or 0.9 % ACTH (Sigma-Aldrich) dissolved in saline (100 nM) for 6 h 
at identical conditions. The supernatant was carefully removed and stored at - 20°C until analysis with an 
enzyme-linked immunosorbent assay (ELISA) for CORT. CORT concentrations were calculated in relation 
to the weight of the respective adrenal explants. 
 
2.2.6 ELISA for CORT and ACTH 
Plasma samples and supernatant from adrenal in vitro stimulation were analysed using a commercially 
available ELISA for CORT (analytical sensitivity < 1.631 nmol / l; intra-assay and inter-assay coefficients of 
variation ≤ 6.35 %; IBL International, Hamburg, Germany) or ACTH (plasma samples only; analytical 
sensitivity 0.22 pg / ml, intra-assay and inter-assay coefficients of variation ≤ 7.1 %; IBL International). 
Plasma CORT and ACTH concentrations were calculated as percentage in relation to vehicle treated SHC 
mice.  
 
2.2.7 Statistical analysis 
For statistical comparisons the software package SPSS (version 12) was used. Validation of the CSC 
paradigm was statistically analysed using two-tailed Student’s t-tests. Experiments involving minocycline 
treatment following the CSC paradigm were statistically compared using a two-way ANOVA (factors stress 
x treatment) followed by a post hoc test using Bonferroni correction for multiple comparisons when 
appropriate. Data are presented as mean + SEM, significance was accepted at p ≤ 0.05.
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3.1 Effects of minocycline, escitalopram, and the combination on behaviour 
and the immune system in rats 
Psychiatric disorders show a strong gender bias and an unsuccessful treatment in 30 % of all cases. Several 
studies propose a manipulation of the inflammatory system and the gut microbiome as promising novel 
treatment target. Thus, in the present study, the effects of minocycline on an model of innate comorbid 
anxiety- and depressive-like behaviour were evaluated in a broader range of behavioural experiments, 
including the SPT, LDB, EPM, and FST in a sex-dependent manner (see chapter 2.1.2 for experimental 
details). Escitalopram is currently viewed as gold standard of available antidepressants and was used as 
positive control. Since minocycline is generally applied as augmentation of a conventional antidepressant 
in clinical studies, it was used to determine the capacity of minocycline as an adjunctive agent. In all 
analyses, an influence of the female cycle could not be detected in keeping with recent meta-analyses (for 
review see Beery, 2018). Importantly, the drinking behaviour of male (Fig. 11A) and female (Fig. 11B) HAB 
and NAB (Fig. 11C & D) rats differed only marginal over time and between treatment groups, except for 
NAB females that drank less drug solution. A statistical comparison was not conducted as fluid intake was 
measured on average per cage, causing a very low n number. The drug concentration was calculated daily 
according to the body weight and drunk volume. Thus, the treatment regimen of minocycline and 
escitalopram was assumed stable and rats received the appropriate concentration of the respective drug. 
Behavioural testing on the respective days did not alter fluid intake on the following days (indicated by 
arrows in Fig. 11).  
 
 
 
Figure 11. Average drinking volume of male and female HAB and NAB rats treated with either vehicle 
(Veh), minocycline (Min), escitalopram (Esc), or a combination of both (Min+Esc) on the first two 
treatment days and during behavioural testing (day 14 -22). Male (A) and female (B) HAB rats and male 
NAB rats (C) showed comparable fluid intake over 22 days independent of treatment and behavioural 
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testing. Female NAB rats (D) seemed to consume less drug solution compared to Veh-treated NAB 
females. Arrows indicate days of behavioural testing, which did not have a major influence on drinking 
volume. Data represents mean + SEM. Statistical comparison was not performed due to a low n number 
of (A) n = 3-5, (B) n = 3-4, (C) n = 2-4, (D) n = 2 per treatment group. 
 
3.1.1 Minocycline facilitates naturally occurring social preference in male and female HAB rats 
After 15 days of treatment with either minocycline (40 mg / kg), escitalopram, or a combination of both 
substances, all rats displayed natural social preference. This was indicated by a higher investigation time 
of the social (cage with conspecific) vs. the non-social stimulus (empty cage; p<0.001 vs. respective non-
social stimulus, significance not indicated; Fig. 12A - D). Post hoc analysis revealed that minocycline alone, 
but not escitalopram or the combination, facilitated social approach in male (Fig. 12A) and female (Fig. 
12B) HAB rats (p<0.05 vs. Veh social stimulus). In NAB rats, social preference remained unchanged by the 
provided treatment in both sexes (Fig. 12C & D).  
 
 
Figure 12. Social preference of male and female HAB and NAB rats with either vehicle (Veh), minocycline 
(Min), escitalopram (Esc), or a combination of both (Min+Esc) on day 15 of treatment. Social preference 
is reflected by a significant increase in investigation of the social (+) vs. the non-social (-) stimulus. Male 
Results  74 
 
 
(A & C) and female (B & D) HAB and NAB rats show natural social preference (significance not indicated) 
which is facilitated in male (A) and female (B) HAB rats by Min. Data represents mean + S.E.M; * p<0.05 
vs. corresponding Veh social stimulus. One-way ANOVA for repeated measures followed by a post hoc 
test using Bonferroni correction; n = 8 - 16 per treatment group. 
 
Chronic minocycline rat study, social behaviour statistics: 
sex Stimulus effect (non-social vs. social stimulus) Stimulus x treatment 
♂ (Fig. 12A) F(1,41) = 169.961; p<0.001 * F(3,41) = 2.483; p = 0.07 (*) 
♀ (Fig. 12B) F(1,42) = 233.512; p<0.001 * F(3,42) = 2.530; p = 0.07 (*) 
♂ (Fig. 12C) F(1,40) = 78.364; p<0.001 * F(3,40) = 0.36; p = 0.78 
♀ (Fig. 12D) F(1,28) = 208.968; p<0.001 * F(3,28) = 0.805; p = 0.50 
 
3.1.2 Anxiety-like behaviour remains unaffected by minocycline in HAB and NAB rats irrespective 
of sex 
To evaluate potential anxiolytic effects of minocycline (40 mg / kg), escitalopram, or the combination, 
male and female HAB and NAB rats were tested in two relevant behavioural tests on day 17 and 19 of 
treatment. In the LDB on day 17, HAB rats displayed the expected sex-independent highly anxious 
phenotype compared to NAB rats as depicted by a decreased time spent in the light box (p<0.001 vs. NAB; 
Fig. 13A & B). Male HAB rats (Fig. 13A) and female (Fig. 13B) HAB and NAB rats did not respond to the 
provided treatment. In male NAB rats, escitalopram increased the time in the light box, indicative of 
anxiolysis (p<0.05 vs. corresponding Veh; Fig. 13A). The distance travelled in the LDB as a measurement 
of locomotor activity remained unchanged in male HAB (Fig. 13C) and female (Fig. 13D) HAB and NAB rats, 
while in male NAB rats, the combination reduced locomotion (p<0.05 vs. corresponding Veh; Fig. 13C). 
Similarly, on the EPM (day 19) the highly anxious HAB rats spent a reduced percentage of time on the 
open arm compared to NAB rats independent of sex and treatment (p<0.001 vs. NAB; Fig. 13E & F). Male 
(p<0.001 vs. NAB; Fig. 13G) and female (p<0.001 vs. NAB; Fig. 13H) HAB rats also showed a decreased 
number of closed arm entries compared to NAB rats which tended to be increased in male HAB rats after 
minocycline treatment (p = 0.066 vs. corresponding Veh; Fig. 13G). 
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Figure 13. Anxiety-like behaviour of male and female NAB and HAB rats treated with vehicle (Veh), 
minocycline (Min), escitalopram (Esc), or a combination of both (Min+Esc), in the light-dark box (LDB; 
day 17) and on the elevated plus-maze (EPM; day 19). Compared to NAB rats, both male (A & C) and 
female (B & D) HAB rats showed increased anxiety-like behaviour and decreased locomotor activity in the 
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LDB. In male NAB rats, Esc increased the time in the light box (A), while the combinatory treatment 
decreased locomotion (C). On the EPM, in both male (E & G) and female (F & H) HAB rats anxiety-like 
behaviour was elevated and locomotor activity was reduced compared to NAB rats. In male HAB rats, Min 
tended to increase closed arm entries (G). Data represents mean + SEM; (*) p = 0.066, * p<0.05 vs. 
corresponding Veh; +++ p<0.001 vs. NAB. Two-way ANOVA followed by a post hoc test using Bonferroni 
correction; n = 8 - 16 per treatment group. 
 
Chronic minocycline rat study, anxiety-like behaviour statistics: 
sex Trait effect (HAB vs. NAB rats) Trait x treatment 
♂ (Fig. 13A) F(1,84) = 35.729; p<0.001 * F(3,84) = 2.030; p = 0.116 
♀ (Fig. 13B) F(1,68) = 113.024; p<0.001 * F(3,68) = 1.785; p = 0.158 
♂ (Fig. 13C) F(1,81) = 47.115; p<0.001 * F(3,81) = 0.379; p = 0.769 
♀ (Fig. 13D) F(1,68) = 39.97; p<0.001 * F(3,68) = 0.557; p = 0.645 
♂ (Fig. 13E) F(1,81) = 54.702; p<0.001 * F(3,81) = 1.080; p = 0.36 
♀ (Fig. 13F) F(1,70) = 180.528; p<0.001 * F(3,70) = 0.875; p = 0.46 
♂ (Fig. 13G) F(1,81) = 128.072; p<0.001 * F(3,81) = 2.689; p = 0.052 (*) 
♀ (Fig. 13H) F(1,70) = 106.146; p<0.001 * F(3,70) = 0.066; p = 0.978 
 
 
3.1.3 Minocycline ameliorates depressive-like behaviour exclusively in male HAB rats 
Concomitant with an anxious phenotype, HAB rats were repeatedly characterized by enhanced 
depressive-like behaviour compared to NAB rats. In accordance, in the FST performed on day 22 of 
treatment with either minocycline (40 mg / kg), escitalopram, or the combination, HAB rats displayed 
reduced struggling (p<0.001 vs. NAB; Fig. 14A & B) and increased immobility (p<0.001 vs. NAB; Fig. 14C & 
D) irrespective of sex. Treatment with minocycline alone, but not escitalopram or the combination, was 
able to reverse this phenotype exclusively in male HAB rats by enhancing struggling (p<0.05 vs. 
corresponding Veh; Fig. 14A) and decreasing immobility (p<0.05 vs. corresponding Veh; Fig. 14C). Female 
HAB as well as male and female NAB rats (Fig. 14B - D) did not respond to the treatment.  
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Figure 14. Depressive-like behaviour after treatment of male and female NAB and HAB rats with either 
vehicle (Veh), minocycline (Min), escitalopram (Esc), or a combination of both (Min+Esc) for 22 days. 
HAB rats showed an increased sex-independent depressive-like phenotype as indicated by a decreased 
total score of struggling (A & B) and an increased total score immobility (C & D). Min alone ameliorated 
depressive-like behaviour exclusively in male HAB rats (A & C). Data represents mean + SEM, * p<0.05 vs. 
corresponding Veh, +++ p<0.001 vs. NAB. Two-way ANOVA followed by a post hoc test using Bonferroni 
correction; n = 8 - 16 per treatment group. 
 
Chronic minocycline rat study, depressive-like behaviour statistics: 
sex Trait effect (HAB vs. NAB rats) Trait x treatment 
♂ (Fig. 14A) F(1,84) = 27.618; p < 0.001 * F(3,84) = 4.082; p = 0.009 * 
♀ (Fig. 14B) F(1,67) = 21.168; p < 0.001 * F(3,67) = 0.024; p = 0.99 
♂ (Fig. 14C) F(1,84) = 16.496; p < 0.001 * F(3,84) = 3.316; p = 0.024 * 
♀ (Fig. 14D) F(1,67) = 22.978; p < 0.001 * F(3,67) = 0.237; p = 0.87 
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3.1.4 An increased dose of minocycline does not alter behaviour in female HAB rats 
In the course of assessing potential sex-dependent differences in effective doses, 80 mg / kg minocycline 
was administered to male and female HAB rats. Again, all HAB rats showed naturally occurring social 
preference (p<0.001 vs. respective non-social stimulus, significance not indicated; Fig. 15A & B) which was 
further increased by minocycline (p<0.05 vs. Veh). Anxiety-like behaviour in both the LDB and EPM 
remained unchanged (Fig. 15C - F). Depressive-like behaviour was ameliorated in male HAB rats (p<0.05 
vs. Veh; Fig. 15G & H), whereas female HAB rats (Fig. 15I & J) did not respond to a higher dose of 
minocycline. Hence, in all subsequent analyses, samples from the 40 mg / kg minocycline experiments 
were used. 
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Figure 15. Behavioural outcome after treatment of male and female HAB rats with vehicle (Veh) or 
minocycline (Min) at a higher dose (80 mg / kg) for 22 days. Both male (A) and female (B) HAB rats 
showed natural occurring social preference for a social (+) over a non-social (-) stimulus (significance not 
indicated) on day 15 of treatment, which was facilitated by Min. Anxiety-like behaviour remained 
unchanged in both the light-dark box (LDB, day 17; C & E) as well as on the elevated plus-maze (EPM, day 
19; D & F). In the FST, Min alleviated depressive-like behaviour in male (G & H), but not female (I & J), 
HAB rats. Data represents mean + SEM; * p<0.05 vs. Veh. One-way ANOVA followed by a post hoc test 
using Bonferroni correction, or Student’s T-test; n = 8 - 10 per treatment group. 
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Chronic minocycline increased dose rat study, behavioural statistics: 
sex Stimulus effect (non-social vs. social stimulus) Stimulus x treatment 
♂ (Fig. 15A) F(1,16) = 190.714; p < 0.001 * F(1,16) = 14.798; p = 0.001 * 
♀ (Fig. 15B) F(1,15) = 97.423; p < 0.001 * F(1,15) = 32.958; p < 0.001 * 
 Treatment effect 
♂ (Fig. 15C) T(16) = 0.912; p = 0.375 
♂ (Fig. 15D) T(17) = 1.581; p = 0.132 
♀ (Fig. 15E) T(15) = 1.160; p = 0.264 
♀ (Fig. 15F) T(16) = -0.660; p = 0.525 
♂ (Fig. 15G) T(17) = 2.273; p = 0.036 * 
♂ (Fig. 15H) T(18) = -2.427; p = 0.026 * 
♀ (Fig. 15I) T(14) = -1.032; p = 0.32 
♀ (Fig. 15J) T(14) = 0.554; p = 0.589 
 
 
3.1.5 Minocycline reduces microglia quantity in the PFC exclusively in male HAB rats 
The effects of minocycline (40 mg / kg), escitalopram, or the combination on microglia quantity in 
infralimbic/prelimbic PFC slices were assessed using Iba-1 as a marker of both resting and reactive 
microglia. In the PFC of male (p<0.001 vs. NAB; Fig. 16A) and female (p<0.01 vs. NAB; Fig. 16B) HAB rats, 
overall lower counts of microglia cells were detected in comparison to the respective NAB brains. A 
treatment effect was seen exclusively in male HAB rats with post hoc analysis revealing reduced microglial 
numbers after minocycline treatment (p<0.05 vs. corresponding Veh; Fig. 16A).  
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Figure 16. Quantity of Iba+ microglia cells on day 22 of treatment with either vehicle (Veh), minocycline 
(Min), escitalopram (Esc), or the combination (Min+Esc) in the prefrontal cortex (PFC; infralimbic / 
prelimbic) of male and female NAB and HAB rats. Both male (A) and female (B) HAB rats showed reduced 
microglial numbers in the PFC in general compared to NAB rats. Min alone further reduced microglial 
numbers in male HAB rats (A). (C & D) Representative microphotographs of the analysed PFC with Iba+ 
microglia (green) and DAPI+ (blue) staining. Data represents mean + SEM; * p<0.05 vs. corresponding Veh 
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group; ++ p<0.01, +++ p<0.001 vs. NAB. Two-way ANOVA followed by a post hoc test using Bonferroni 
correction; n = 6 per treatment group. Scale bar: 50 µm.  
 
Chronic minocycline rat study, microglia statistics: 
sex Trait effect (HAB vs. NAB rats) Trait x treatment 
♂ (Fig. 16A) F(1,40) = 70.586; p < 0.001 * F3,40 = 2.650; p = 0.062 (*) 
♀ (Fig. 16B) F(1,40) = 7.616; p < 0.01 * F3,40 = 0.272; p = 0.845 
 
 
3.1.6 Minocycline reduces IFN-γ, but not IL-12p40, concentrations in male rats 
As only male HAB rats responded to minocycline treatment regarding depressive-like behaviour and 
microglial numbers, subsequent analyses of peripheral pro-inflammatory cytokine concentrations and 
microbiome composition were restricted to minocycline-treated male HAB vs. NAB rats. Plasma 
concentrations of both IFN-γ (Fig. 17A) and IL-12p40 (Fig. 17B) were comparable between male HAB and 
NAB rats. Minocycline reduced IFN-γ levels in male HAB and NAB rats (p<0.05 vs. corresponding Veh; Fig. 
17A), whereas IL-12p40 levels were not significantly changed (Fig. 17B). 
 
 
 
Figure 17. Cytokine concentrations in plasma of male HAB and NAB rats on day 22 of vehicle (Veh) or 
minocycline (Min) treatment. Min reduced interferon (IFN)-γ concentrations in both HAB and NAB rats 
(A), while interleukin (IL)-12p40 levels were not affected (B). Data represents mean + SEM, * p<0.05 vs. 
corresponding Veh group. Mann-Whitney U test; n = 11 – 16 per treatment group. 
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Chronic minocycline rat study, peripheral cytokine statistics: 
Parameter NAB HAB 
IFN-γ (Fig. 17A) U = 71.000; p = 0.032 * U = 67.000; p = 0.022 * 
IL-12p40 (Fig. 17B) U = 115.000; p = 0.642 U = 102.000; p = 0.35 
 
 
3.2 Influence of minocycline on microbiota in the caecum 
Host microbiota is known to control maturation and function of microglia and to modulate many aspects 
of behaviour (Erny et al, 2015). To assess (i) breeding line-dependent differences as well as (ii) 
minocycline-induced alterations in the intestinal microbiome accompanying the observed differences and 
changes in depressive-like behaviour and microglial density, the bacterial composition in cecal contents 
of male HAB and NAB rats was analysed using 16S-rRNA-based deep sequencing.  
 
3.2.1 Minocycline is detectable in both liver and fecal boli 
As prerequisite for microbial analysis, the distribution and absorption of minocycline in both liver and 
fecal boli after 22 days of treatment were analysed by HPLC. Minocycline was detectable in fecal boli and 
the liver of both male and female rats in comparable concentrations irrespective of trait anxiety (Table 2). 
This correlated with liquid (i.e. minocycline) intake on the last treatment day (data not shown).  
 
Table 2. Minocycline concentration in liver and fecal boli of male and female rats after 22 days of vehicle 
(Veh) or minocycline (Min) treatment. Data depicts mean concentration values of pooled HAB and NAB 
rats per sex; n (liver) = 13 (♀) and 36 (♂), n (fecal boli) = 6; n.a. = not assessed. 
Sex treatment Liver [µg / mg] Fecal boli [µg / mg] 
♂ Veh 0.00 ± 0.00 0.00 ± 0.00 
♂ Min 1.05 ± 0.08 1.26 ± 0.11 
♀ Veh 0.00 ± 0.00 n.a. 
♀ Min 1.12 ± 0.1 n.a. 
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3.2.2 Gut microbiota composition differs between male HAB and NAB rats and is altered by 
minocycline 
The overall diversity of the cecal microbiota in vehicle-treated rats, as assessed by principal coordinates 
analysis of Bray-Curtis distances, disclosed significant differences between HAB and NAB rats (p = 0.012 
vs. NAB; Fig. 18B). No differences were detected regarding bacterial copy numbers and diversity between 
the two lines (Fig. 18A, C & D). A 22-day treatment with minocycline significantly reduced the bacterial 
copy numbers (p<0.01 vs. Veh; Fig. 18A) as well as the microbial richness, as represented by OTU counts 
(p<0.001 vs. Veh; Fig. 18C), in male HAB and NAB rats. Interestingly, in samples of HAB rats – as opposed 
to NAB rats (p<0.05) – the mean Shannon index, integrating richness and evenness of individual taxa to 
an estimate of bacterial diversity, was only marginally altered by minocycline treatment (Fig. 18D). 
Comparing the overall diversity between minocycline- and vehicle-treated rats by principal coordinates 
analysis of Bray-Curtis distances, four distinct clusters corresponding to the two treatment conditions in 
HAB and NAB rats each were detected (Fig. 18B).  
Results  85 
 
 
 
 
Figure 18. Cecal microbiota composition and profiling after 22 days of vehicle (Veh) or minocycline (Min) 
treatment. Male HAB and NAB rats showed comparable numbers of bacterial 16S-rRNA gene copies (A) 
and bacterial richness indicated by operational taxonomic units (OTU) numbers (C) that were both 
decreased by Min. An unchanged Shannon Index in HAB, but not NAB, rats suggested increased 
equitability throughout the taxa present within the HAB microbiome (D). Β-diversity of bacterial 
communities prevalent in cecal contents, as illustrated by principal coordinates analysis (PCoA) of Bray – 
Curtis distances with the first two coordinates plotted, showed four distinct clusters corresponding to all 
treatment groups (B). Box plots depict the median and interquartile range, whiskers represent minimum 
and maximum values, and outliers indicate values more than 1.5 times of upper / lower quartile. Kruskal-
Wallis test followed by Dunn’s multiple comparison test; n= 6 – 8 per treatment group. 
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3.2.3 Minocycline increases 3-OH-butyrate concentration and abundance of butyrate producer 
Deeper taxonomic analysis of the microbiome composition revealed striking differences between HAB 
and NAB rats regarding the highly prevalent Lachnospiraceae family of the Clostridiales order (p<0.05 vs. 
NAB; Fig. 19A). Minocycline treatment elevated the lower frequency in HAB rats (p<0.05 vs. Veh) to the 
level of NAB rats that — in terms of this family — were not affected by treatment. Further, a relative 
increase in the abundance of the Clostridiales Family XIII in both lines was observed after minocycline 
(p<0.01 vs. Veh; Fig. 19B). Significantly augmented levels of 3-OH-butyrate after minocycline treatment 
were found in both lines that were even higher in HAB than in NAB rats (p<0.05 vs. Veh; Fig. 19C). 
Spearman’s rank analysis disclosed positive correlations between 3-OH-butyrate levels and abundance of 
the two mentioned Clostridiales families in individual HAB rats (p<0.001; Fig. 19D & F). In NAB rats, 
minocycline-induced augmentation of the Family XIII population, but not of Lachnospiraceae, positively 
correlated with 3-OH-butyrate levels (p<0.001; Fig. 19E & G).  
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Figure 19. Relative abundance of butyrate-producing bacteria and plasma 3-OH-butyrate levels after 22 
days of vehicle (Veh) or minocycline (Min) treatment in male HAB and NAB rats. Regarding Clostridiales 
families, HAB rats showed a reduced abundance of Lachnospiraceae that was increased to NAB level by 
Min (A). Both breeding lines demonstrated comparable levels of Clostridiales Family XIII abundance that 
increased after Min treatment (B). These changes were accompanied by increased plasma 3-OH-butyrate 
levels with an even higher increase in HAB compared to NAB rats (C). In HAB rats, plasma 3-OH-butyrate 
levels correlated positively with both Clostridiales families (D & F) whereas in NAB rats, a positive 
correlation was only observed with Family XIII (E & G). Box plots represent interquartile range with 
horizontal lines indicating the median of values. Outliers indicate values more than 1.5 times of 
upper/lower quartile, and whiskers show minimum and maximum of remaining values; ANOVA with a 
subsequent Tukey’s analysis. Bars represent mean + SEM; Two-way ANOVA followed by a post hoc test 
using Bonferroni correction. Open symbols indicate Veh-treated, coloured symbols Min-treated rats in 
correlations; Spearman’s correlation; n = 6-8 per treatment group.  
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3.3 Effects of minocycline on chronic psychosocial stress 
A second approach to analyse the underlying pathophysiological mechanisms of diseases is environmental 
manipulation, like chronic stress. Minocycline has been proven effective in stress-induced depressive-like 
behaviour and numerous studies propose it as a treatment option for anxiety-like behaviour (Arakawa et 
al, 2012; Levkovitz et al, 2015; Wang et al, 2017, 2018; Wong et al, 2016). However, the current evidence 
was only provided in models of stress-induced comorbid anxiety- and depressive-like behaviour. The CSC 
model, which induces only anxiety-like behaviour, represents a unique opportunity to unravel a 
behaviour-specific mode of action for minocycline. As the department moved to a new building in 2014, 
it was essential to provide evidence for a functional CSC in the new facility, i.e. verify previously reported 
stress-induced behavioural and physiological alterations (Langgartner et al, 2015), before treatment-
specific effects could be evaluated. Further, the effects of acute, as well as subchronic, minocycline 
treatment on CSC-induced physiological and behavioural parameters were assessed.  
 
3.3.1 Validation of the CSC paradigm 
3.3.1.1 CSC exposure induces anxiety-like behaviour  
On day 19 of CSC exposure, CSC mice spent less time in the light box compared to SHC mice, which is 
indicative for increased anxiety-like behaviour (p<0.05 vs. SHC; Fig. 20A). Locomotor activity, reflected by 
the distance travelled, did not differ between the groups rendering activity-dependent behavioural 
changes unlikely (Fig. 20B). This anxious phenotype was partly confirmed on the following day on the 
EPM. Here, CSC entered the open arms less frequently (p<0.05 vs. SHC; Fig. 20D), though the percentage 
of open arm time was unchanged (Fig. 20C).  
  
 
Figure 20. Effects of CSC on anxiety-like behaviour and locomotor activity. After 19 consecutive days of 
CSC exposure, all mice were tested in the light-dark box. CSC mice showed reduced time in the light box 
(A) but unaltered locomotor activity (B) compared to SHC mice. Tested on the elevated plus-maze on the 
following day, the percentage of time spent on the open arms remained comparable between CSC and 
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SHC mice (C), however CSC mice entered the open arm at a lower percentage (D). Data represents mean 
+ SEM; * p<0.05 vs. SHC. Student’s t-test; n = 14-17 per group. 
 
Validation CSC study behavioural statistics: 
Parameter Stress effect (SHC vs. CSC) 
Time light box (Fig. 20A) T(28) = 2.555; p = 0.016 * 
Distance travelled (Fig. 20B) T(28) = -0.056; p = 0.955 
% time on open arm (Fig. 20C) T(29) = 0.672; p = 0.507 
% open arm entries (Fig. 20D) T(29) = 2.745; p = 0.01 * 
 
 
3.3.1.2 CSC exposure alters physiological parameters 
To further validate the CSC paradigm in the new facility, body weight gain as well as adrenal and thymus 
weight were analysed in comparison to SHC mice immediately after EPM. CSC exposure did not alter body 
weight gain (p = 0.086 vs. SHC; Fig. 21A) but increased absolute adrenal weight (p<0.01 vs. SHC; Fig. 21B) 
and decreased absolute thymus weight (p<0.001 vs. SHC; Fig. 21C). 
 
 
Figure 21. Effects of 20 consecutive days of CSC exposure on physiological parameters. CSC mice 
appeared to gain less body weight during CSC exposure (A) together with an increased absolute adrenal 
weight (sum of all adrenals; B) and a decreased absolute thymus weight (C). Data represents mean + SEM; 
** p<0.01, *** p<0.001 vs. SHC. Student’s t-test; n = 14-17 per group. 
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Validation CSC study physiological statistics: 
Parameter Stress effect (SHC vs. CSC) 
Body weight gain (Fig. 21A) T(31) = 1.770; p = 0.086 
Absolute adrenal weight (Fig. 21B) T(27) = -3.493; p = 0.002 * 
Absolute thymus weight (Fig. 21C) T(22) = 4.116; p < 0.001 * 
 
 
3.3.2 Effects of acute and subchronic minocycline treatment on CSC-induced behavioural and 
physiological parameters 
As CSC mice showed the previously reported CSC-induced physiological and behavioural alterations, the 
capability of acute (1 h) and subchronic (8 days) minocycline treatment to reverse these alterations was 
evaluated. Thus, on day 20, mice received a single i.p. injection of 80 mg / kg minocycline 1 h prior to LDB. 
Starting from day 21, mice were treated for additional 7 days of subchronic treatment via the drinking 
water.  
 
3.3.2.1 Acute minocycline treatment does not alter CSC-induced anxiety-like behaviour 
CSC exposure for 20 consecutive days reliably increased innate anxiety-related behaviour compared to 
SHC mice in the LDB, while an i.p. injection of 80 mg / kg minocycline one hour prior to behavioural testing 
did not affect behaviour (p<0.01 vs. SHC; Fig. 22A). Further, CSC mice showed unchanged locomotor 
activity compared to SHC mice, indicated by the distance travelled, independent of treatment (Fig. 22B). 
SHC mice in general did not respond to acute minocycline treatment in any behavioural parameter 
assessed.  
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Figure 22. Anxiety-like behaviour and locomotor activity after 20 consecutive days of CSC exposure and 
acute treatment with either vehicle (Veh) minocycline (Min). CSC mice showed the expected stress-
induced increase in anxiety-like behaviour, reflected by decreased time in the light box (A), and 
comparable distance travelled (B) independent of Min treatment. Data represents mean + SEM; ++ p<0.01 
vs. SHC. Two-way ANOVA followed by a post hoc test using Bonferroni correction; n = 12-14 per treatment 
group. 
 
Acute minocycline CSC study behavioural statistics: 
Parameter Stress effect (SHC vs. CSC) Stress x treatment 
Time light box (Fig. 22A) F(1,44) = 8.553; p<0.01 * F(1,44) = 3.293; p = 0.076 
Distance travelled (Fig. 22B) F(1,44) = 2.346; p = 0.133 F(1,44) = 1.641; p = 0.207 
 
 
3.3.2.2 Subchronic minocycline treatment does not improve CSC-induced anxiety-like behaviour 
The acute treatment on day 20 of CSC was continued for 7 days in the respective groups with minocycline 
administration in the drinking water to investigate potential beneficial effects of a subchronic minocycline 
treatment. Drinking behaviour of SHC and CSC mice (Fig. 23) did not differ over time within the respective 
groups. CSC mice drank significantly more on day 2 and day 4 of the subchronic treatment (p<0.05 vs. 
SHC), while minocycline treatment did not affect fluid intake. The drug concentration was calculated daily 
according to the body weight and drunk volume. Therefore, the treatment regimen of minocycline was 
assumed stable and mice received the appropriate dose of minocycline. Behavioural testing on day 6 (day 
Results  92 
 
 
27 of experiment) and day 7 (day 28 of experiment) did not affect drinking behaviour (indicated by arrows 
in Fig. 23). 
 
 
Figure 23. Drinking volume of SHC and CSC mice treated with either vehicle (Veh) or minocycline (Min) 
for 7 additional days after acute minocycline injection. The fluid intake over 7 days after acute Min 
injection (experimental day 21 to 28) remained stable within each group. CSC mice drank more than SHC 
mice on days 2 and 4, while Min treatment and behavioural testing on day 6 and 7 did not affect drinking 
behaviour. Data represents mean + SEM; + p<0.05 vs. SHC. Two-way ANOVA for repeated measures 
followed by a post hoc test using Bonferroni correction; n = 11-14 per treatment group. 
 
Subchronic minocycline CSC study drinking volume statistics: 
Parameter 
Stimulus effect 
(day 1 – 7) 
Stress effect (SHC vs. CSC) Stimulus x treatment 
Drinking volume 
(Fig. 23) 
F(6,282) = 0.695; p = 
0.654 
F(1,47) = 1.978; p = 0.166 
F(6,282) = 0.379; p = 
0.892 
 
 
The increased anxiety-like behaviour observed in the LDB on day 20 was persistent in the OF on day 27. 
Here, CSC mice spent less time in the inner zone of the OF (p<0.01 vs. SHC; Fig. 24A) with comparable 
levels of locomotor activity between SHC and CSC mice (Fig. 24B). Subchronic minocycline treatment was 
not able to reverse this anxious phenotype of affect SHC mice. Neither CSC exposure nor subchronic 
minocycline treatment in SHC and CSC mice affected depressive-like behaviour in the FST on day 28 as 
reflected by the time spent immobile (Fig. 24C).  
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Figure 24. Anxiety- and depressive-like behaviour after 8 days of vehicle (Veh) or minocycline (Min) 
treatment following 20 days of CSC. Anxiety-like behaviour was elevated in CSC mice compared to SHC 
mice, as demonstrated by a reduced time in the inner zone of the OF, independent of Min treatment (A), 
whereas locomotor activity was similar between SHC and CSC mice (B). SHC and CSC mice showed similar 
times of immobility in the FST that were not affected by Min treatment (C). Data represents mean + SEM; 
++ p<0.01 vs. SHC. Two-way ANOVA followed by a post hoc test using Bonferroni correction; n = 12-14 per 
treatment group. 
 
Subchronic minocycline CSC study behavioural statistics: 
Parameter Stress effect (SHC vs. CSC) Stress x treatment 
Time immobility (Fig. 24A) F(1,44) = 0.000; p = 0.985 F(1,44) = 0.601; p = 0.422 
Time inner zone (Fig. 24B) F(1,44) = 10.154; p<0.01 * F(1,44) = 1.398; p = 0.243 
Distance travelled (Fig. 24C) F(1,44) = 0.508; p = 0.48 F(1,44) = 1.062; p = 0.308 
 
 
3.3.2.3 Subchronic minocycline treatment does not reverse CSC-induced physiological and 
neuroendocrine alterations 
Besides behavioural alterations, physiological and neuroendocrine consequences of CSC exposure were 
assessed after 8 days of minocycline treatment. CSC mice gained significantly more weight after stressor 
termination compared to SHC mice which was unaffected by subchronic minocycline treatment (p<0.001 
vs. SHC; Fig. 25A). Further, CSC exposure enhanced absolute spleen (p<0.001 vs. SHC; Fig. 25B) and adrenal 
(p<0.001 vs. SHC; Fig. 25C) weight irrespective of minocycline.  
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Figure 25. CSC-induced physiological parameters following 20 days of CSC and subchronic (8 days) 
minocycline treatment. 8 days after stressor termination, CSC mice showed increased body weight gain 
compared to SHC mice (A). This was accompanied by increased absolute spleen (B) and absolute adrenal 
(sum left and right adrenal) weight (C). Data represents mean + SEM; +++ p<0.001 vs. SHC. Two-way 
ANOVA followed by a post hoc test using Bonferroni correction; n = 12-14 per treatment group. 
 
Subchronic minocycline CSC study physiological statistics: 
Parameter Stress effect (SHC vs. CSC) Stress x treatment 
Body weight gain (Fig. 25A) F(1,47) = 10.915; p<0.01 * F(1,47) = 0.394: p = 0.533 
Absolute spleen weight (Fig. 25B) F(1,46) = 15.649; p<0.001 * F(1,46) = 0.138; p = 0.712 
Absolute adrenal weight (Fig. 25C) F(1,46) = 16.286; p<0.001 * F(1,46) = 0.139; p = 0.711 
 
 
Eight days after stressor termination and minocycline administration, plasma ACTH (Fig. 26A) and CORT 
levels (Fig. 26B) remained similar between CSC and SHC mice, irrespective of minocycline treatment. In 
vitro stimulation of adrenal explants revealed an increased CORT secretion in response to ACTH compared 
to basal (saline) stimulation in both SHC and CSC mice (p<0.001 vs. basal; significance not indicated). 
Analysing adrenal functionality using a two-way ANOVA as separate statistics, ACTH-stimulated adrenal 
CORT secretion was significantly reduced in CSC compared to SHC mice (p<0.01 vs. SHC; Fig. 26C). This 
effect was also visible in basal stimulated adrenal explants (p<0.05 vs. SHC) and indicative for reduced 
adrenal sensitivity. A treatment effect was only seen in adrenal explants of SHC mice showing reduced 
basal CORT secretion after subchronic minocycline treatment (p<0.05 vs. corresponding SHC/Veh; Fig. 
26C).  
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Figure 26. CSC-induced alterations in HPA axis functionality after 8 days of minocycline (Min) treatment. 
Relative plasma ACTH (A) and CORT (B) levels were unchanged by CSC and Min treatment. In vitro ACTH 
stimulation of adrenal explants induced CORT secretion compared to basal (saline) stimulation in both 
SHC and CSC mice that was diminished by CSC exposure. Min reduced CORT secretion after basal 
stimulation in SHC mice (C). Data represents mean + SEM; * p<0.05 vs. corresponding SHC/Veh, ++ p<0.01 
vs. SHC. Two-way ANOVA followed by a post hoc test using Bonferroni correction; n = 6-14 per treatment 
group. 
 
Subchronic minocycline CSC study neuroendocrine statistics: 
Parameter Stress effect (SHC vs. CSC) Stress x treatment 
Plasma ACTH (Fig. 26A) F(1,42) = 0.000; p = 0.994 F(1,42) = 0.165; p = 0.686 
Plasma CORT (Fig. 26B) F(1,46) = 1.335; p = 0.254 F(1,46) = 0.045; p = 0.833 
 Stimulation Stress effect (SHC vs. CSC) Stress x treatment 
Adrenal CORT (Fig. 26C) 
basal F(1,20) = 1.485; p = 0.237 F(1,20) = 4.470; p = 0.047 * 
ACTH F(1,20) = 15.079; p = 0.001* F(1,20) = 1.723; p = 0.204 
  
 
 
 
 
 
 
 
 
 
 
Discussion 
The Discussion includes sections taken, and adapted, from one first author publication: Anna K. 
Schmidtner, David A. Slattery, Joachim Gläsner, Andreas Hiergeist, Katharina Gryksa, Victoria Malik, Julian 
Hellmann-Regen, Isabella Heuser, Thomas C. Baghai, André Gessner, Rainer Rupprecht, Barbara Di 
Benedetto, Inga D. Neumann. Minocycline alters behavior, microglia and the gut microbiome in a trait-
anxiety-dependent manner. (In preparation) 
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In the present thesis, I was able to advance the understanding of two novel targets for the treatment of 
depression, namely the inflammatory system and the gut microbiome, and extend our knowledge 
regarding the potential use of minocycline in the treatment of psychiatric disorders. I could show that 
chronic minocycline was able to increase social preference in male and female HAB rats and reverse innate 
depressive-, but not anxiety-like, behaviour exclusively in male HAB rats. In addition, HAB rats showed 
reduced microglia quantity in the prelimbic and infralimbic PFC independent of sex that was further 
reduced by minocycline in male HAB rats. Male HAB and NAB rats showed a distinct difference in β-
diversity of the microbiome composition. Treatment with minocycline “normalized” the microbiome 
composition in HAB rats with corresponding changes in the metabolome, providing additional evidence 
for a role of the microbiome in psychiatric disorders. I was also able to recapitulate the lack of effect of 
minocycline on anxiety-related behaviour in a second model. In detail, acute and subchronic treatment 
with minocycline did not reverse CSC-induced behavioural, physiological, and neuroendocrine 
maladaptations. These results extend the HAB model of depression to a model of inflammation- and gut 
microbiome- associated processes involved in depressive-like behaviour and its treatment. Moreover, 
they provide evidence for minocycline as a novel treatment option, but urge for caution in terms of 
application conditions. In detail, it shows sex- and trait-specific effects on behaviour, microglia, and the 
microbiome in HAB and NAB rats and a lack of effect in stress-induced behavioural and physiological 
alterations. Thus, minocycline seems to require certain conditions to elicit a treatment response and 
further research is warranted to delineate its specifics and detailed mode of action as a prerequisite for 
clinical application in psychiatric disorders.  
 
4.1 Minocycline alters behaviour, microglia and the gut microbiome in a trait-
dependent manner 
Minocycline has received growing attention during the last years due to its promising results in clinical 
studies (reviewed in Rosenblat and McIntyre, 2017). These results are supported by a number of 
preclinical studies, demonstrating antidepressant properties of minocycline in male rodents. In detail, 
minocycline ameliorates depressive-like behaviour in naïve rats in the FST (Molina-Hernández et al, 
2008b, 2008a) as well as in the learned helplessness paradigm (Arakawa et al, 2012) or in the olfactory 
bulbectomy model of depression (Burke et al, 2014). A similar antidepressant effect of minocycline is 
achieved when depressive-like behaviour is induced by an inflammatory challenge with either LPS (Henry 
et al, 2008; O’Connor et al, 2009b) or IFN-α (Zheng et al, 2015) in mice. In chronically stressed rodents, 
minocycline acts antidepressant in the FST and sucrose preference in rats (Wang et al, 2017, 2018) and in 
the FST, TST, and sucrose preference in mice (Kreisel et al, 2014; Tong et al, 2017; Wong et al, 2016). 
Interestingly, these preclinical results of an antidepressant effect are mainly achieved following chronic 
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stress or an inflammatory challenge, but not in the context of an innate behavioural alteration or under 
baseline conditions. In addition, a sex-specificity of minocycline has been proposed in rats (Posillico et al, 
2015) and mice (Chen et al, 2018) in the context of pain perception. Thus, I aimed to extend this 
knowledge to an innate animal model of high anxiety- and depressive-like behaviour that is reflective of 
the clinical high comorbidity between MDD and anxiety disorders and the sex difference found in most 
mood disorders. As the recent evidence suggests anxiolytic and pro-social effect of minocycline after 
acute or chronic stress, or an immune challenge, in male rodents (Henry et al, 2008; Kreisel et al, 2014; 
Levkovitz et al, 2015; Majidi-Zolbanin et al, 2016; Zhu et al, 2014b), I included additional tests to specify 
the effects of minocycline on social and anxiety-like behaviour. Escitalopram is currently viewed as the 
gold standard of available antidepressants (Kasper et al, 2006; Santarsieri and Schwartz, 2015). Like 
minocycline, escitalopram acts anxiolytic and antidepressant in male rats after chronic stress (Lin et al, 
2016; Montgomery et al, 2001; Sánchez et al, 2003). Therefore, it was included as positive control and, 
corresponding to clinical treatment regimen, to determine the capacity of minocycline as an adjunctive 
agent.  
 
4.1.1 Minocycline affects social and / or depressive-like behaviour of male and female HAB, but 
not NAB, rats 
All rats displayed natural occurring social preference in the SPT, independent of sex or trait. In male and 
female HAB rats, minocycline facilitated social approach without changing social behaviour in NAB rats. 
Fittingly, previous studies show that a 3-day minocycline administration reverses LPS-induced social 
avoidance in male rats (Zhu et al, 2014b). Chronic minocycline treatment ameliorates social avoidance 
after chronic stress in male mice (Kreisel et al, 2014) and after LPS administration in male rats (Zhu et al, 
2014c, 2014a) and mice (Henry et al, 2008). However, HAB rats generally do not show impairments in 
social interaction. The elevated social preference, therefore, may rather reflect an alleviation of 
depressive-like behaviour (Krishnan et al, 2007; Krishnan and Nestler, 2008) than an improvement in 
social approach per se, supporting an antidepressant effect of minocycline. Importantly, in the 
aforementioned studies minocycline facilitates social preference only in rodents that were previously 
affected. Similar to the results obtained in the present thesis, control animals do not respond to 
minocycline treatment. Escitalopram, and the combinatory treatment, did not alter social behaviour in 
male and female HAB and NAB rats. In line, citalopram treatment ameliorates deficits in social behaviour 
in FSL rats but not in Wistar rats that show normal social behaviour (Overstreet et al, 2004). These studies 
indicate that both minocycline and escitalopram might require an abnormal precondition for an effect on 
social behaviour. The combinatory treatment abolished the effect of minocycline on social behaviour, 
indicating an inhibitory effect of SSRIs on minocycline function (see below). 
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Furthermore, the high anxiety phenotype of HAB compared to NAB rats was confirmed in males and 
females and remained unchanged after minocycline treatment in both lines and sexes. Escitalopram 
decreased anxiety-like behaviour in male NAB rats while the combinatory treatment did not affect 
behaviour. A role of minocycline in anxiety-like behaviour was previously proposed in male rodent models 
of cardiac arrest / cardiopulmonary resuscitation (Fan et al, 2006; Neigh et al, 2009), mild traumatic brain 
injury (Kovesdi et al, 2012), a genetic model of ASD (Shigemori et al, 2015), or acute stress (Levkovitz et 
al, 2015; Soczynska et al, 2012). In addition, minocycline reverses anxiety-like behaviour induced by a 
neonatal inflammatory challenge in male mice (Majidi-Zolbanin et al, 2016). Treatment of control animals 
with minocycline does not alter anxiety-like behaviour in the aforementioned studies, proposing, similar 
as in social behaviour, an absent anxiolytic effect of minocycline in NAB rats that did not show abnormal 
behaviour. These studies also suggest that anxiety-like behaviour in HAB rats is manifested via a 
minocycline-independent mechanism. However, an acute icv NPS infusion can attenuate anxiety-like 
behaviour male HAB rats (Slattery et al, 2015) and chronic icv oxytocin infusion in male and female HAB 
rats alleviates anxiety-like behaviour in females, but not in males (Slattery and Neumann, 2010). 
Furthermore, diminishing the SNP-induced AVP overexpression in HAB rats with a AVP antagonist (Wigger 
et al, 2004) or infusion of a CRH 1 receptor antagonist to counteract CRH overexpression (Keck et al, 
2001b) acted anxiolytic, suggesting alternative objectives in anxiety-like behaviour of HAB rats. Moreover, 
the antidepressant effect of minocycline was seen after 22 days. A longer treatment duration could be 
necessary to ameliorate anxiety-like behaviour in HAB rats, especially as a prolonged treatment of 8 weeks 
is needed in the context of paroxetine (Jochum et al, 2007). The same might be true for an anxiolytic effect 
of escitalopram, an SSRI like paroxetine, since the results for anxiety-related behaviour in HAB rats are 
obtained after 17 (LDB) and 19 (EPM) days of treatment. A required longer treatment with SSRIs in HAB 
rats might be attributable to a dysregulated 5-HT signalling. In support, male HAB rats show an increased 
SERT binding and reduced 5-HT1A receptor expression in the hippocampus and raphe nucleus. This induces 
an increased 5-HT clearance from the synaptic cleft (Keck et al, 2005) and proposes an impaired 5-HT 
transmission that might contribute to the delayed response to antidepressants. As a bidirectional 
communication between the HPA axis and the 5-HT system is known (Dinan, 1996; Leonard, 2005; 
Linthorst et al, 2002; Ressler and Nemeroff, 2000), this impaired 5-HT signalling might be caused by the 
hyper-reactive HPA axis in HAB rats (Landgraf et al, 1999). Indeed, 8 weeks of paroxetine not only 
improves behaviour but normalizes the HPA axis response to stress (Keck et al, 2003) and the SERT binding 
in the hippocampus (Keck et al, 2005). Further, escitalopram decreased anxiety-like behaviour in male 
NAB rats. Fittingly, an anxiolytic effect of escitalopram under basal and chronic stress conditions has been 
shown before in male rats (Lin et al, 2016; Sánchez et al, 2003).  
The present results also extend the antidepressant effect of minocycline (see Introduction chapter 1.2.3) 
to rats with high levels of innate anxiety- and depressive-like behaviour, but normal social behaviour, that 
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were otherwise unchallenged. While there are different behavioural tests available for the assessment of 
antidepressant-like activity, the FST is by far the most commonly used test and viewed as the gold 
standard (Anyan and Amir, 2017). It is largely based on predictive validity, though, as evidence from 
rodents studies show that antidepressant substances reduce immobility (Cryan et al, 2005). Thus, the FST 
is critically discussed in its interpretation of “immobility” as representation of “despair” and struggling as 
the opposite, meaning the absence of a depressive-like phenotype. Immobility can easily be influenced 
by locomotor activity, which may lead to false positive or negative findings. Male and female HAB rats 
show reduced locomotor activity in the LDB and OF (Liebsch et al, 1998b; Ohl et al, 2001), which is not 
causally related to the anxiety phenotype (Landgraf and Wigger, 2002). In the present study, male HAB 
rats showed reduced locomotion that was unchanged by minocycline in the LDB, deeming activity-
dependent effects of minocycline in the FST rather unlikely (De Kloet and Molendijk, 2016; Slattery and 
Cryan, 2014). Moreover, in a controversial discussion the FST has recently been suggested as a 
measurement of anxiety-like behaviour, more precisely an inverse relationship between the performance 
in the FST and on the EPM in male rats (Anyan and Amir, 2017). In more detail, the more immobility those 
rats show in the FST, the lower anxiety measures are found on the EPM (Anyan and Amir, 2017; Estanislau 
et al, 2011). Nevertheless, the present results strongly imply an antidepressant-like and facilitating effect 
on active stress coping of minocycline. The sustained high anxiety and depressive phenotype of HAB rats 
was affected by minocycline in the SPAT and FST, but not in the more specific anxiety tests EPM and LDB, 
contradicting the theory of an anxiety measurement.  
In addition, though two studies demonstrate an antidepressant effect of minocycline on naïve male 
animals (Molina-Hernández et al, 2008a, 2008b), the majority of all studies shows no effect of minocycline 
on control animals. In line, in the present thesis male and female NAB rats did not react to minocycline 
treatment, strengthening the hypothesis that minocycline requires pathological behaviour to be effective. 
This hypothesis is supported by subgroup analyses of a recent meta-analysis including 22 preclinical 
studies that reveals an antidepressant effect of minocycline only in diseased animals (Reis et al, 2019). 
Thus, the present data demonstrates a fast antidepressant effect of minocycline. Interestingly, an 
influence of minocycline on female rodents is rarely tested. Three studies could show that minocycline 
abolished inflammatory neuropathic pain (Chen et al, 2018) and reversed morphine-induced analgesia 
(Posillico et al, 2015) and arthritis-induced pain (Fernandez-Zafra et al, 2018), but only in male mice. 
Similarly, in the present thesis minocycline did not ameliorate depressive-like behaviour in female HAB 
rats, underlining the proposed sex difference in its effectiveness. Although the exact reason for this 
difference remains unknown, some factors might contribute to or underlie the lacking effect in female 
HAB rats. First, a pathological dexamethasone / CRH test is observed in male, but not in female HAB rats 
(Keck et al, 2002). Thus, a HPA axis functionality-restoring effect of minocycline as underlying mechanism 
could account for the sex difference seen in HAB rats. Similarly, minocycline reversed CUMS-induced 
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elevated plasma CORT levels (Zhang et al, 2019). In addition, male and female rats also show a strong 
difference in immune functioning and response (Klein and Flanagan, 2016; see chapter 1.4.2), which might 
contribute to the sex-dependent effect of minocycline. A frequently mentioned factor influencing 
behavioural differences between sexes are hormonal fluctuations in oestrogen. Clinical studies provide 
evidence that a decline in oestradiol in women is associated with increased rates of MDD, while in female 
rodents, treatment with oestradiol exerts antidepressant-like effects (Bernardi et al, 1989; Harlow et al, 
2003; López-Rubalcava et al, 2012; Parry, 2008; Walf et al, 2004; Walf and Frye, 2010). Therefore, a – at 
least partial – dysregulation in oestrogen signalling in female HAB rats might contribute to their 
behavioural phenotype. As a cycle activity was observed in the majority female rats, though, a complete 
lack of oestrogen signalling is deemed rather unlikely; however, a partial impairment might also explain 
the reduced breeding success (personal observation) seen in those animals. If the oestrus cycle generally 
affects behaviour in female HAB rats remains to be studied, especially as it was recently proposed that 
female oestrus variability is not greater than intrinsic variability in males (Beery, 2018). Further, if a 
dysregulation of oestrogen signalling is responsible for the lacking effect of minocycline in female HAB 
rats has to be evaluated in the future. Moreover, a sex dependence in minocycline metabolism as cause 
for the behavioural difference was considered. Minocycline is generally not metabolized by the body but 
subject to biotransformation in the liver. The microbiologically inactive metabolites are then excreted via 
the urine and faeces (Jonas and Cunha, 1982; Saivin and Houin, 1988). Therefore, a sex difference in 
behaviour and microglial density in female HAB rats due to a different minocycline metabolism seems 
unlikely. Besides, although no difference on antibiotic effectiveness of minocycline between males and 
females is reported so far, the behavioural effect might require a higher dose in female rats than in males 
or a longer treatment duration. In support, sex-dependent sensitivity in antidepressant treatment is 
reported. In rats, the anxiolytic-like effect of diazepam as well as the antidepressant effect of desipramine 
is found in males while females do not respond to the treatment (Simpson et al, 2012), proposing a 
sensitivity difference between male and female HAB rats as underlying mechanism for the sex difference 
in the behavioural response to the treatment. To explain the behavioural outcome and microglia in female 
HAB rats, though, a detailed knowledge about the exact mechanism of minocycline is required. 
Nevertheless, as female HAB rats did not respond to minocycline treatment, it is tempting to speculate 
that in female HAB rats, depressive-like behaviour might be mediated by another system than in male 
HAB rats. 
Further, the given behavioural results imply a mechanism for the antidepressant action of minocycline. 
Minocycline treatment increased struggling and decreased immobility (Molina-Hernández et al, 2008b; 
Wang et al, 2018). Previous studies, using the same protocol for the FST as here, show that swimming 
behaviour is increased in response to SSRI administration, while struggling behaviour is increased after 
administration of antidepressants that selectively target catecholaminergic signalling. As in the present 
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thesis minocycline also increased struggling behaviour, but not swimming, it might rather target the 
catecholaminergic transmission (Cryan et al, 2002; Detke et al, 1995; Lucki, 1997; Slattery and Cryan, 
2014). In line, minocycline does not restore elevated levels of tryptophan or 5-HT in the brain of male 
mice after LPS injection (O’Connor et al, 2009b). In the learned helplessness paradigm, minocycline failed 
to reverse the elevated 5-HT turnover in the orbitofrontal cortex, pointing towards a lack of effect on 5-
HT signalling (Arakawa et al, 2012). In turn, minocycline restores DA levels after E. coli infection (Mansour 
et al, 2018) and prevents nigrostriatal dopaminergic degeneration in a mouse model of Parkinson’s 
disease (Du et al, 2001). Thus, together with the present results showing increased struggling, these data 
indicate a catecholaminergic mechanism of action. A stronger effect on catecholamines like DA might also 
contribute to the sex difference seen in HAB rats. Female rats have a higher DA uptake und greater DA 
release in the striatum and PFC than male rats (Duchesne et al, 2009; Walker et al, 2000). As minocycline 
affect rather catecholamine levels, a high DA level in female rats from the beginning might prevent a 
beneficial effect. Thus, measurement of DA levels in male compared to female HAB rats might give some 
indication about a potential mechanism. 
In addition, in the present thesis male and female HAB and NAB rats did not respond to escitalopram 
treatment. Previously, repetitive transcranial magnetic stimulation (Keck et al, 2001a) as well as transient 
inactivation of the infralimbic cortex (Slattery et al, 2011) had an antidepressant effect in male HAB rats. 
Further, chronic citalopram treatment of 8 weeks is necessary to ameliorate the depressive-like 
phenotype in male HAB rats (Keck et al, 2003). In turn, 4-week treatment with escitalopram (Montgomery 
et al, 2001; Yilmaz et al, 2011) or 5 weeks with citalopram (Rygula et al, 2006) ameliorates chronic stress-
induced depressive-like behaviour in male rats. In contrast, unstressed rats do not show behavioural 
alterations in those studies in response to citalopram or escitalopram. The SSRI fluoxetine is likewise not 
able to increase struggling behaviour in unstressed male rats (Molina-Hernández et al, 2008a) In the 
present thesis, an amelioration of the depressive-like phenotype was not present in male and female NAB 
rats. The current study applied a dose of 10 mg / kg escitalopram based on previous publications showing 
a behavioural effect (Burke, 2002; Jayatissa et al, 2006; Papp and Sánchez, 2001; Yilmaz et al, 2011). 
However, an 8-week treatment regimen with 10 mg / kg citalopram was required previously to reverse 
depressive-like behaviour in male HAB rats (Keck et al, 2003). Therefore, the present lack of escitalopram 
effects on HAB rats are probably due to the fact that escitalopram was applied for only 3 weeks. Also, only 
one dose of escitalopram was tested, a higher dose might be able to affect depressive-like already at this 
point. Moreover, it is assumed that the treatment effect of antidepressants is not primarily caused by the 
immediate increase in monoamines as it takes weeks of treatment for a mood-enhancing effect (Krishnan 
and Nestler, 2008) but via secondary changes in molecular and cellular neuroplasticity (Nestler et al, 2002; 
Pittenger and Duman, 2008). Thus, a longer treatment period with escitalopram might be necessary to 
improve the treatment-resistant behavioural phenotype of HAB rats. Minocycline was effective during 
Discussion  103 
 
 
this timeframe, though, demonstrating a faster and stronger effect than escitalopram that is potentially 
mediated due to faster or direct secondary changes. 
Importantly, the combinatory treatment abolished the antidepressant effect of minocycline in male HAB 
rats. When minocycline is given in humans in combination with several conventional antidepressants like 
SSRIs or tricyclics, mood stabilizers and antipsychotics, an overall improvement in MDD symptoms can be 
observed (Dean et al, 2017; Husain et al, 2017; Rosenblat and McIntyre, 2017). However, two studies 
analysing data from the large-scale real-world human study “sequenced treatment alternatives to relieve 
depression” (STAR*D), concentrating exclusively on the SSRI citalopram, reveal that administration of 
citalopram in combination with a non-steroidal anti-inflammatory drug reduces the probability of 
remission (Gallagher et al, 2012; Warner-Schmidt et al, 2011). In this thesis, augmentation of minocycline 
with escitalopram abolished the antidepressant effect of minocycline. Interestingly, in rats a combination 
of minocycline with glutamate antagonists or the tricyclic desipramine, which is a relatively selective 
noradrenaline reuptake inhibitor, improves depressive-like behaviour (Molina-Hernández et al, 2008b, 
2008a). However, and similar to the obtained results in the present experiment, when combined with the 
SSRI fluoxetine either systemically (Molina-Hernández et al, 2008a) or locally into the nucleus accumbens 
(Molina-Hernández et al, 2008b), the antidepressant effect of minocycline is abolished. Citalopram or 
fluoxetine reduce the density of cell positive for tyrosine hydroxylase, the limiting enzyme for DA 
biosynthesis, in the substantia nigra (MacGillivray et al, 2011). This mechanism might counteract the 
previously mentioned beneficial effects of minocycline on DA signalling. Further, this strengthens the 
hypothesis of a catecholaminergic mechanism for minocycline and strongly suggests that minocycline 
does not synergize with the mechanism responsible for the antidepressant effect of SSRIs. Nevertheless, 
though minocycline and escitalopram do not synergize in their action in this experiment, minocycline does 
not necessarily target the monoaminergic mode of action, but might affect substance-specific secondary 
mechanisms or elicit local pharmacokinetic interactions. Of note, an influence of repeated testing 
(Bouwknecht et al, 2004; Cryan and Holmes, 2005; Holmes et al, 2001; McIlwain et al, 2001) on 
minocycline-induced behavioural improvement was considered. To counteract this phenomenon, the 
order of tests for the present thesis was chosen from the least stressful (SPAT) to the most stressful test 
(FST) and all rats were granted a day of rest between two behavioural tests to avoid stress- or experience-
induced bias.  
As the behavioural effect of minocycline was restricted to male HAB rats at this dose (40 mg / kg), anxiety-
like behavioural was generally not affected, and female HAB rats only showed facilitated social prefence, 
a dose-dependent effect of minocycline was considered. Most studies apply minocycline in a dose ranging 
from 10 to 100 mg / kg (Yong et al, 2004). The dose of 40 mg / kg in the first experiment was chosen based 
on previous studies demonstrating a physiological and behavioural effect in both male rats and mice 
without affecting locomotor activity (Chen et al, 2009; Hinwood et al, 2012, 2013; Kreisel et al, 2014; 
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Saeedi Saravi et al, 2016a; Tong et al, 2017; Xu et al, 2017). Even a high dose of minocycline, up to 160 mg 
/ kg, does not affect locomotor activity in rats but shows beneficial behavioural effects (Amorim et al, 
2017; Festoff et al, 2006; Saeedi Saravi et al, 2016b). Thus, a higher dose of 80 mg / kg minocycline was 
administered exclusively to male and female HAB rats. Interestingly, the higher dose led to identical 
results as obtained with 40 mg / kg, namely an increase in social preference in both sexes and alleviated 
depressive-like behaviour only in male HAB rats, while anxiety-like behaviour and locomotor activity 
remained unchanged. Dose-response studies of acute or repeated minocycline indicate the same 
treatment response to 40, 80, and 160 mg / kg minocycline on depressive-like behaviour (Molina-
Hernández et al, 2008a; Saeedi Saravi et al, 2016b). Further, studies using the highest doses of minocycline 
administer it only acutely (Burke et al, 2014; Chen et al, 2009; Molina-Hernández et al, 2008a) or 
subchronically (Du et al, 2001; Saeedi Saravi et al, 2016a) in both male rats and mice. A higher dose than 
80 mg / kg minocycline for a longer time might eventually exert beneficial effects in female HAB rats. 
However, a higher dose for a longer duration to elicit a treatment response in female HAB rats might also 
lead to negative side effects or locomotor changes. Nevertheless, a beneficial effect cannot be excluded.  
 
4.1.2 Minocycline reduces microglial quantity specifically in male HAB rats 
Given the lack of success and delayed onset of action of current antidepressants, research turned towards 
other systems as potential treatment. Since 1991, the inflammatory hypothesis of depression was 
developed and extended throughout the last years, studies focus on the analysis of immune functions as 
a role in psychiatric disorders. Various groups find dysregulations in peripheral cytokine concentrations 
and, importantly, abnormalities in microglia numbers and activation in the brain in both clinical and 
preclinical studies (Dantzer et al, 2011; Maes, 1995; Smith, 1991; Soczynska et al, 2012; Yirmiya et al, 
2015). Most studies linking neuroinflammation to MDD show that increased microglial activation is 
associated with mood disorders (Dheen et al, 2007; Yirmiya et al, 2015). Minocycline is known to intervene 
in microglial functioning by dampening microglial activity and proliferation, and, thereby, potentially 
executing its antidepressant effects (see Introduction chapter 1.2.3). Therefore, microglial quantity in 
male and female HAB rats in comparison to NAB rats were assessed after 22 days of minocycline, 
escitalopram, or combinatory treatment as potential mechanism contributing to the behaviour 
phenotype of HAB rats. The PFC is a brain region highly implicated in MDD. Deep brain stimulation of 
Brodmann Area 25 (infralimbic PFC) in MDD patients normalizes its hyper-functioning and ameliorates 
symptoms of MDD (Mayberg et al, 2005), corresponding to an antidepressant effect of a transient 
inactivation of the PFC in rats (Slattery et al, 2011). Patients suffering from MDD also show reduced grey-
matter volume and glial density in the PFC (Krishnan and Nestler, 2008; Rajkowska, 2003; Rajkowska et 
al, 1999), correlating with the severity of symptoms (Carlson et al, 2015). Similarly, in a model of 
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depression, neonatal clomipramine, male rats show a reduced PFC volume and increased depressive-like 
behaviour that is both reversed by intracranial self-stimulation (Chakraborty et al, 2019). Microglial 
activation in response to stress is also found in the PFC (Hinwood et al, 2012, 2013; Tynan et al, 2010) and 
in the olfactory bulbectomy model of depression, microglial inhibition in the PFC acted antidepressant 
(Burke et al, 2014). Therefore, the analysis was performed in the prelimbic and infralimbic prefrontal 
cortex of male and female HAB and NAB rats.  
HAB rats showed reduced microglial numbers in the infralimbic and prelimbic PFC compared to NAB rats 
independent of treatment and corresponding to their behavioural phenotype. Recently, a dynamic and 
bi-directional alteration in microglial status rather than an upregulation in microglial function has been 
hypothesized to underlie depressive-like behaviour. In this study in male rats, chronic stress leads to an 
initial short-term upregulation of microglial quantity followed by increased microglial apoptosis and a 
permanent decline in microglial numbers in both the hippocampus and PFC (Kreisel et al, 2014). This effect 
was recapitulated in male mice (Gong et al, 2018; Tong et al, 2017; Zhu et al, 2018) and female rats 
(Bollinger et al, 2017). Additionally, repeated social defeat during adolescence leads to reduced microglial 
numbers but with a strongly activated profile in the PFC of adult male mice (Rodríguez-Arias et al, 2018) 
and repeated CORT injection, mimicking a repeated stress response, inhibits microglia proliferation in the 
hippocampus (Wennström et al, 2006). Therefore, the lower microglial density in the PFC of HAB rats 
might be caused by their permanent stressed stage, as expressed by the hyper-reactive HPA axis (Keck et 
al, 2002; Landgraf et al, 1999), inducing a constant microglial activation and, thus, apoptosis. Interestingly, 
an abnormal glial activity and immune function is reported in two other rat models of depressive-like 
behaviour. Female Wistar Kyoto rats show increased Iba-1 immunoreactivity in the hippocampus but 
normal levels in the amygdala which is indicative for a higher microglial activity (Mileva et al, 2017). In 
male Wistar Kyoto rats, in the infralimbic cortex an astrocytic deficit is linked to the behavioural 
phenotype (Gosselin et al, 2009) as well as a potential attenuation in microglia expression in response to 
stress (Sherwin et al, 2014). Unfortunately, the authors of the latter paper did not specify whether male 
or female rats were used. A reduced hippocampal volume and neuronal numbers together with increased 
astrocyte immunoreactivity in the hippocampus were found in male FSL rats (Gómez-Galán et al, 2012; 
Kaae et al, 2012), the latter a phenomenon that is also observed in reactive astrocytes (Eddleston and 
Mucke, 1993). If the resident microglia in the PFC of HAB rats are continuously and stronger activated 
than microglia of NAB rats or have impaired functioning with increased apoptosis remains to be studied, 
though. Considering the long-term effects of social defeat during adolescence (Rodríguez-Arias et al, 
2018) and the age-independent behavioural and neuroendocrine phenotype of HAB rats, the reduced 
microglial numbers in the PFC might occur already at a very early stage and induce a long-lasting microglial 
dysfunction that contributes to the HAB phenotype. Therefore, the analysis of microglial activation stages 
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and dynamics in HAB rats already from postnatal until an adult age might reveal a mechanism underlying 
the behavioural phenotype in HAB rats. 
Interestingly, minocycline further reduced microglial density exclusively in male HAB rats, an effect that 
was attenuated by escitalopram co-administration and paralleled the antidepressant behavioural 
outcome. Likewise, minocycline reduced chronic stress-induced activation of microglia in the infralimbic 
and prelimbic PFC (Hinwood et al, 2012) in male rats. Minocycline prevents microglial proliferation and a 
subsequent reduction in microglial density after chronic stress in male rats (Gong et al, 2018; Kreisel et al, 
2014; Tikka et al, 2001; Tong et al, 2017). Thus, the minocycline-induced decline in microglial density in 
male HAB rats might be caused by inhibited microglial proliferation, but not apoptosis, in the PFC of male 
HAB rats. Thereby, the dysregulated inflammatory phenotype in HAB rats might be ablated and alleviate 
depressive-like behaviour in HAB rats. Similar to the reduction in microglial numbers, a transient 
inactivation of the infralimbic cortex of male HAB rats had antidepressant effects (Slattery et al, 2011). 
Importantly, in the aforementioned studies, rats that were not stressed but treated with minocycline did 
not show changes in microglial density. A related condition was observed in behaviour when minocycline 
did not affect social or depressive-like behaviour in rodents that were not challenged beforehand. 
Consequently, the present results together with the available literature indicate that pathological 
behaviour is connected to altered microglia activity and minocycline requires not only behavioural 
aberrations but also an inflammatory state for an effective treatment. In support, in a recent clinical study 
minocycline failed to alleviate symptoms of schizophrenia, presumably due to a lack of inflammatory 
activation in the patients (Deakin et al, 2018). 
 
Microglial activation and dysregulation can also occur via activation from peripheral immune components 
that cross the BBB (reviewed in Langgartner et al, 2019). Essential for the maintenance of BBB integrity is 
coverage of blood vessels with astrocytes; a state that can be compromised by an inflammatory state 
(Malik and Di Benedetto, 2018). Male HAB rats show a reduced astrocyte coverage of blood vessels in the 
brain (Di Benedetto et al, 2016), indicating an impaired BBB integrity. During CNS inflammation, stress, or 
increased BBB permeability, macrophages can infiltrate the brain and enhance inflammatory processes 
(Wohleb et al, 2011; Yin et al, 2017). Recently, minocycline has been shown to restore BBB permeability 
in male rats (Soczynska et al, 2012; Yang et al, 2015a, 2015b). Together with its anti-inflammatory effects, 
minocycline might restore the potentially impaired BBB permeability in male HAB rats and thereby reduce 
the number of macrophages in the brain. This is of importance, as Iba-1, used as a marker for microglia, 
is also expressed and detectable in macrophages (Imai and Kohsaka, 2002). Therefore, a prevented 
macrophage infiltration into the brain might contribute to the reduced microglial number in the PFC of 
male HAB rats after minocycline treatment. In order to validate these hypotheses, a more detailed analysis 
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of the immune system in HAB rats is necessary. An alternative marker like the microglia-specific 
transmembrane protein 119 will distinguish between infiltrating macrophages and resident microglia. On 
a translational level, reduced glial density is found in the amygdala (Bowley et al, 2002), anterior cingulate 
cortex (Cotter et al, 2001a), Brodmann’s area 24 (anterior cingulate cortex; Öngür et al, 1998), and the 
orbitofrontal cortex (Rajkowska et al, 1999) of patients that suffer from MDD (for review see Cotter et al, 
2001b). Further, reduction in grey-matter volume negatively correlates with the severity of MDD 
symptoms in men (Carlson et al, 2015). The decline in microglia seen especially in male HAB compared to 
male NAB rats hence might – at least in part – explain the known volume reductions. Although the 
underlying mechanisms of microglial dynamics need to be revealed in more detail, the present results 
substantiate the hypothesis of an impaired microglial homeostasis and functioning as underlying 
mechanism for depressive-like behaviour. A more specific manipulation of microglia will be necessary to 
study their influence on behaviour in HAB rats. Recently, the application of a colony-stimulating factor 1 
receptor antagonist was shown to eliminate about 99 % of all microglia in the brain (Elmore et al, 2014). 
As this method does not inhibit but eliminate microglia in the whole brain, though, their ablation is neither 
reversible nor region-specific inactivation. Alternatively, microglial activation or inhibition can be induced 
by LPS and IFN-γ or IL-4 and IL-13, respectively (Subramaniam and Federoff, 2017), enabling in a region-
specific manipulation of cellular activity. However, these substances activate the whole immune system 
of the brain. To achieve a cell-specific manipulation of microglia, a cell-targeted manipulation, like 
chemogenetic silencing or activation of microglia, is necessary.  
The minocycline-induced diminished microglial density in the PFC of male HAB rats was abolished in 
combination with escitalopram. Interestingly, the SSRIs citalopram and fluoxetine increase cytokine 
concentrations in the frontal cortex of male mice (Warner-Schmidt et al, 2011) and escitalopram is 
proposed to activate microglia (MacGillivray et al, 2011). The lack of behavioural effect of escitalopram 
treatment and the abolished effect of minocycline in the combinatory treatment of the present thesis 
might be accounted for by this pro-inflammatory effect of escitalopram. Escitalopram alone also did not 
affect microglial density in male or female HAB rats, probably due to the presence of an inflammatory 
status per se in HAB rats. Microglia of female HAB rats did also not react to the provided treatment. A 
genetic component as underlying mechanism for the gender mismatch in MDD has to be considered in 
male vs. female HAB rats. A recent gene expression study provides a comprehensive characterization of 
transcriptional profiles of men and women suffering from MDD in comparison to a mouse model of 
depression. Here, transcriptional changes in six different brain regions, like the ventromedial PFC and the 
orbitofrontal cortex, only marginally overlap between women and men. In men, gene modules regulating 
catecholamine metabolism, while in women rather the inflammatory response and synaptic transmission 
is upregulated. Similarly, chronically stressed male and female mice exhibit a transcriptional overlap of 
only 20 – 25 % between sexes in response to stress (Labonté et al, 2017), suggesting in both organisms a 
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profound sex difference in transcriptional and therefore physiological responses, especially regarding 
inflammation and catecholamines. In general, both the innate and adaptive immune system show a 
distinctly different response pattern in male and female rodents as well as humans with a higher immune 
response in females in the majority of studies (for review see Klein and Flanagan, 2016; Pitychoutis and 
Papadopoulou-Daifoti, 2010). Regarding central immune responses, male and female rats appear to have 
comparable microglial densities in various brain regions. Interestingly, female rats show an increased ratio 
of primed to ramified microglial morphology in the medial PFC after chronic stress compared to male rats 
(Bollinger et al, 2016, 2017), indicating a stronger microglial activation. Additionally, early perturbations 
in microglial development show profound effects on adult female, but not male, microglia (Thion et al, 
2018) that might cause the higher immune activation. A similar phenomenon could be present HAB rats. 
An even higher immune activation in female HAB rats, together with the modulatory role of microglia in 
behaviour, neuronal structure, and plasticity (see chapter 1.2), might account for the lacking effect of 
minocycline on microglia and depressive-like behaviour at the studied time point and dose. Since female 
HAB rats showed facilitated social preference but not depressive-like behaviour in response to 
minocycline, accompanying microglial changes might still occur but in another brain region (e.g. 
amygdala).  
 
4.1.3 Minocycline alters the gut microbiome composition and dampens peripheral immune 
functioning 
The multidirectional communication network within the MGB axis modulates not only on behaviour but 
also microglia proliferation and maturation (Erny et al, 2015) and – in case of a gut microbiota dysbiosis – 
can result in neuroinflammation mediated by chronic microglial activation (Kim and de La Serre, 2018). As 
an antibiotic, minocycline modulates – beside the inflammatory system – the microbial composition of 
the gut (Wong et al, 2016), supporting the robust link between microbiome and behaviour known as the 
microbiome-gut-brain axis (see introduction chapter 1.3.2). Therefore, the gut microbiome and one of its 
major metabolites, 3-OH-butyrate, as well as peripheral cytokine concentrations of HAB and NAB rats 
were analysed to unravel potential modulations in the microbiome-gut-brain axis that might contribute 
to the behavioural phenotype. As the microbiome analysis is extensive, the evaluation of the obtained 
microbiome data of general phyla was focused on butyrate-producing bacteria. Further, as only male HAB 
rats responded regarding depressive-like behaviour and microglial density in the PFC, analyses were 
restricted to male HAB vs. NAB rats. Male HAB and NAB rats originating from the same breeding facility 
showed comparable total bacterial numbers in their cecal content. However, profound differences were 
found in global gut microbiota composition, reflecting the robust phenotypic differences between the two 
breeding lines. Interestingly, in chronic stress-induced (Wong et al, 2016) or OB-induced depressive-like 
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behaviour in mice (Park et al, 2013) and in patients suffering from MDD (Jiang et al, 2015; Kelly et al, 2016; 
Peter et al, 2018; Zheng et al, 2016) a marked shift in microbial composition was observed. 
Transplantation of MDD patient fecal microbiota into male rats or mice induced the same depressive-like 
phenotype and even physiological features, like a dysregulated tryptophan metabolism, compared to 
rodents colonized with “healthy microbiota” from control individuals (Kelly et al, 2016; Zheng et al, 2016), 
underlining the crucial role of gut microbiota in health and disease. The reported visible shift in 
microbiome composition similar in humans and rodents also might serve as a prerequisite for clinical 
studies. 
As expected, 3 weeks of minocycline treatment significantly reduced bacterial richness analogous in both 
lines and resulted in yet persisting, but diminished, group differences. A decline of gut bacterial diversity 
represents a frequent side effect of antibiotic exposure that was only observed within NAB microbiomes, 
yet not within HAB rats. Since the calculated Shannon diversity index integrates richness and evenness of 
taxa, this implies a more even distribution of species in HAB rats following treatment. In healthy humans, 
22 days of minocycline treatment induced a shift in microbiome composition, which could be shown by a 
reduced Shannon diversity index even after a 1-week (Zaura et al, 2015). This suggests a partial 
equalization of the microbiota between HAB and NAB rats that might contribute to the observed 
antidepressant effect of minocycline in HAB rats. Importantly, in both humans and rats, a comparable 
shift in microbial composition in MDD and rats with high depressive-like behaviour as well as a comparable 
reaction of the microbiome to minocycline is observed. Thus, current research indicates that an alteration 
in specific aspects of gut microbiota might underlie the depressive-like phenotype and, together with the 
obtained results in this thesis, discloses a crucial prerequisite for a translational approach and facilitate 
the implementation of preclinical results into clinical practice.  
A detailed taxonomic analysis of the microbiome composition between HAB and NAB rats revealed 
distinct differences in bacterial families. HAB rats showed reduced levels of Lachnospiraceae in 
comparison to NAB rats, which is in line with two recent studies demonstrating that underrepresentation 
of the Lachnospiraceae family in human fecal microbiota correlated with depression (Naseribafrouei et 
al, 2014; Peter et al, 2018). Minocycline treatment expanded the Lachnospiraceae abundance of HAB rats 
to the level of NAB rats. A similar dynamic change in Lachnospiraceae was found in a model of chronic 
restraint stress-induced depressive-like behaviour. Minocycline treatment was able to reverse the 
behavioural phenotype and increased Lachnospiraceae abundance in microbiome samples (Wong et al, 
2016). Further, minocycline increased the relative abundance of the Clostridiales Family XIII in both HAB 
and NAB rats. Both Lachnospiraceae and Clostridiales Family XIII accommodate a large part of butyrate-
producing bacterial genera (Ueki et al, 2018). Correspondingly, both HAB and NAB rats show an increase 
in plasma 3-OH-butyrate levels that was higher in HAB than in NAB rats. Plasma 3-OH-butyrate levels 
positively correlated with both bacterial families in HAB rats, while in NAB rats only a positive correlation 
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between 3-OH-butyrate and the Clostridiales Family XIII was detectable, proposing a rather 
Lachnospiraceae-mediated antidepressant effect. Butyrate itself is crucial in promoting colonic 
homeostasis and both butyrate and 3-OH-butyrate are known for its anti-inflammatory effects on the 
peripheral and central immune system (see Introduction chapter 1.3.3). In the periphery, butyrate inhibits 
macrophage and T cell activity (reviewed in Kim et al, 2014). In line, after minocycline treatment a 
decreased plasma IFN-γ concentration in both HAB and NAB rats was observed. IFN-γ is produced by IL-
12-activated T helper type 1 cells and though there is no significant difference or even a trend in IL-12 
concentrations between HAB and NAB rats after minocycline treatment, minocycline seemed to reduce 
IL-12 levels. Thus, minocycline might exert its peripheral anti-inflammatory effects by inhibiting T cell 
activation (reviewed in Garrido-Mesa et al, 2013; Giuliani et al, 2005) together with butyrate and 
decreasing IFN-γ concentrations in the plasma, supporting a regulatory role of both minocycline and 
butyrate on peripheral T cells and inflammation. The gut microbiome has also profound impact on the 
appropriate development of microglia (Erny et al, 2015; Thion et al, 2018). An involvement of the central 
immune system remains to be studied, however an anti-inflammatory effect of butyrate on microglia has 
been reported in terms of inhibition of microglial activation (Fu et al, 2015) and induction of microglial 
apoptosis (Chen et al, 2007). Butyrate-mediated microglial apoptosis might therefore contribute to the 
reduced microglial numbers in the PFC of male HAB rats seen in this study. Recently, 3-OH-butyrate and 
butyrate have shown antidepressant-like effects in both rats (Wei et al, 2015) and mice (Resende et al, 
2013; Valvassori et al, 2015). These findings point towards a crucial role of bacteria-produced butyrate as 
a mediator of behaviour and microglia alterations in male HAB rats.  
A microbiome dysbiosis in HAB rats might have long-lasting and severe effects on microglia in female than 
in male HAB rats, thereby preventing a beneficial effect of minocycline on microglia and depressive-like 
behaviour. Moreover, the gut microbiota has profound influence on BBB permeability (Braniste et al, 
2014). A dysbiosis in gut microbial composition can impair gut barrier function and increase bacterial 
infiltration into the mucosal layer and eventually into systemic circulation (Abdel-Haq et al, 2018; Kelly et 
al, 2015b). Increased circulation, and a subsequent immune response, can compromise the BBB and cause 
a heightened microglial activation and a pro-inflammatory status in the brain (Riazi et al, 2008), causing 
the behavioural and microglial phenotype seen in HAB rats. In support, certain bacterial strains not only 
activate microglia but induce microglial apoptosis (Lehnardt et al, 2007), which might contribute to the 
decreased microglial numbers in HAB rats. In GF mice, an increased BBB permeability could be rescued by 
colonization with butyrate-producing bacteria or butyrate administration (Braniste et al, 2014; Kelly et al, 
2015b), underlining the regulatory role of microbiota in BBB homeostasis. It is therefore tempting to 
speculate that in HAB rats an increased BBB permeability, potentially caused by gut microbial dysbiosis, 
induces the behavioural and microglial phenotype. The minocycline-mediated increase in butyrate levels 
might exert beneficial effects on HAB gut barrier and BBB function and thus on behaviour and microglia. 
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4.1.4 Conclusion and outlook of chronic minocycline treatment in rats 
In summary, the present results provide evidence that the high depressive- and anxiety-like phenotype of 
HAB rats is accompanied by reduced microglial numbers in the infralimbic/prelimbic PFC and a distinct 
shift of the gut-bacterial composition. This emphasizes that HAB rats are a valid model for inflammation- 
and microbiome-associated depressive-like behaviour. Additionally, it points towards a complex interplay 
between microbiota/microbial metabolites and the immune system determining behaviour in HAB rats, 
as proposed by the MGB axis. Chronic minocycline treatment, but not escitalopram or the augmentation 
strategy, reversed depressive-like behaviour in a sex- and trait-specific manner, proposing HAB rats as 
model for treatment-resistant depression and minocycline as potential treatment. The behavioural results 
were accompanied by decreased microglial numbers in the PFC. Minocycline also changed the microbial 
composition markedly by increasing Lachnospiraceae abundance to NAB levels, indicating a 
“normalization” of the HAB microbiome corresponding to the behavioural and microglial alterations. 
Thus, modulation of the MGB axis reverses behavioural aberrations and thus represents a valid novel 
treatment target in psychiatric disorders. The observed changes in the metabolite 3-OH-butyrate likely 
contribute to the phenotypical effects. Although the attributable contribution of minocycline and butyrate 
to the anti-inflammatory and behavioural effect in this study remains to be identified, they strengthen 
the multimodal effects of minocycline. Importantly, the observed results in microglia and depressive-like 
behaviour were restricted to male HAB rats, underlining a sex-dependent effect of minocycline. This sex-
dependence might be caused be several mechanisms like a differentially regulated HPA axis and 
differences in immune reactivity. Therefore, the anti-inflammatory effect of minocycline might be the 
driving force in HAB rats that leads to its beneficial effects, whereas a different immune regulation in 
female HAB rats might prevent this. In addition, as the microbiome composition of females was not 
studied in the present thesis, the impact of minocycline on female gut microbiota and consequential 
changes in composition and / or metabolome has to be considered as an underlying mechanism for the 
lack of effect in female HAB rats.  
In the course of clinical application, the present results indicate that promoting an anti-inflammatory state 
by control of microglial activation and/or modulation of the gut microbiome and metabolome, as shown 
after prolonged minocycline treatment, offers promising potential as a therapeutic strategy in treatment-
resistant MDD. However, the present results together with the currently available literature recommend 
a cautious consideration as to whether minocycline is suitable in humans. The augmentation with SSRIs 
like escitalopram seems ineffective regarding both behaviour and microglia. Combining minocycline with 
SNRIs or SDRIs might elicit a faster and stronger treatment response. Moreover, a pro-inflammatory 
profile might be necessary for minocycline to elicit a treatment effect and the distinct sex difference in 
depressive-like behaviour of HAB rats strongly discourages the application in women. Indeed, a recent 
clinical study with minocycline failed to alleviate symptoms of schizophrenia, presumably due to a lack of 
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inflammatory activation in the patients (Deakin et al, 2018), which may explain some of the recent high 
profile clinical failures of minocycline. It might therefore be recommended to include the use of 
inflammatory biomarkers to identify the subpopulation of patients responding to immune-targeted 
treatment.  
Nevertheless, the present study was designed to detect an early response (3 weeks) to minocycline and 
did not mimic a clinical antidepressant treatment. A longer treatment duration or a higher dose might 
reveal different effects. Besides, some limitations of the executed experiments and analyses have to be 
considered. The present results are of exploratory and descriptive nature, and a causality between the 
observed effects has to be shown yet. Therefore, future studies are needed to identify the mechanism 
underlying the distinct effects of minocycline in the complex interplay of gut microbiome, the immune 
system, and behaviour. In particular, fecal transplantation and administration of microbiome metabolites, 
especially butyrate, in HAB rats might give direct evidence for an involvement of gut microbiota and the 
peripheral immune system. Further, a more comprehensive analysis of microglia activation and function, 
potentially via morphological changes or the expression pattern of activation, proliferation, and apoptosis 
marker, will provide evidence for a more mechanistical background. Following this, a specific activation 
and inhibition of microglia will reveal a more detailed view on their effects in HAB rats. Beyond a systemic 
effect of minocycline, its detailed intracellular mechanisms remain elusive. Several intracellular signalling 
cascades, like IDO signalling, were proposed as underlying mechanism of action for minocycline. Overall, 
these approaches should provide a causal link between the microbiota-gut-brain axis and behaviour in 
depression and a valid foundation for translation into clinical practice. 
 
4.2 Minocycline does not reverse CSC-induced behavioural, physiological and 
neuroendocrine consequences 
In the course of specifying the effects of minocycline on symptoms of psychiatric disorders, an alternative 
model to the genetically inherited anxiety- and depressive-like behaviour of HAB rats was employed. As 
chronic stress is a major risk factor for psychiatric disorders (see Introduction chapter 1.4), the CSC 
paradigm was chosen. The CSC paradigm has been developed at the University of Regensburg (Reber et 
al, 2007) and has been successfully established at the University of Ulm (Reber et al, 2016b). It is well 
characterized for its diverse effects on behavioural, immunological, and physiological parameters 
(reviewed in Langgartner et al, 2015; Reber et al, 2007; Reber and Neumann, 2008a; Uschold-Schmidt et 
al, 2012). Among those, increased anxiety-like behaviour shown in several behavioural tests and elevated 
adrenal, but decreased thymus, weight (Langgartner et al, 2018a) are the most prominent and reliable 
biomarkers. As minocycline has shown beneficial effects on behavioural consequences of chronic stress, 
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an amelioration of CSC-induced symptoms seems probable. Importantly and in contrast to HAB rats, CSC 
mice do not show changes in depressive-like behaviour. Therefore, it offers the opportunity to identify 
minocycline-induced effects specifically on anxiety-like behaviour that were not achieved in the comorbid 
phenotype of HAB rats. However, in 2014 the department moved into a novel facility and hence, 
experiments are now conducted in novel laboratories. An a priori re-establishment of the paradigm was 
hence crucial in order to determine potential minocycline-induced changes in the CSC paradigm. Thus, I 
aimed to re-establish the CSC paradigm in the laboratory facilities to ensure valid experimental results on 
later manipulations. After confirming an established CSC, I analysed the effects of 80 mg / kg minocycline 
applied acute and subchronically following 20 days of chronic psychosocial stress. In the course of this, 
the influence of acute minocycline on anxiety-like behaviour and the impact of subchronic minocycline 
treatment on anxiety- and depressive-like behaviour as well as physiological and neuroendocrine 
parameters were evaluated.  
 
4.2.1 Successful validation of the CSC paradigm 
The present thesis demonstrated a successfully established CSC paradigm after the department moved to 
a novel facility, pronounced by increased anxiety-like behaviour in the LDB and on the EPM and increased 
adrenal, but decreased thymus, weight after 20 consecutive days of CSC. In line, previous studies showed 
a robust increase in anxiety-like behaviour in the LDB and the EPM after 19 and 20 days of CSC exposure, 
respectively (Langgartner et al, 2015; Reber et al, 2007; Reber and Neumann, 2008a). Further, CSC mice 
showed increased adrenal weight while thymus weight was decreased (Langgartner et al, 2018a; Reber 
et al, 2007, 2016b). Therefore, the CSC-induced physiological and behavioural parameters could be 
induced at the new facility and provide evidence for a valid CSC paradigm. 
These results are of importance, as a critical issue in using animal models and interpreting the obtained 
results is experimental reproducibility between laboratories. False positive or negative results by flawed 
preclinical studies can create wrong expectations and study designs in clinical and preclinical studies that 
eventually lead to costly inefficiencies (Freedman et al, 2015; Slattery and Cryan, 2014). This is all the 
more true since about 50 % of all conducted studies seem to be irreproducible (Freedman et al, 2015), 
like the light-enhanced startle test (Walker et al, 2003), and minor environmental changes like water 
composition (Langgartner et al, 2017a) can influence the outcome of experiments. In the course of 
identifying potential beneficial effects of minocycline on CSC-induced maladaptations, a validation and 
reliable reproduction of the CSC paradigm and its stress biomarkers after moving to the new facility was 
an essential prerequisite. 
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4.2.2 8 days of minocycline after stressor termination is not sufficient to alleviate stress-induced 
physiological and affective symptoms 
In addition, the capability of an 8-days minocycline treatment (80 mg / kg) to reverse CSC-induced 
physiological as well as affective disorders was evaluated, as previous studies demonstrate CSC-induced 
consequences lasting for this period. Immediately after 20 days of CSC, the time spent in the light box of 
the LDB was reduced in CSC mice concomitant with decreased locomotor activity. 8 days after stressor 
termination, CSC mice persistently showed increased anxiety-like behaviour in the OF / NOR test but 
comparable locomotion and time spent immobile in the FST as SHC mice. Further, CSC mice had an 
increased spleen weight and gained significantly more weight than SHC mice. A CSC-induced increase in 
adrenal was sustained after 8 days, paralleled by reduced adrenal sensitivity after in vitro stimulation and 
unchanged plasma ACTH and CORT levels in comparison to SHC mice. In line with the present results, a 
long-term presence of several CSC-induced physiological, immunological, and behavioural symptoms was 
postulated previously. Thus, 8 days after stressor termination, CSC mice still express the highly anxious 
phenotype accompanied by reduced locomotor activity during the dark phase. Body weight changes 
during the CSC paradigm remain variable. However, after stressor termination an increased body weight 
gain is observed. These symptoms are concomitant with a long-term elevated release of pro-inflammatory 
cytokines from in vitro stimulated mesenteric lymph nodes. Additionally, a CSC-induced dysregulation of 
the HPA axis is robustly reported on the level of the adrenal gland and plasma ACTH and CORT responses 
(Langgartner et al, 2015; Reber et al, 2008; Slattery et al, 2012). Although plasma morning ACTH and CORT 
level in general remain unchanged in the CSC paradigm, an acute mild heterotypic stressor on the last day 
of CSC is able to enhance plasma CORT levels (Uschold-Schmidt et al, 2012) while a strong heterotypic 
stressor like the FST elevates both plasma ACTH and CORT levels (Füchsl et al, 2013). Though a FST was 
performed on the last day in the present experiment, plasma CORT and ACTH concentrations remained 
unchanged between SHC and CSC mice. A delay between the performed FST and sample collection is 
crucial to detect changes as the release of CORT into the plasma is earliest seen after 15-30 min (de Kloet 
et al, 2005). The latter was not considered in the present experiment, explaining the lack of increased 
plasma concentrations of ACTH and CORT in the current experiment.  
Interestingly, 8 days of minocycline were not able to alleviate increased anxiety-like behaviour, increased 
spleen weights, and HPA axis maladaptations in CSC mice in contrast to all expectations. These were based 
on multiple studies demonstrating that the CSC paradigm increases peripheral immune activation in terms 
of elevated plasma cytokine levels and splenomegaly with reduced in vitro GC sensitivity. In detail, 19 days 
of CSC reduces regulatory T cell counts and increases T cell effector function in peripheral lymph nodes 
that secrete elevated concentrations of pro-inflammatory cytokines upon stimulation (Schmidt et al, 
2010a). CSC mice further develop spontaneous colitis and impaired colonic barrier function, accompanied 
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by more colonic macrophages, dendritic cells and T cells, and increased plasma cytokine concentrations 
(Langgartner et al, 2018b; Reber et al, 2007, 2011). Another consequence of the CSC paradigm is an 
increased spleen weight and a GC resistance of splenocytes, an effect dependent on bite wounds inflicted 
during CSC (Foertsch et al, 2017). Interestingly, chronic treatment with a mixture of antibiotics before and 
during the CSC procedure is able to prevent the development of colitis and an increased inflammatory 
response (Reber et al, 2011). In addition, CSC exposure leads to a robust shift in gut microbiota 
composition that is attenuated by administration of the immunomodulatory bacteria mycobacterium 
vaccae (Reber et al, 2016b), while transplantation of SHC faeces into CSC mice has mild stress-protective 
effects (Langgartner et al, 2018c). These studies demonstrate the role of peripheral immune activation 
and gut microbiota in the CSC-induced phenotype and the necessity of a balance between inflammatory 
and immunoregulatory microbial input that determines the stress response. Fittingly, minocycline is 
known to act anti-inflammatory in the periphery (reviewed in Garrido-Mesa et al, 2013; Giuliani et al, 
2005), modulate gut microbiome composition (Wong et al, 2016), and effectively attenuate inflammation-
induced anxiety- and depressive-like behaviour (see Introduction chapter 1.2.3). An acute application of 
minocycline reverses acute stress-induced anxiety-like behaviour in rats (1 h prior to testing; Levkovitz et 
al, 2015), while a subchronic treatment of 4 days ameliorates mild traumatic brain injury-induced anxiety 
(Kovesdi et al, 2012). In mice, anxiety-like behaviour is reversed after cardiac arrest and prevented in 
repeated social defeat stress with 5 (Neigh et al, 2009) or 8 (McKim et al, 2018) days of minocycline 
treatment, respectively. Of note, though minocycline also attenuates stress-induced behavioural changes, 
the influence of minocycline on HPA axis reactivity has been rarely studied so far. Two studies in rats 
demonstrate a beneficial effect in this context, showing that minocycline prevents increased HPA axis 
activity caused by a neonatal immune challenge (Majidi-Zolbanin et al, 2016) and chronic stress-induced 
elevated CORT levels (Zhang et al, 2019). Thus, considering that minocycline has anti-inflammatory, 
antibiotic, and beneficial effects on chronic stress-induced behaviour, in contrast to the obtained results, 
an amelioration of CSC-mediated behavioural and physiological symptoms was expected to occur after 8 
days of treatment. Since HAB rats in the present thesis showed an innate pro-inflammatory phenotype 
and pathological behaviour, and responded to minocycline treatment, a treatment effect in the CSC 
should have been visible. Nevertheless, in line with the obtained results of this experiment a recent study 
displayed unsuccessful acute minocycline treatment in anxiety- and depressive-like behaviour in mice 
(Vogt et al, 2015). Chronic minocycline treatment likewise failed to ameliorate chronic stress-induced 
depressive-like behaviour in mice (Kreisel et al, 2014). Therefore, the present thesis indicates that the 
anxious phenotype of CSC mice might not solely be mediated by the inflammatory system but also 
potentially by an inflammatory-independent mechanism. Additionally, an antidepressant effect of 
minocycline was not achieved in this experiment. However, as CSC mice generally do not show enhanced 
depressive-like behaviour (Slattery et al, 2012), a lack of effect might be contributed to a missing 
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pathological state in CSC mice. The same assumption can be utilized for the lacking effect of minocycline 
on plasma GC concentrations.  
The exact underlying mechanism for a failed amelioration of CSC-induced symptoms by minocycline 
remains to be studied, though some assumptions can be made. First, the dose applied in this experiment 
was chosen, as previously mentioned (see chapter 4.1.1), based on literature demonstrating a behavioural 
effect of minocycline at a broad range and should therefore not account for the observed behavioural 
effect. As locomotor activity was unchanged, it seems also rather unlikely that a possible effect was 
concealed by an overdose. Although all mice were single-housed and single-housing is known to induce 
anxiety- and depressive-like behaviour in rats (Wang et al, 2017), previous studies showed that for male 
mice group housing is stressful per se (Singewald et al, 2009). A counteracting mechanism of isolation-
induced enhanced anxiety-like behaviour in CSC mice appears, therefore, implausible. Hence, it can be 
concluded that a treatment of 8 days might not be sufficient to reverse CSC-induced symptoms but a 
longer duration might yield beneficial effects of minocycline.  
 
4.2.3 Conclusion and Outlook of CSC studies 
In summary, the CSC paradigm was successfully validated in the new facility at the University of 
Regensburg and its long-term effects were confirmed. Further, the present thesis recapitulates a lack of 
effect of minocycline on anxiety-like behaviour, HPA axis maladaptations and increased spleen weight in 
a chronic psychosocial stress model in contrast to previous expectations. However, at this point a 
conclusion about the effectiveness of minocycline in the context of CSC-induced behavioural, 
physiological, and immunological alterations should be drawn carefully. Under the applied experimental 
conditions, minocycline was not effective but to qualify a statement concerning a general hypothesis, 
additional studies have to be performed. It has to be considered that minocycline was applied only for 8 
days and thus a longer treatment duration might yield a different outcome. Beside an increased treatment 
duration, previous studies indicate another approach. The anxiolytic effect of minocycline has been shown 
before, albeit minocycline was able to prevent the development of high anxiety, but not reverse it (Kreisel 
et al, 2014; Majidi-Zolbanin et al, 2016; Zhang et al, 2019). As mentioned above, both treatment with 
mycobacterium vaccae and a mixture of antibiotics ameliorated symptoms when applied prior to CSC 
exposure (Reber et al, 2011, 2016b). These studies indicate that rather a prevention than a reversal of 
symptoms might be efficient. Therefore, the time point of application might be crucial and minocycline 
treatment before CSC exposure might be able to prevent stress-induced effects. To specify the influence 
of minocycline on CSC-induced maladaptations, the immune system has to be considered. Evaluation of 
peripheral and central immunological parameters like microglia and cytokine concentrations might reveal 
alternative explanations for a failed treatment success and simultaneously offer a new mode of action for 
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minocycline effects. In addition, as the CSC is known to induce spontaneous colitis that might contribute 
to an altered treatment response. Finally, it is crucial to factor in the bactericidal effects of minocycline. 
Future studies to unravel minocycline-induced microbiome and metabolome changes will give some 
indication about potential mechanisms underlying the behavioural and physiological phenotype as well 
as the treatment response of CSC mice. Nevertheless, although deemed rather unlikely due to the anti-
inflammatory and anxiolytic effects of minocycline, it cannot be excluded that minocycline in not 
beneficial in the context of CSC.  
 
4.2.4 Overall conclusion  
In conclusion, the present thesis reveals a specific effect pattern of minocycline and further outlines the 
conditions of its effectiveness. Concerning behaviour, minocycline ameliorated depressive-like behaviour 
in male, but not female, HAB rats. In the first instance, this demonstrates, to my knowledge, for the first 
time a sex-dependent effect of minocycline on depressive-like behaviour. In addition, in NAB rats or CSC 
mice, no antidepressant effect was visible. Those behavioural results indicate, in line with a recent meta-
analysis (Reis et al, 2019), that minocycline requires an alteration in depressive-like behaviour a priori to 
the treatment, as both CSC mice and NAB rats do not show a depressive phenotype. Interestingly, it 
remains unknown why CSC mice do not express a depressive-like phenotype. Unravelling this mechanism 
might give some indication about the actual target of minocycline. Moreover, in both the innate and the 
stress-induced model of anxiety-like behaviour, minocycline was not able to ameliorate the phenotype. 
The anxiolytic effect of minocycline is shown only after traumatic injury, acute stress, or a direct 
inflammatory challenge (Fan et al, 2006; Kovesdi et al, 2012; Levkovitz et al, 2015; Majidi-Zolbanin et al, 
2016; Neigh et al, 2009; Soczynska et al, 2012). These models include an acute and strong traumatic 
impact on the animal that likely induces an acute inflammatory response. In the CSC model, stress is 
applied in a chronic fashion and the anxiety-like behaviour in HAB rats is independent of age. Likewise, 
the CSC induces chronic inflammation and the inflammatory phenotype in HAB rats develops presumably 
already during early development. This leads to the assumption that minocycline shows no or only delayed 
effects on anxiety-like behaviour that might be dependent on an acute inflammatory activation. Hence, 
minocycline does not only show a trait- and sex-dependence but also demands specific preconditions. 
Thus, with the present results I could advance the current knowledge about minocycline towards a more 
fine-tuned outline of the prerequisites that have to be considered to elicit a behavioural response. The 
anti-inflammatory effect of minocycline is postulated as underlying mechanism for its impact on 
behaviour. In male HAB rats, a pro-inflammatory phenotype was expressed by reduced microglial density 
in the infralimbic and prelimbic PFC that might underlie the antidepressant effects of minocycline. 
However, CSC mice do not respond to minocycline treatment despite a high inflammatory state. 
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Therefore, the present results extend the presumed sole effect of minocycline on inflammation to a 
multimodal effect that is not restricted to its anti-inflammatory mechanism. In addition, a pathological 
dexamethasone suppression test is found in male HAB rats, while female HAB rats and CSC mice do not 
show a pathological negative feedback loop of the HPA axis. It is tempting to speculate that a mechanism 
of minocycline is the restoration of HPA axis functionality and might therefore be effective in male HAB 
rats, but not female HAB rats or CSC mice.  
Considering these results, I could extend the mechanistic background of minocycline and provide a more 
defined picture for its effectiveness, potentially serving as a prerequisite for a translation into clinical 
application. Thus, a future translation of minocycline treatment into clinical application for psychiatric 
disorders requires a careful consideration of the patient’s circumstances, i.e. sex, inflammatory state, or 
potential cause of the disease. This emphasizes that minocycline rather represents medication for 
personal tailored treatment of psychiatric disorders than an antidepressant for a broad spectrum of 
patients. Nevertheless, a modulation of the complex interplay of the MGB axis reveals promising potential 
in the treatment of psychiatric disorders.  
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3-OH-butyrate β-hydroxybutyrate 
5-HT  5-hydroxytryptamine, serotonin     
 
ACTH  adrenocorticotropic hormone        
ASD  autism spectrum disorder      
AVP  vasopressin        
 
BBB  blood brain barrier         
BL6  C57BL/6N          
   
CD  cluster of differentiation molecule      
CNS  central nervous system       
CORT  corticosterone        
CRH  corticotropin-releasing hormone     
CRP  C-reactive protein       
CSC  chronic subordinate colony housing      
CSF  cerebrospinal fluid       
CUMS  chronic unpredictable mild stress       
  
 
DA  dopamine        
DSM   Diagnostic Statistical Manual for Mental disorders   
 
EDTA  ethylendiamintetraacetic Acid 
ELISA  enzyme-linked immunosorbent assay     
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EPM  elevated plus-maze       
Esc  escitalopram 
 
FSL  Flinders Sensitive Line    
FST  forced-swim test       
 
GABA  γ-aminobutyric acid       
GAD  Generalized Anxiety disorder      
GC  glucocorticoid        
GF  germ-free        
GIT  gastrointestinal tract       
 
HAB  high anxiety-related behaviour      
HPA  hypothalamic-pituitary-adrenal     
HPLC  high-pressure liquid chromatography     
 
IBD  inflammatory bowel disease      
Iba-1  ionized calcium-binding adapter molecule 1    
icv  intracerebroventricular       
IFN  interferon         
IL  interleukin         
i.p.  intraperitoneal        
 
KO  knockout        
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LAB  low anxiety-related behaviour      
LDB  light-dark box        
LPS  lipopolysaccharide       
      
MDD  Major Depressive Disorder      
MGB  microbiota-gut-brain      
Min  minocycline 
mRNA  messenger RNA 
      
NAB  rats non-selected for anxiety-like behaviour    
NLR  NOD-like receptor          
OF / NOR open field / novel object recognition   
OTU  operational taxonomic unit 
 
PBS   phosphate buffered saline   
PCR  polymerase chain reaction 
PCoA  principal coordinates analysis 
PFC  prefrontal cortex 
PVN  paraventricular nucleus of the hypothalamus 
 
qPCR  quantitatice PCR 
 
rpm  revolutions per minute 
RT  room temperature 
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SAD  social anxiety disorders 
SB  sodium butyrate 
SCFA  short-chain fatty acid 
SDRI  selective dopamine reuptake inhibitor 
SERT  serotonin transporter 
SHC  single-housed control 
SNP  single nucleotide polymorphism 
SNRI  serotonin and noradrenaline reuptake inhibitor 
SPAT  social preference / avoidance test 
SSRI  selective serotonin reuptake inhibitor 
     
TLR  toll-like receptor       
TNF  tumour necrosis factor       
TST  tail-suspension test       
 
Veh  vehicle  
vs.  versus 
 
YLD  Years lived with disability       
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